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tests for the rapid diagnosis of bacterial food poisoning
in clinical and public health practice and to estimate the
cost-effectiveness of these assays in a hypothetical
population in order to inform policy on the use of 
these tests.
Data sources: Studies evaluating diagnostic accuracy
of rapid tests were retrieved using electronic databases
and handsearching reference lists and key journals.
Hospital laboratories and test manufacturers were
contacted for cost data, and clinicians involved in the
care of patients with food poisoning were invited to
discuss the conclusions of this review using the nominal
group technique.
Review methods: A systematic review of the current
medical literature on assays used for the rapid diagnosis
of bacterial food poisoning was carried out. Specific
organisms under review were Salmonella,
Campylobacter, Escherichia coli O157, Staphylococcus
aureus, Clostridium perfringens and Bacillus cereus. Data
extraction was undertaken using standardised data
extraction forms. Where a sufficient number of studies
evaluating comparable tests were identified, meta-
analysis was performed. A decision analytic model was
developed, using effectiveness data from the review
and cost data from hospitals and manufacturers, which
contributed to an assessment of the cost-effectiveness
of rapid tests in a hypothetical UK population. Finally,
diagnostic accuracy and cost-effectiveness results were
presented to a focus group of GPs, microbiologists and
consultants in communicable disease control, to assess
professional opinion on the use of rapid tests in the
diagnosis of food poisoning.
Results: Good test performance levels were observed
with rapid test methods, especially for polymerase
chain reaction (PCR) assays. The estimated levels of
diagnostic accuracy using the area under the curve of
the summary receiver operating characteristic curve
was very high. Indeed, although traditional culture is
the natural reference test to use for comparative
statistical analysis, on many occasions the rapid test
outperforms culture, detecting additional ‘truly’
positive cases of food-borne illness. The significance 
of these additional positives requires further
investigation. Economic modelling suggests that
adoption of rapid tests in combination with 
routine culture is unlikely to be cost-effective, 
however, as the cost of rapid technologies decreases;
total replacement with rapid technologies may be
feasible. 
Conclusions: Despite the relatively poor quality of
reporting of studies evaluating rapid detection
methods, the reviewed evidence shows that PCR for
Campylobacter, Salmonella and E. coli O157 is
potentially very successful in identifying pathogens,
possibly detecting more than the number currently
reported using culture. Less is known about the
benefits of testing for B. cereus, C. perfringens and
S. aureus. Further investigation is needed on how
clinical outcomes may be altered if test results are
available more quickly and at a greater precision than in
the current practice of bacterial culture.
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AUC area under the curve
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CCDC Consultant in Communicable
Disease Control
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MPN most probable number
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aureus
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NGT nominal group technique
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PCR polymerase chain reaction
POC point of care
PPV positive predictive value
QUADAS Quality Assessment of Diagnostic
Accuracy Studies
QUORUM Quality of Reporting of 
Meta-analyses
RPLA reverse passive latex agglutination
rtPCR real-time polymerase chain
reaction
SD standard deviation
SE standard error
SMAC sorbitol MacConkey agar
SROC summary receiver operating
characteristic
STARD standards for reporting studies of
diagnostic accuracy
STEC shiga toxin-producing Escherichia
coli
TN true negative
TP true positive
TPR true positive rate
VCA Vero cell toxicity assay
VTEC verocytotoxin-producing 
Escherichia coli
List of abbreviations
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.Background
Technological advances have increased the speed
of diagnostic testing for many diseases. However,
for bacterial food poisoning, stool culture, which
can take up to 1 week, is still the only method
routinely used for diagnosis in most UK
microbiology laboratories.
The principle methodologies emerging for the
rapid diagnosis of food poisoning are
immunoassays, which detect antigens or antibodies
from pathogens, and polymerase chain reaction
(PCR), a commonly used technique to amplify and
detect pathogenic DNA/RNA. Both techniques
may significantly reduce the detection time for
pathogens in faecal or food samples, compared
with traditional culture methods.
This systematic review focused on the use of rapid
tests for six bacterial food-borne pathogens:
Salmonella, Campylobacter, Escherichia coli O157,
Clostridium perfringens, Staphylococcus aureus and
Bacillus cereus. Diagnostic accuracy was assessed,
and an economic model was subsequently
developed, assessing costs and cost-effectiveness of
PCR and immunoassays, compared with culture.
Methods
Standard systematic review methods were applied.
Literature was identified from electronic databases
and further handsearching. Study findings were
extracted using a predesigned and piloted tool in
duplicate to avoid errors. The methodological
quality of studies was assessed using a standard tool. 
Data synthesis
Sensitivity, specificity and diagnostic odds ratios
were presented in forest plots. Studies within
clinically appropriate groups were subjected to
meta-analysis. Evidence for heterogeneity was
assessed using a 2 test and the I2 statistic. Where
correlation between sensitivity and specificity was
evident (measured using Spearman’s ), a
summary receiver operating characteristic (SROC)
curve was generated. Area under the curve (AUC)
was the main measure of diagnostic accuracy. In
the absence of correlation, pooled estimates of
sensitivity and specificity were presented. Evidence
of publication bias was examined using funnel
plots of log odds ratios.
Results
The electronic search identified 1853 studies, 87
of which were included in this review. The quality
of studies was variable for studies included in
meta-analysis; however, in studies discussed
narratively (principally for toxin-inducing
pathogens), reporting was generally poor.
Clinical effectiveness
Campylobacter
SROC analysis was performed on six studies,
evaluating PCR for the 16s rRNA gene.
Combining 4495 samples, AUC was 0.987 [95%
confidence interval (CI) 0.984 to 0.989]. Four
studies (2078 samples) evaluated the ProSpecT
immunoassay (Alexon-Trend), and reported an
overall AUC of 0.862 (95% CI 0.568 to 1.000). 
Salmonella
Identified test methods included PCR, Wellcolex
Colour agar, MUCAP test, Wampole Bactigen and
AutoMicroBic identification system. Combining
2134 samples (from seven studies), the AUC value
for PCR was 0.995 (95% CI 0.985 to 1.000);
however, publication bias was evident. Other tests
exhibited very high diagnostic odds ratios (DORs),
ranging from 264 (95% CI 116.9 to 597.6)
(Wampole Bactigen) to 2951 (95% CI 710.9 to
12000) (Wellcolex Colour). 
E. coli
SROC analysis for PCR assays showed very high
diagnostic accuracy (AUC 0.996, 95% CI 0.990 to
1.000); however, publication bias was evident,
compared with VTEC-Screen reverse passive latex
agglutination (RPLA) results (AUC 0.994, 95% CI
0.982 to 1.000), which was not affected by
publication bias. The Premier enterohaemorrhagic
Escherichia coli (EHEC) immunoassay had high
pooled sensitivity and specificity values (0.935 and
0.997, respectively), which were not correlated.
Other entrohaemorrhagic E. coli tests evaluated
included ProSpecT, Duopath Verotoxin,
ImmunoCard Stat and RidaScreen Verotoxin.
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Executive summaryA very limited number of studies evaluated rapid
diagnostic methods against an appropriate
reference standard for C. perfringens, B. cereus and
staphylococcal food poisoning. Therefore, it was
not possible to assess effectiveness using statistical
methods. 
Although traditional culture is the logical
reference test to use, on many occasions the rapid
test outperformed culture, detecting more positive
cases of food-borne illness. Immunological and
PCR tests may be useful for ‘multiplexing’, thereby
providing simultaneous speciation or
characterisation. 
Cost-effectiveness
Cost estimates for each test method were derived
from published sources, contact with manufacturers
and discussion with laboratory staff. A decision
analytic model was developed to assess their cost-
effectiveness and the sensitivity of these results to
changes in various parameters in the model was
assessed. 
Evidence about the relative costs of implementing
rapid diagnostic methods in practice is sparse and
highly uncertain. The isolation rate of the
reviewed pathogens is low in laboratories. This
implies that the provision of routine tests can be
very expensive. At the baseline, testing one sample
for Campylobacter, Salmonella and E. coli will cost
£18.85 with PCR, £15.66 with immunoassays and
£15.01 by culture methods. The most sensitive
parameter in the decision analytic model is the
isolation rate for each pathogen. Adoption of
rapid tests in combination with routine culture is
unlikely to be cost-effective; however, as the cost of
rapid technologies decreases, total replacement
with rapid technologies may be feasible. With
multiplex PCR tests, if multiple pathogens could
be simultaneously detected in the same reaction
tube, molecular diagnosis may prove very cost-
effective; however, there are insufficient published
evaluations of these assays at present. 
Conclusions
Evidence from this systematic review suggests that
rapid diagnostic assays, especially PCR, for
Salmonella, Campylobacter and E. coli O157 are
highly accurate. Less is known about the 
benefits of testing for toxin-producing pathogens
and the significance of additional positives
detected by these assays. It is unclear whether the
additional benefits derived from early diagnosis
and more sensitive detection can justify the large
set-up costs of rapid tests, particularly if they
remain diagnostic adjuncts to culture. Any
decisions regarding the use of these assays must
consider the speed of diagnosis (including
transportation and reporting delays), effect on
clinical outcome and costs of implementation
simultaneously.
Implications for research
The effectiveness and cost-effectiveness of
emerging tests for more than one organism at a
time, such as multiplex PCR and DNA 
microarrays technologies, require further
investigation.
Substantial evidence suggests that rapid assays
may be more sensitive than culture methods.
Attempting to evaluate diagnostic tests in the
absence of a true gold standard creates
methodological challenges. 
Implications for practice
The feasibility of conversion to rapid methods is
dependent on localised considerations, including
the community prevalence rates for specific
pathogens, the skill base and subsequent 
training costs for laboratory staff and spare
capacity available to ensure adequate laboratory
space for new equipment. Although these tests
show good promise for the future, further studies
are needed to assess their immediate use in
practice.
x
Executive summaryT
echnological advances in the past two decades
have substantially increased the possibility of
rapid diagnostic testing for many diseases.
However, for bacterial pathogens which cause
food-borne infections or food poisoning,
traditional culture methods, which can take up to
1 week, are still the only method routinely used
for diagnosis in many microbiology laboratories
throughout the UK.
This systematic review of rapid tests for food-
borne pathogens was commissioned by the NHS
R&D Health Technology Assessment (HTA)
programme, in order to assess the accuracy and
cost-effectiveness of these emerging technologies.
A principal aim of this review was to address
important questions regarding the reliability,
accuracy and cost-effectiveness of the tests from
both clinical and public health viewpoints. The
review also sought to address the feasibility of such
tests being adopted more widely by microbiology
laboratories throughout the UK.
Rapid diagnostic tests may be more expensive
than traditional culture methods. However, this
potential for an increase in laboratory costs needs
to be balanced against a possible reduction in
overall costs, such as those that may result from
delays in identification of a pathogen with culture.
Clinical staff such as microbiologists and GPs may
also vary in their views of how much clinical
impact a change in test usage might have, and
changes of health service technologies will need to
take into account not only clinical but also human
and practical factors.
Key research aims
Key research aims were the following:
1. to identify studies on rapid diagnostic methods
for food poisoning due to Salmonella spp.,
Campylobacter, Escherichia coli O157, Clostridium
perfringens, Staphylococcus aureus and Bacillus
cereus relevant to both the food chain and
clinical samples
2. to assess and summarise the sensitivity and
specificity of each diagnostic test for each
organism compared to a gold standard
3. for tests designed and/or currently applied only
to food samples, to assess usefulness for
transfer to clinical testing
4. to assess the time for full laboratory analysis
and reporting for each diagnostic test
5. to develop a decision analytic model to assess
the cost and cost-effectiveness of each
diagnostic test in a clinical setting and in the
management of outbreaks
6. to make recommendations for future research
based on this systematic review of evidence. 
Health Technology Assessment 2007; Vol. 11: No. 36
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Chapter 1
Aim of the reviewDescription of the underlying
health problem
Food poisoning or food-borne illness may occur
after the consumption of food containing toxins or
organisms that multiply to cause disease.1 The
Advisory Committee on the Microbiological Safety
of Food (ACMSF) has defined food poisoning as
“any disease of an infectious or toxic nature
caused by or thought to be caused by the
consumption of food or water”.2 The Food
Standards Agency (FSA) has set a target to reduce
cases of food poisoning by 20% between 2001 and
2006. The FSA chose to focus on microorganisms
that cause the greatest number of cases of food
poisoning, Salmonella, Campylobacter and
C. perfringens, and those that cause severe disease:
Escherichia coli O157 and Listeria.
The largest study of infectious intestinal disease
(IID) carried out in the UK to date3 estimated that
20% of the population of England suffer from
food poisoning (approximately 10 million persons)
each year. It was estimated that, at 1993–5 prices,
IID in England costs some £750 million per year.
About 20% of these results were directly due to the
consumption of food. The contribution of
individual pathogens as causative agents appears
to have changed over the last decade, with
developments in food technology and changes in
both dietary habits and certain methods of food
retailing combining to bring about a resurgence of
some food-borne infections. The importance of
food poisoning as a significant cause of morbidity
remains high. Table 1 includes the number of
laboratory reports in 1995 and 2005.
Food-borne infection, for the majority of sufferers,
does not require medical treatment. However, it is
important not to underestimate its significance. A
factor to consider when investigating food-borne
pathogens is the potential for outbreaks of the
disease to occur. A food-borne outbreak is defined
as an occurrence of two or more cases of a similar
illness resulting from the ingestion of a common
food. In addition, the consequences of food-borne
Health Technology Assessment 2007; Vol. 11: No. 36
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Chapter 2
Background
TABLE 1 Features of the six bacterial pathogens included in this review
Laboratory reports in 
England and Wales
Usual Usual  duration  Common  Common 1995 2005
incubation  of symptoms clinical  mode of 
period features transmission
Bacterial intestinal infection
Campylobacter spp. 2–5 days 2 days–1 week D, P , Fe, B F, W, An 43,876 44,342
Salmonella (non-typhoid) 12–72 hours <3 weeks V, D, Fe F, X 29,314 6,639
E. coli O157a 1–6 days 4–6 days (not HUS) D, B, HUS F, X, W, An 792 946
Toxin-induced food poisoning
Clostridium perfringens 12–18 hours 24 hours D, P F 342 41
Bacillus cereus – emetic 1–5 hours 24 hours N, V, D, P F NA NA
Bacillus cereus – diarrhoeal 8–16 hours 24 hours D, V, N, P F 87 NA
Staphylococcus aureus 2–4 hours <12–48 hours V, P , Fe F 59 0
An, animal contact; B, blood in stool; D, diarrhoea; F, food; Fe, fever; HUS, haemolytic uraemic syndrome; N, nausea; 
P , abdominal pain; V, vomiting; W, water; X, person to person (faecal–oral).
a The nomenclature of enterohaemorrhagic E. coli is still confusing. The toxins are referred to as ‘verocytotoxins’ or ‘shiga-
toxins’, and the toxin-producing strains verocytotoxin-producing Escherichia coli (VTEC) or shiga toxin-producing
Escherichia coli (STEC). The term enterohaemorrhagic E. coli (EHEC) refers to a subset of VTEC strains belonging to
serogroup O157 and to a few other serogroups that cause a clinical illness similar to that caused by E. coli O157.
Source: Report of the Study of Infectious Intestinal Disease in England (2001). London: Food Standards Agency and Centre for
Infections Statistics: 2001.infection are often not confined to the primary
patient alone, owing to the risk of person-to-
person spread. In this sense, there is an increased
urgency in identifying and confirming the cause of
gastrointestinal illness. Delay in diagnosis may
cause prolongation of the period during which a
case remains infectious in the community. Most
food-borne illnesses are self-limiting, particularly
those caused by toxins formed in the food before
consumption. However, a proportion of patients,
especially those who are particularly vulnerable or
infected with certain pathogens, may require a
specific therapy and a delay in diagnosis may result
in delayed treatment, with consequential increases
in morbidity. Occasionally, food-borne infections
may progress to more severe conditions such as
septicaemia,4 meningitis,5 haemolytic uraemic
syndrome,6 reactive arthritis7 and Guillain–Barré
syndrome (GBS).8 The appropriate identification
of the aetiologic agent of infectious gastroenteritis
is important, since there are major differences in
the treatment required for the different agents.9
It is difficult to differentiate potential causes of
enteric illness based on clinical features alone.
Therefore, when a sample is microbiologically
investigated, a collection of pathogens must be
screened for.
Bacterial food-borne illnesses can be classed in two
main groups: gastrointestinal infections, leading to
proliferation of pathogenic microbes in the
infected host (e.g. salmonellosis), and toxin-
induced food poisoning, due to the presence of a
preformed toxin resulting from bacterial growth
(e.g. B. cereus) in the food. The mechanism of
pathogenicity for some gastrointestinal infections
also involves toxin production in vivo after
consumption of the organism (e.g. C. perfringens).
There is a wide variety of food-borne pathogenic
microorganisms and natural toxins. This
systematic review will concentrate on six bacterial
causes of food poisoning: Salmonella spp.,
Campylobacter jejuni and E. coli O157, which all
cause gastrointestinal infection, S. aureus and
B. cereus, which cause food-borne intoxications,
and C. perfringens, which can act as an infection or
an intoxication. These organisms were selected
mainly because they are the commonest causes of
bacterial food poisoning and outbreaks of food
poisoning in the UK.10 The inclusion of VTEC is
necessary due to the severity of the disease it
causes, and S. aureus and B. cereus because, like C.
perfringens, they are diagnosed with toxin
detection methods. Other organisms were not
included individually either because they are
uncommon, not relevant in community or caused
primarily by food poisoning (Clostridium difficile),
or predominantly transmitted through other
routes (Shigella spp.). Viral food poisoning and
food-borne disease relating to parasites are
substantially different from bacterial causes, and
are excluded from this review.
Shigella infection has decreased rapidly since the
peak incidence period of 1950–69, when
20,000–40,000 cases per annum were reported in
the UK. Most years since 1980 have seen less than
5000 reports. Humans are the only significant
reservoir of infection, and food-borne outbreaks
are relatively uncommon.11
Table 1 summarises the aetiological features of the
six bacterial pathogens included in this review.
Trends in microbiological identification are
summarised in Table 2 and reporting trends are
illustrated in Figure 1.
As indicated, the estimated volume of food-borne
illness each year far outweighs the number of
laboratory reports recorded. It is impracticable
and unnecessary to refer all patients with acute
diarrhoea for microbiological investigation. The
existence of a ‘reporting pyramid’ is notable with
food-borne illnesses. It is estimated that for every
1000 cases of food-borne illness in the community,
160 present to their GP, 45 have a stool sent for
routine microbiological examination and only 10
have positive results reported. Only a fraction of
all food-borne illnesses are ever diagnosed and
officially reported, or can be traced to a certain
vehicle or a specific causative agent.3
Campylobacter jejuni
Bacteriological background
Campylobacters are Gram-negative bacteria which
are important animal and human pathogens.
Although there are 11 different species in total,
this review focuses on C. jejuni, the cause of most
reported Campylobacter-related human illnesses.
Most laboratories routinely use selective media
designed for C. jejuni alone, hence incidence of
the less common species may be under-reported.12
Incidence
Campylobacter is the most commonly identified
food-borne bacterial infection encountered in the
world. In 2000, approximately 56,000 cases were
formally recorded in UK laboratory reports, with
as many as 400,000 expected to occur in total.10
The number of laboratory reports has decreased
Background
4slightly in recent years, but a high degree of
under-reporting is still expected. Although some
outbreaks have been reported, most cases occur
sporadically. It is most commonly transmitted by
raw poultry, raw milk and water contaminated by
animal faeces.
Symptoms
Campylobacteriosis is an acute bacterial enteric
disease ranging from asymptomatic to severe, with
diarrhoea, nausea, vomiting, fever and abdominal
pain, with illness usually lasting 2–5 days.
Although Campylobacter is in itself a relatively
harmless pathogen, it can cause post-infectious
complications which are potentially very serious.
Campylobacter is believed to be a leading cause of
GBS, an autoimmune reaction that causes
paralysis and kills between 5 and 10% of its
victims. Approximately 1 in 1000 cases of C. jejuni
develops into GBS after 7–21 days of infection.13
Reitter’s syndrome, a form of reactive arthopathy,
can also occur in up to 1% of campylobacteriosis
patients.9
Treatment
In the general population, campylobacteriosis is a
self-limiting disease, for which antimicrobial
therapy is not required.14 However, as with many
intestinal infections, infants and
immunocompromised individuals are at higher
risk of developing more severe infection.
Current diagnosis
Identification methods for Campylobacter have
traditionally involved the use of selective culture
media which contain several antimicrobial agents
to suppress the growth of other bacteria. This
process is followed by biochemical tests such as
nitrate/nitrite reduction, hippurate hydrolysis and
nalidixic acid susceptibility. Although selective
media are very useful for the initial isolation of
Campylobacter, biochemical methods for
identification are often tedious and may give
ambiguous results. Isolation of the organism
requires inoculation of faecal samples on a selective
medium, followed by microaerobic incubation at
37 or 42°C for 48 hours. A further 24–48 hours
are required for full phenotypic identification.15
Salmonella
Incidence
Salmonellae have been some of the most frequently
reported aetiological agents in fresh produce-
associated outbreaks of human infections in recent
years, with over 15,000 laboratory diagnoses in
2000 arising from an estimated 41,616 cases.10
The highest incidence rates occur in patients aged
under 1 year and in individuals older than
70 years.
More prudent food hygiene regulations have seen
the reported cases of Salmonella enteritis PT4 (long
associated with egg consumption) decline
considerably. However, other PT4 strains have
been slowly and steadily increasing in incidence.
In 2005 there were 1771 reported cases of
S. enteridis PT4 and 4868 reported cases of
S. enteridis (other PTs) in the UK.
Transmission
Most infections are acquired by eating
contaminated poultry, eggs or dairy products.
According to some estimates, almost three-
quarters of all broiler chickens are contaminated
Health Technology Assessment 2007; Vol. 11: No. 36
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TABLE 2 Trends in microbiological identification of Campylobacter jejuni, Salmonella enteriditis and Escherichia coli O157:
1995–2005
Year C. jejuni S. enteriditis E. coli O157
1995 43,449 15,691 792
1996 43,978 17,880 660
1997 51,360 22,254 1,087
1998 56,852 16,048 890
1999 56,254 10,454 1,084
2000 57,674 8,267 896
2001 54,917 10,491 768
2002 47,834 9,505 595
2003 46,178 9,767 675
2004 42,146 8,203 701
2005 44,342 6,639 946
Source: Health Protection Agency laboratory reports.with Salmonella during defeathering, slaughtering
and evisceration, when faeces splatter the skin.16
The Salmonella also spreads easily from raw or
undercooked poultry to innocent vegetables, fruit
or other foods via contaminated hands, knives,
countertops or cutting boards. Due to the ability of
Salmonella to multiply in a wide variety of foods, it
is important to be able to isolate the organisms
even when present in very small numbers in the
faeces.
Symptoms
The symptoms of Salmonella infection are
abdominal pain, diarrhoea, mild fever, chills,
headache, nausea and vomiting, developing
12–72 hours (but occasionally as long as 7 days)
Background
6
0
200
400
600
800
1000
1200
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Year
C
a
s
e
s
 
o
f
 
E
.
 
c
o
l
i
 
O
1
5
7
 
r
e
p
o
r
t
e
d
 
t
o
 
H
e
a
l
t
h
 
P
r
o
t
e
c
t
i
o
n
 
A
g
e
n
c
y
70,000
60,000
50,000
40,000
30,000
20,000
10,000
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
44,342
42,146
46,178
47,834
54,917
57,674
56,254
56,852
51,360
43,978
43,449
15,691
17,880
22,254
16,048
10,454
8267
10,491
9383
9767 8203
6639
Campylobacter
S. enteridilis
C
a
s
e
s
 
r
e
p
o
r
t
e
d
 
t
o
 
H
e
a
l
t
h
 
P
r
o
t
e
c
t
i
o
n
 
A
g
e
n
c
y
Year (a)
(b)
792
660
1087
890
1084
896
768
595
675
701
946
FIGURE 1 Reporting trends in England and Wales for (a) Campylobacter and Salmonella and (b) E. coli O157, 1995–2005. Source:
Health Protection Agency laboratory reports. after infection. The discomfort generally lasts a
few days. It can be dangerous for the elderly,
infants and the immunocompromised, who may
become extremely ill. Salmonella is also one of the
leading predictors for reactive arthritis, a painful,
chronic and potentially debilitating condition that
causes joint inflammation.17
Treatment
Salmonella infection in older children and adults is
usually a self-limiting disease (presenting as acute
gastroenteritis), and therapy should mainly be
directed at preventing dehydration. A recent
Cochrane review18 of antibiotic treatment for
Salmonella gut infections suggested that they
provided no clinical benefits to otherwise healthy
children and adults with non-severe cases.
Antibiotic administration may, in fact, prolong
Salmonella.19 However, it is justified to use
antimicrobial therapy for infants under 3 months
old with Salmonella gastroenteritis, and also in
immunocompromised patients and patients with
septicaemia. In these patients, antibiotic treatment
will be most successful in the early stages of illness,
and delaying treatment may result in septicaemia-
related dehydration and renal failure.9 Because
the early stage is often clinically difficult to
determine, these patients might benefit from
rapid tests that can be done quickly in the place
where the patient is receiving care.
Traditional methods for the isolation of
Salmonellase use enrichment and selective media
followed by serological and biochemical
identification. These methods require a large
amount of technical expertise and are labour
intensive. Positive identification may be time
consuming, with a positive result taking up to
3 days before confirmation. There are several
selective plating media for the isolation of
Salmonellae from human faeces and other
specimens, but their sensitivity and specificity vary
considerably. Due to the high rates of false-
positive results, screening of stool samples for
Salmonella becomes labour intensive, with
additional costs for subsequent identification.
Escherichia coli O157
Background
The genus Escherichia consists of five species, of
which E. coli is the most common and clinically
most important. Since its recognition in 1982, E.
coli O157:H7 has been noted as one of the most
dangerous pathogens, as only very small numbers
of the organism may be required to cause illness.
For this reason, suspect colonies must be handled
with care. All tests need to be carried out in a
safety cabinet, usually in a biohazard room. It is
the only pathogen in this discussion classed as
‘category three’ risk.
Incidence
The incidence of E. coli O157 tends to fluctuate,
reflecting the outbreak-specific nature of disease.
The highest levels (1087 cases) in the UK were
recorded in 1997, largely associated with a highly
publicised outbreak in Central Scotland.20 On
average there are approximately 600–800
confirmed cases each year, with 946 recorded in
2005, linked to a large outbreak in South Wales.
Transmission
Cattle are the principal reservoir of
enterohaemorrhagic E. coli (EHEC) and the
majority of large outbreaks have been food-
borne.21 A major source of E. coli O157 is ground
beef; other sources include consumption of
unpasteurised milk and juice, sprouts, lettuce and
salami and contact with cattle. The organism is
easily transmitted from person to person and has
been difficult to control in schools and nurseries.
Rapid detection of the causative pathogen is
therefore an important contribution to the
effective prevention of infection.22
Symptoms
E. coli O157 can cause acute bloody diarrhoea and
abdominal cramps. Persons who only have
diarrhoea usually recover completely, without
antibiotics or other specific treatment, in
5–10 days. There is no evidence that antibiotics
improve the course of disease, and it is thought
that treatment with some antibiotics may
precipitate kidney complications. Antidiarrhoeal
agents, such as loperamide (Imodium®), should
also be avoided.
Complications
Certain patients, particularly infants, the elderly
and the immunocompromised, are at higher risk
of developing secondary complications, which can
substantially increase the potential risks of E. coli
infection. EHEC has been strongly associated with
haemorrhagic colitis and the more severe
complications of haemolytic uraemic syndrome
(HUS),23 the major reason for an acute loss of
kidney function in childhood. Blood transfusions
and kidney dialysis are often required. Patients
who develop HUS often require prolonged
hospitalisation, dialysis and long-term follow-up.
With intensive care, the death rate for HUS is
3–5%. Although reported cases of E. coli O157 are
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pathogens, such as Campylobacter and Salmonella,
due to the morbidity and mortality associated with
secondary complication, this pathogen is now
considered a major public health problem of
worldwide importance.
Diagnosis
Vero cell cytotoxicity assays are probably the most
sensitive method of detecting shiga toxin E. coli
strains such as O157:H7. However, most hospital
laboratories would not routinely perform tissue
culture work with Vero cell monolayers available
on demand. Moreover, Vero cell assay results are
generally not available for 48–72 hours. Instead,
sorbitol MacConkey agar is currently used to
detect E. coli O157 in UK laboratories. Isolation of
E. coli O157:H7 from water and other
environmental samples is laborious. Culture is
problematic due to the large numbers of other
flora that either overgrow or mimic the non-
sorbitol-fermenting E. coli O157:H7.24
Non-O157 strains
Although several EHEC serotypes have been
associated with human infection, recent well-
publicised outbreaks of infection with E. coli
O157:H7 have resulted in a focus on the
development of methods for the identification of
the specific EHEC serotype. The number of
documented infections with stec other than
O157:H7 is probably an underestimate, due to the
use of serotype-specific methods.25 This single
serotype-directed effort is in part justifiable, in that
the majority of HUS cases are caused by E. coli
O157:H7. However, this may lead to a failure in
the assessment of the prevalence of other EHEC
isolates associated with human disease and also
may leave health authorities unprepared for the
emergence of new clones of these organisms.
Clostridium perfringens
C. perfringens has been shown to be a common,
although often under-reported, cause of bacterial
food poisoning, with its enterotoxin being
responsible for the disease symptoms of diarrhoea
and abdominal pain. Diagnosis and outbreak
analysis of C. perfringens food poisoning can often
be difficult, since this organism can exist as part of
the normal gut flora in humans.
These pathogens are considered of economic
importance, even in the cases of mild, self-limiting
illnesses, due to the high sanitary costs and also
their negative repercussions in the food processing
industry. C. perfringens is one of the most easily
preventable food-borne pathogens, as temperature
abuse in prepared foods is the most common
cause of infection. The refrigeration of food after
preparation prevents the production of
enterotoxin. Alternatively, reheating of the food
can destroy the heat-labile enterotoxin. Good food
handling practices will also reduce the risk of
disease. 
Diarrhoea due to C. perfringens may arise from
consumption of contaminated food, be associated
with antibiotic treatment or be the result of spread
of the organism by person-to-person transmission
among residents of institutions. Diarrhoea is
caused by enterotoxin, which is released in the
intestine during sporulation.
Incidence
Food-borne C. perfringens intoxication is a
relatively common but underappreciated bacterial
disease. The estimated total number of cases of
C. perfringens was as high as 276,266 in 1992,
although only 806 of these were confirmed by
laboratory diagnosis. By 2000, the annual number
of cases had fallen to 84,081, and the number of
laboratory reports also decreased substantially to
245.10 It is ubiquitous in the environment and
frequently occurs in the intestinal tract; however, a
large number of vegetative cells (more than 106)
need to be ingested before infection occurs. 
Foods commonly associated with C. perfringens
food-borne disease are cooked meats or poultry
held at improper temperatures. Infection is most
likely to occur when large quantities of food are
prepared several hours before serving, such as in
institutions such as school cafeterias and nursing
homes.
Symptoms
C. perfringens food poisoning may cause mild to
acute gastroenteritis. Symptoms, including watery
diarrhoea and intense abdominal cramps, are
usually experienced within 8–22 hours after eating
contaminated food. The illness is usually self-
limiting, lasting less than 24 hours.
Individuals most at risk include pregnant women,
newborn babies, the elderly and the
immunocompromised.26 Elderly people, in
particular, may experience prolonged or severe
symptoms. In the past 5 years, 58% of patients
admitted to hospital with food-borne C. perfringens
intoxication were aged 75 years and above, with
duration of hospital stay as long as 80 days. On the
whole, fatal cases of C. perfringens are very rare.
Background
8Current diagnosis
C. perfringens serotyping is available in only a few
laboratories worldwide. This organism loses
viability rapidly in foods that have been stored
refrigerated, and faecal counts can still be high in
elderly people in the absence of illness. Detection
of enterotoxin may be the only test available when
investigating an outbreak of food poisoning.
Unfortunately, C. perfringens does not readily
produce toxin in vitro and no single method has
been found to induce toxin production in all
strains. Because of this, testing isolates for toxin
production is not performed routinely, indicated
by the very low proportion of suspected cases
which are formally identified. If specifically
requested by the sending clinician, serological
assays are used for detecting enterotoxin in the
faeces of patients. Bacteriological confirmation can
also be possible by finding extremely large
numbers of the causative bacteria in implicated
foods or in the faeces of patients.
Bacillus cereus
Bacterial background
B. cereus is a Gram-negative, spore-forming,
motile, aerobic rod that also grows well
anaerobically. It has been recognised as an
opportunistic pathogen of increasing importance.
Two types of illness have been attributed to the
consumption of food contaminated with B. cereus:
emetic and diarrhoeal food poisoning syndromes,
each formed from separate toxins (see Table 3). For
both types of food poisoning, the food involved
has usually been heat treated, and surviving spores
germinate to produce somatic cells and toxins.
Some food types that are preferentially
contaminated with B. cereus are crude cereals,
starchy food, dairy products, meat, dehydrated
foods and spices. B. cereus grows well after cooking
and cooling (<48°C).
Symptoms
B. cereus food poisoning is under-reported as both
types of illness are relatively mild and usually last
for less than 24 hours. However, occasional reports
have described fatal incidents associated with
emetic toxins.27
Emetic strains
The emetic syndrome is caused by toxin formed in
food. The number of organisms needed for illness
is thought to be in the region of 105 colony-
forming units (cfu) g–1 food. Emetic activity is
extremely stable, being unaffected by heating or
by extremes of pH.
Diarrhoeal strains
Diarrhoeal B. cereus syndrome is caused by
enterotoxin which is released in the intestine and
may also be preformed in foods. The number of
organisms needed to cause illness is thought to be
at least 105 cfu g–1 food. Laboratory confirmation
of B. cereus diarrhoeal food poisoning requires
demonstration of 105 cfu g–1 of food or faeces,
or the detection of enterotoxin in food or faeces.
B. cereus occurs widely in pasteurised dairy
products and a significant proportion of these
isolates is capable of psychotrophic growth and
enterotoxin production,28 which has prompted an
interest in the examination of strains for the
ability to produce toxin.
Conventional procedures for the detection of
B. cereus involve the plate count method and the
most probable number (MPN) method. B. cereus
does not ferment mannitol, and most strains
Health Technology Assessment 2007; Vol. 11: No. 36
9
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
TABLE 3 Characteristics of the two types of disease caused by Bacillus cereus
Diarrhoeal syndrome Emetic syndrome
Infective dose (cells g–1)1 0 5–107 (total) 105–108
Toxin produced In small intestine of host Preformed in cells
Type of toxin Protein Cyclic peptide
Incubation period (hours) 8–16 (occasionally >24) 0.5–5
Duration of illness (hours) 12–24 (occasionally several days) 6–24
Symptoms Abdominal pain, watery diarrhoea and  Nausea, vomiting and malaise (sometimes 
occasionally nausea followed by diarrhoea, due to additional
enterotoxin diarrhoea)
Foods most frequently implicated Meat products, soups, vegetables,  Fried and cooked rice, pasta, pastry and 
puddings/sauces and milk/milk  noodles
productsdevelop a positive egg yolk reaction. Detection of
low numbers of B. cereus is especially difficult if the
foods are heavily contaminated with other
microorganisms. 
Staphylococcus aureus
Incidence
Staphylococcal food poisoning is caused by
ingestion of enterotoxins that are produced in
foods by some strains of S. aureus. The most
common toxins implicated in staphylococcal food
poisoning are sea to sej, which cause 95% of all
outbreaks.29 Since most people recover within
1–2 days, many do not seek medical advice, and
the incidence of disease is thought to be under-
reported. In 1995 there were an estimated 13,989
cases of infectious intestinal illness caused by S.
aureus in England and Wales, yet only 59
laboratory reports were recorded.10
Symptoms
The most common symptoms experienced with
staphylococcal food poisoning are nausea,
vomiting, diarrhoea and abdominal cramping,
and illness is commonly confused with that of
emetic B. cereus. These symptoms usually appear
within 1–6 hours of consuming infected food;
however, the onset and severity of illness are
usually dependent on the amount of contaminated
food eaten, the amount of toxin ingested and the
individual’s susceptibility to it. Growth of
enterotoxigenic strains to 105 cfu g–1 food is
generally considered necessary to produce enough
to induce illness. Detection of staphylococcal
enterotoxin in a suspect food is very strong
evidence of involvement of that food in an
outbreak.
Illness usually lasts 1–2 days, including abrupt,
sometimes violent, onset with nausea, cramps,
vomiting, diarrhoea, hypotension and
prostration.11
Transmission
A wide variety of foods have been associated with
staphylococcal food poisoning, including meat,
eggs, bakery and dairy products. S. aureus usually
contaminate the food during the handling stage
after cooking.
Current diagnosis
Due to the self-limiting nature of the illness,
diagnosis of staphylococcal food poisoning is
usually determined by clinical presentation. Faecal
testing for S. aureus is performed after specific
requests from the sending clinician. In these cases,
a commercially available reverse passive latex
agglutination assay (SET-RPLA) is the most
commonly used assay for S. aureus detection. The
production of a sufficient amount of toxin is
essential for successful detection. Subsequently, the
propensity for this test to produce false-negative
results is elevated.
Current service provision
Current diagnosis of infectious intestinal disease
in the UK, and most other countries, still relies on
traditional culture methods. Although
considerable research has been carried out to
develop new detection techniques, little advance
has been made to implement them on a routine
basis. The Health Protection Agency Laboratory 
of Enteric Pathogens (LEP) is a reference
laboratory service which provides further
phenotyping and epidemiological referencing for
culture-positive samples from UK and abroad.
Although the methods used have the potential to
provide rapid results, this service is not primarily
used as a way to achieve faster diagnosis, but
rather as a confirmatory reference service using
the most sensitive typing techniques currently
available.
In-surgery laboratory services are usually limited
to dipstick urine testing, pregnancy tests and
finger-stick blood glucose determinations. Point of
care testing for food poisoning is unavailable in
the UK. Testing on faecal samples does not
routinely occur outside of the microbiology
laboratory, nor is it likely to in the future. Instead,
the local hospital or regional Health Protection
Agency laboratory provides this service.
Background
10Conventional culture methods
For over a century, the detection of enteric
pathogens has relied on culture techniques to
isolate bacteria. A variety of selective, non-selective
and differential media, and also enrichment
broths, are traditionally used by clinical
microbiology laboratories for the screening of
stool cultures. Suspect colonies, screened using
various media, are selected for further
confirmatory biochemical tests. When a pathogen
is detected, serological typing and more detailed
biochemical testing are performed, and data from
these tests facilitate epidemiological analyses.
Although these conventional methods are very
valuable, they are both time and material
consuming and may be unsuitable in outbreak
situations. One of the key criticisms of
conventional methods is that results are available
relatively late in the clinical illness, limiting the
overall value of the test. Treatment decisions are
usually based on clinical severity of illness prior to
receipt of culture confirmation of microbial cause.
This lengthy time taken to diagnose food-borne
illness by culture methods may have an impact on
the clinical route for each patient.
Pre-enrichment and enrichment of
samples
Organisms are traditionally cultured from stool by
inoculating the specimen on to a combination of
enteric selective and differential media. One of the
reasons why culture methods are time consuming
is the pre-enrichment and enrichment process
required, which is usually performed overnight.
Pre-enrichment involves the use of a non-selective
medium which allows the recovery of stressed cells
in food or faeces. This is followed by an
enrichment step in a second broth, which is
usually selective due to inclusion of antimicrobials
against non-target organisms in their formulation.
Pre-enrichment ensures that stressed cells are
competent to grow in the relatively toxic
conditions of the selective enrichment. Without
the recovery (pre-enrichment) stage, growth can
be inhibited in the selective broths. A comparative
study of five plating media for Salmonella spp.
suggests that the sensitivity of assays will be
substantially increased if the sample is pre-
enriched, with sensitivity ranging from 0.365 to
0.784 for direct plating and from 0.909 to 0.932
after enrichment in selenite broth.30 This suggests
that the increase in accuracy gained from pre-
enriching samples would justify the increased time
taken to report back results.
Culture is by no means ‘perfect’. For instance,
Hektoen Enteric Agar, although showing high
sensitivity in the detection of Salmonella, is not
very specific,31 and a high level of false-positive
results require time-consuming complementary
testing to identify or, in most cases, to exclude the
presence of Salmonella colonies. Problems with
using culture are experienced with other enteric
pathogens also, such as non-O157 strains of
EHEC.32,33 These EHEC ferment sorbitol and
therefore, on diagnostic agars, are visually
different from E. coli O157 strains, and therefore
may not be identified, even though they have the
potential to cause the same disease.
Standard culture tests usually require 3–7 days to
issue final results because bacterial identification
requires further biochemical confirmatory tests.
Rapid technologies
‘Rapid diagnosis’ is an umbrella term describing a
wide range of novel testing procedures which can
significantly reduce the reporting time compared
with that of conventional bacterial culture. With
more rapid laboratory diagnosis, the clinician
could be informed of the microbial cause of food
poisoning prior to making treatment decisions, in
addition serving as a trigger for a suspected food-
borne outbreak if further cases are present. This
could be exceptionally important in, for example,
the case of EHEC infection where the use of
antibiotics is contraindicated and rapid treatment
is essential to prevent kidney damage in infected
individuals.
From a public health perspective, faster detection
times are essential to prevent the spread of
infectious diseases or the identification of a
continuing source of infection. Extensive research
has been carried out to develop rapid tests for
food-borne pathogens and/or bacterial toxins, but
it remains to be seen whether they can make a
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Chapter 3
Diagnostic test backgroundsignificant diagnostic impact by being
implemented in routine practice. 
Rapid methods developed include a variety of
assays such as highly specific nucleic acid-based
methods, antibody-based tests, simple miniaturised
biochemical assays and physicochemical tests that
measure bacterial metabolites such as
bioluminescence and fluorescence.
Antigen detection
An antibody is a large protein produced in an
animal in response to an invasion by a ‘foreign’
molecule, i.e. one not recognised as ‘self ’. The
antibody binds to the foreign structure, often with
a very high affinity, as part of the general immune
response, which leads to neutralisation of the
‘invader’. Although binding of an antibody to the
analyte (e.g. bacterial cell, toxin) is the key event
in the technique, recognition that this event has
taken place is needed to discover if the analyte is
present. This is done by labelling (or ‘tagging’) the
antibody with another molecule which can
produce a measurable signal. The signal
generated by the tag can be a colour change,
production of light or fluorescence, an electrical or
optical output or by simple visual recognition. In
many cases the signal is quantifiable. The test
formats include:
● Enzyme-linked immunosorbent assay (ELISA):
ELISA is the most common format, in which
the tag is an enzyme, usually one which
catalyses the formation of a coloured product
from a colourless substrate to give the assay
endpoint. ELISAs can take several forms, the
most widespread of which is based on a 96-well
polystyrene microplate. Within this assay format
there are several types. In one, for example,
antibodies are immobilised on the surface of the
well and samples are added; the target analyte
in the sample is bound by the antibody.
Unbound material is washed away and a
second, enzyme-labelled, antibody is then
added. After a further washing stage, substrate
is added and the colour change recorded,
usually with a dedicated spectrophotometer.
Tags other than enzymes are used in some
assays, and such tags can offer the possibility of
multiplexing the assay, for example, in
fluorescence immunoassays (FIAs).
● Lateral flow: These assays are housed in a
completely self-contained cassette device. They
require less technical knowledge to interpret,
and could be used ‘in the field’ or, potentially,
for ‘bedside’ testing, and are formulated as a
one-off, disposable, single-sample test. 
● Latex agglutination: The third common format
relies on the ability of antibodies to form cross-
linked complexes with the target cells or toxins
in a process known as agglutination. In some
forms of agglutination tests, the antibody is in
solution; in others, it is coated on the surface of
latex particles. The sample is mixed with the
antibody or coated particles on a solid surface,
such as a tray or microscope slide, and observed
for the formation of visible agglutinated clumps
in the liquid, usually within a few minutes.
Multiplex detection of different cells or toxins
in the same sample by formation of separate
coloured complexes is possible. Due to the high
volume of background flora in faecal samples,
without pre-enrichment all detection methods
face inhibitors which drastically reduce the
sensitivity and specificity of each test.
● Immunomagnetic separation (IMS): This
technique uses binding properties of antibodies
to separate and/or concentrate bacterial cells
from a dilute or complex sample. Antibodies
are immobilised on magnetic microparticles and
these are added to the sample. After a suitable
incubation period in which cells bind to the
antibodies, the particles are removed from the
sample with a powerful magnet and washed to
remove unbound cells and matrix material (e.g.
food). They can then be transferred to an
analytical system or culture medium for further
analysis or manipulation.
Although ELISA tests can increase the speed of
detection, it is a very labour-intensive technique.
As laboratory budgets are tightened and
diagnostic capabilities advance, laboratory
managers will aim for the minimum technician
time spent while retaining high sensitivity and
specificity. Immunoassay techniques, which rely 
on repetitive washing cycles, may become
redundant as automated, large-scale tests 
become available. 
Nucleic acid-based detection methods
The genetic material of each living organism –
plant or animal, bacterium or virus – possesses
sequences of its nucleotide building blocks (usually
DNA, sometimes RNA) that are uniquely and
specifically present only in its own species.
Provided that at least partial sequences of the
DNA target are known a priori, these sequences
can be used to design synthetic oligonucleotide
primers that hybridise specifically to target
sequences. Various nucleic acid-based 
techniques have been developed, including 
direct DNA probes, polymerase chain reaction
(PCR), amplification of the hybridising 
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12probes (e.g. ligase chain reaction and Q-beta
replicase amplification), amplification of the
signals generated from hybridising probes 
(e.g. branched DNA and hybrid capture) and
transcription-based amplification (e.g. nucleic acid
sequence-based amplification and transcription-
mediated amplification). PCR is the most versatile
and widely used amplification technique.
There are three basic steps in PCR:
1. The target genetic material must be denatured
– unwinding the strands of its double-helix.
This is accomplished by heating to 90–96°C.
2. Hybridisation or annealing: primers bind to
their complementary bases on the now single-
stranded DNA.
3. DNA synthesis by a polymerase: starting from
the primer, the polymerase can read a template
strand and match it with complementary
nucleotides very quickly. The result is two
helixes in place of the first.
These steps are repeated, usually for 25–30 cycles.
The creation of new copies of the original DNA
strand is exponential, so that within a short period
(usually 1 hour) there is enough of the target DNA
to detect. The DNA product of amplification is of
a fixed length (i.e. covering the distance between
the two primers), and detection of this defined
product indicates a positive PCR result.
PCR tests are considered especially attractive due
to their relative ease of use, low cost and potential
application in large-scale screening programmes
by means of automated technologies. As nucleic
acid-based methods are exquisitely sensitive, the
use of an imperfect gold standard is likely to
undermine their true diagnostic accuracy.
Although there is always a risk that dead/non-
viable cells are detected in PCR assays, nucleic
acid-based methods are generally more sensitive
than culture, and so pathogens detected by PCR
but not culture (defined here as ‘false positives’)
may be ‘true’ positives (Figure 2).
● Choosing suitable targets: The most important
aspect of PCR is the analyst’s choice of genetic
target to be amplified. As sequencing of
genomes of infectious pathogens becomes more
widespread, researchers can begin to
understand which primer sets would provide
the most clinically useful diagnostic test.
Frequently, there are minor sequence
differences between strains of a pathogen, even
within a species, so careful study of all available
sequences of the target organism is necessary
when designing primer sets to ensure that all
the desired coverage is achieved.
● Commercial and ‘in-house’ PCR test: With the
increasing number of genomes of infectious
pathogens being sequenced, there is
opportunity for any research scientist to attempt
to design a diagnostic test based on any
segment of a genetic sequence. Over the past
decade, a vast number of laboratories worldwide
have developed their own ‘in-house’ PCR assays
for food-borne pathogens. As a result, the test
methods and primers used are heterogeneous,
and validation and optimisation of in-house
assays need further study. On the other hand,
there are a very limited number of commercial
tests available for the detection of enteric
pathogens. 
● Conventional and quantitative real-time PCR
(rtPCR): Most conventional first-generation
PCR assays have cumbersome procedures for
detecting amplification products; after initial
DNA purification, there is a 2-hour PCR stage,
followed by gel electrophoresis and ethidium
bromide staining. In addition, many lack
sequence-specific identification of the gene
being amplified. In comparison, quantitative
real-time PCR involves the amplification and
detection of amplified products coupled in a
single reaction vessel, greatly increasing the
speed of detection. This allows for the direct
detection of the PCR product during the
exponential phase of the amplification reaction,
combining amplification and detection in one
step. Unlike conventional PCR methods, rtPCR
does not require post-PCR sample handling,
preventing carry-over contamination and
resulting in much faster and higher throughput
assays. Measurement of the rate of increase in
amplification product in real time also offers
the possibility of extrapolating back to the
starting DNA concentration, thus offering the
possibility of quantification. 
● Multiplex PCR: A disadvantage of nucleic acid
diagnostic kits and many user-developed tests is
that they are narrow in scope. Current
organism-specific PCR methods assume that the
microbiologist knows which pathogen is causing
the disease – an assumption which, if true,
makes the test useful only as an expensive
confirmation for the clinical diagnosis.
Significant interest therefore rests on multiplex
PCR, which uses numerous primers within a
single reaction tube in order to amplify nucleic
acid fragments from different targets. Specific
nucleic acid amplification (NAA) should occur if
the appropriate target DNA is present in the
sample tested. It has been argued that the costs
Health Technology Assessment 2007; Vol. 11: No. 36
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multiplex PCR than in systems where several
tubes of uniplex PCR are used. However, the
primers used in multiplex reactions must be
designed carefully to have similar annealing
temperatures and to lack complementarity.
Extensive empirical testing is often needed and,
as yet, multiplex PCR tests for enteric
pathogens are not commercially available.
Limitations
PCR methods (particularly rtPCR) potentially
offer faster detection time and increased accuracy
compared with traditional culture. PCR tests are
attractive due to their ease of use, relatively low
cost in terms of laboratory manpower, rapid
turnaround time and potential to be fully
automated. However, some problems still exist
with nucleic acid diagnosis. 
● Costs: A high level of investment is required for
PCR testing, in terms of both initial technician
training and high capital costs, particularly for
real-time equipment. 
● Inhibitors in sample: NAA for faecal specimens
can be particularly difficult due to the high
level of background flora present that PCR may
fail to detect in samples where the presence of
unusually high concentrations of inhibitory
compounds that were not sufficiently reduced
by the level of dilution used. 
● DNA extraction: Although extraction of DNA
can eliminate inhibitory substances in faeces,
these procedures are also labour intensive and
expensive. Because of the heterogeneous nature
of faecal specimens, it is very difficult to
develop a DNA extraction method that will
successfully remove inhibitors that may be
present in various amounts in different samples
Diagnostic test background
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SAMPLE
Pre-enrichment
DNA extraction
Contact GP
Confirm pathogen
Results available 
<48 hours with pre-enrichment;
<24 hours without pre-enrichment
Selective enrichment
Selective
differential plating Real-time PCR 
amplification 
and automated 
reading
Amplification by 
conventional PCR
Analysis by gel 
electrophoraesis or 
other methods
Presumptive
identification
Biochemical 
identification
Results available in
3–5 days
Confirm
pathogen
Contact
GP
48 hours
1 hour
18 hours
<3 hours
48 hours
FIGURE 2 Simplified flowchart of culture methods versus PCR detection (all times approximated; several other algorithms possible)to ensure that DNA of comparable quality is
extracted from every sample.
● Laboratory set-up: False-positive results may be
caused by contamination, and very strict
guidelines must be adhered to, including the
separation of pre- and post-amplification
samples within the laboratory suite. 
● Lack of an isolate: A further limitation is that a
cultured specimen may still be required for
identification at the species level and for
epidemiological typing. Enrichment culture of
the faecal specimen would provide a simple
specimen preparation and a cultured isolate
available for subsequent confirmation.
Health Technology Assessment 2007; Vol. 11: No. 36
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his section summarises the methods used for
the systematic review and meta-analyses.
There were five stages of article appraisal:
1. search of databases and handsearching
2. abstract appraisal
3. full article appraisal of relevant evaluative
papers
4. data extraction and quality assessment
5. meta-analysis for homogeneous rapid test
methods and narrative synthesis of
heterogenous studies.
Search strategy
A search strategy was developed to find studies
that covered the main subject areas addressed in
this systematic review: infectious intestinal disease,
rapid diagnostic test methods and diagnostic
accuracy information. Literature was identified
from several sources, including electronic
databases and other sources. The following
databases were searched:
● MEDLINE (1966 to April 2005)
● EMBASE (1980 to April 2005)
● BIOSIS (1969 to April 2005)
● Web of Science (Science Citation Index) (1945
to April 2005)
● CINAHL (Cumulative Index to Nursing and
Allied Health Literature) (1982 to April 2005)
● AOAC Method Validation Programme (1992 to
April 2005).
The search strategy was developed initially for
MEDLINE. The MEDLINE search strategy was
subsequently modified for use in EMBASE,
CINAHL and BIOSIS databases. Details of
algorithms used are described in Appendix 1. 
A review of reference lists from all included
articles was undertaken. Attempts to identify
unpublished literature included contacting
manufacturers and searching the National
Research Register. Abstracts from conference
proceedings were included only if additional
information was available from the authors or
from other publications from that group.
International and national experts working the
fields relevant to each organism were contacted to
check the completeness of the searches conducted.
The following journals were also handsearched
from January 2000 to June 2005 to validate
electronic searching:
● Journal of Clinical Microbiology
● European Journal of Clinical Microbiology and
Infectious Disease
● Applied and Environmental Microbiology
● Journal of Medical Microbiology.
Updates to electronic databases were checked
throughout the data extraction period to ensure
inclusion of studies up to September 2005. 
A database of relevant articles was constructed
using Reference Manager 11. 
Selection of papers:
inclusion/exclusion criteria
Abstracts of all papers were appraised
independently by four members of the review
team (LI/IA for studies on rapid diagnostic
methods conducted on clinical samples and
CFA/GMW for food-based assays). 
The criteria for study inclusion in the systematic
review were as follows:
● Outcome measures: The main focus of this
review was to assess test accuracy. As a minimum,
included studies had to report summary
accuracy statistics (sensitivity and specificity), or
present sufficient raw data to allow these
statistics to be calculated when compared with a
suitable gold standard. Some articles were
identified that did not necessarily meet the
appraisal criteria, but contained detailed
descriptions of novel diagnostic techniques and
their technical efficiency, or referred to
economic costs of such methods. These were
obtained at the abstract appraisal stage for
potential use as background information.
● Tests performed on either human faecal
samples or food. A systematic review of clinical
diagnostic studies was performed at the
Health Technology Assessment 2007; Vol. 11: No. 36
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Systematic review methodsUniversity of East Anglia, with a supporting
review of rapid test technologies for food
samples undertaken at the Institute of Food
Research, Norwich. Tests evaluated on veterinary
samples were excluded from this review.
● Related to food poisoning: As some of the
organisms included in this review can cause
other clinical manifestations and syndromes
outside the intestinal tract, a significant number
of studies mixed the pool of samples so that
faecal specimens were only a fraction of those
tested. This was particularly evident with
S. aureus studies, where most studies evaluated
nasal or wound specimens. Despite an attempt
to eliminate studies focused on methicillin-
resistant strains in our search strategy, a large
number of staphylococcal diagnostic studies
identified were not relevant to our review. All
studies in which food-borne illness was not the
primary concern were excluded.
● Setting: Studies conducted in microbiology
laboratories were included in the review. 
● Study design: All studies that compared a new
test or strategy with an established reference
test in patients suspected of having the target
disorder were included. This could take the
form of inter-laboratory collaborative trials or
evaluation in a single laboratory. Both
retrospective and prospective study designs were
included, with their appropriateness considered
during quality assessment.
● Eligibility assessment: Full copies of articles were
obtained for papers meeting all three criteria.
When it was unclear whether one or more of
these criteria were satisfied, full articles were also
obtained to ensure search completeness. When
single articles evaluated more than one test
method, or evaluated them within more than one
study population, the component evaluations
were processed individually.
All clinical studies were assessed for inclusion by
two reviewers (LI and IA), and disagreements were
resolved by consensus. Following abstract
appraisal, it became apparent that very old studies
were generally of poor quality or technically
irrelevant. The decision was then made to include
only assays evaluated within the past 20 years (that
is, to exclude all studies pre-1985). 
Appendix 5 details all papers which were excluded
after initial review, with justifications.
Quality assessment criteria
Quality issues in diagnostic test studies are
considerably different from those in effectiveness
studies.34 Certain types of study designs are likely
to produce results that are more favourable to new
technologies than they should be. Non-
randomised, non-blinded trials commonly
overestimate the diagnostic accuracy of index
tests,35 and may lead to incorrect inferences. The
preferred study design for assessing test accuracy
is one which prospectively recruits all eligible
participants, uses a reference test to confirm or
refute the presence of disease, determines the
accuracy with which the index test identifies
disease and reports all results explicitly to allow
computation of summary statistics (recently,
guidelines for diagnostic evaluations have 
been produced by the TDR Diagnostic 
Evaluation Expert Panel36,37). Quality assessment
must take account of these, and other factors,
when measuring the validity and accountability 
of results from a wide range of evaluation 
studies. The Quality Assessment of Diagnostic
Accuracy Studies (QUADAS) tool was used to
assess the quality of diagnostic accuracy 
studies:236
QUADAS tool Yes No Unclear
1. Was the spectrum of patients  ( ) ( ) ( )
representative of the patients 
who will receive the test in 
practice?
2. Were selection criteria clearly  ( ) ( ) ( )
described?
3. Is the reference standard likely  ( ) ( ) ( )
to correctly classify the target 
condition?
4. Is the period between  ( ) ( ) ( )
reference standard and index 
test short enough to be 
reasonably sure that the target 
condition did not change 
between the two tests?
5. Did the whole sample, or a  ( ) ( ) ( )
random selection of the sample, 
receive verification using a 
reference standard of diagnosis?
6. Did patients receive the same  ( ) ( ) ( )
reference standard regardless 
of the index test result?
7. Was the reference standard  ( ) ( ) ( )
independent of the index test 
(i.e. the index test did not form 
part of the reference standard)?
8. Was the execution of the index  ( ) ( ) ( )
test described in sufficient detail 
to permit replication of the test?
9. Was the execution of the  ( ) ( ) ( )
reference standard described 
in sufficient detail to permit its 
replication?
10. Were the index test results  ( ) ( ) ( )
interpreted without knowledge 
of the results of the reference 
standard?
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results interpreted without 
knowledge of the results of the 
index test?
12. Were the same clinical data  ( ) ( ) ( )
available when test results were 
interpreted as would be available 
when the test is used in practice?
13. Were uninterpretable/ ( ) ( ) ( )
intermediate test results 
reported?
14. Were withdrawals from the  ( ) ( ) ( )
study explained?
Data extraction strategy
Extraction of study findings was conducted in
duplicate (by IA and LI) using a predesigned and
piloted data extraction form. Any disagreements
between reviewers were resolved by consensus. The
detailed forms used for each step are included in
Appendix 3. The form was used to collect
information on study design, methods, participants,
testing procedures and accuracy details. 
Extracted data from selected studies were entered
into a separate Excel spreadsheet independently
by two reviewers. Reviewers were not blinded to
the names of study authors, institutions or
publications. Where raw outcome data could not
be extracted from a paper, the authors were
contacted, with varying degrees of success. 
Basic statistical analysis
Diagnostic performance indices (sensitivity,
specificity, predictive values) were extracted from
each study. The number of false positives, true
positives, false negatives and true negatives 
were used to recalculate measures of accuracy for
each test compared with an appropriate reference
test:
Reference test
+–
+ a = TP b = FP A+b
– c = FN d = TN C+d
A + c B+dA +b+c+d
TPR = a/(a + c) 1– FPR = d/(b+d)
a = TP = the number of true positives, defined
as the number of individuals for
whom the test is positive and who
actually have the disease
b = FP = the number of false positives, defined
as the number of individuals for
whom the test is positive but who do
not have the disease
c = FN = the number of false negatives,
defined as the number of individuals
for whom the test is negative but who
actually have the disease
d = TN = the number of true negatives, defined
as the number of individuals for
whom the test is negative but who do
not have the disease.
TPR = sensitivity, defined as a/(a + c)
FPR = specificity, defined as d/(b + d)
PPV = positive predictive value, defined as 
a/(a + b)
NPV = negative predictive value, defined as 
d/(c + d)
Diagnostic odds ratio (DOR) = ad/bc
Studies reporting test accuracy were grouped
according to the index test evaluated, and the
sensitivity, specificity, DOR were calculated for
each evaluation. Due to the high sensitivity of
most NAA tests, a large proportion of cells in the
two-by-two table had zero entries. As is accepted
practice, 0.5 was added to each cell for studies
with either 100% sensitivity or specificity to
conduct meta-analyses.
With very high diagnostic accuracy estimates for
many rapid tests, generation of confidence
intervals (CIs) by conventional methods was not
appropriate. In this instance, the Wilson score
method was applied, to provide more precise
estimates of two-sided CIs for proportions.38,39
All data were presented in forest plots, with
horizontal lines representing 95% CIs for
estimates and size of points reflecting total sample
size. Statistical pooling was used where
appropriate (see below). Where there was evidence
of significant clinical heterogeneity, narrative
synthesis was used and a meta-analysis was not
conducted.
Statistical heterogeneity and use
of random/fixed-effect models 
Correlation of sensitivity and specificity
With diagnostic accuracy studies, the decision to
pool sensitivity and specificity results is dependent
on whether they are correlated. Spearman’s rank
correlation test can be applied to assess this. For
highly correlated data (estimated as Spearman’s 
 of |0.5| or above), sensitivity and specificity
estimates were combined using summary receiving
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t
e
s
t
Health Technology Assessment 2007; Vol. 11: No. 36
19
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.operating characteristic (SROC) curve analysis.
Where they were not correlated (i.e. Spearman’s 
 |0.5| or less), separate pooled measures of
sensitivity and specificity were presented in forest
plots.
Random or fixed-effect model
Where it was reasonable to assume that the
underlying diagnostic accuracy was the same in all
studies, and that the observed variation in
sensitivity or specificity is due entirely to sampling
variation, a fixed-effect model was applied. Where
heterogeneity existed, statistical analysis involved a
random-effects model.
If differences in the results cannot be attributed to
known sources of variation, pooling of the results
should not be attempted because it will not be
possible to interpret the summary estimate.40 A 
2 test (or Fisher’s exact test for small studies) was
used to test the hypothesis that there is no
statistically significant evidence of heterogeneity in
the DOR. This statistical test for differences in
proportions provides a conservative test of the null
hypothesis that the study results are
homogeneous. In addition, the I2 statistic was used
to assess heterogeneity.41
Summary receiver operating
characteristic curve and area
under the curve analysis
Within clinically appropriate groups, meta-analytic
methods were used to combine diagnostic studies
[all meta-analyses were carried out using SAS
(Version 9) and STATA (Version 9.0)]. There is no
universally accepted measure of test accuracy in
meta-analyses of screening and diagnostic data.
An SROC curve was generated for each
comparison and the area under the curve (AUC)
was used as the main measure of overall diagnostic
accuracy. The greater the AUC value, the higher is
the estimate of test accuracy. Summary estimates
of AUC were produced with 95% CIs.
Paired sensitivity and 1 – specificity results for
each study were plotted in the ROC plane to
display the trade-off between sensitivity and
specificity, detect heterogeneity, and identify
outliers.
Assuming the logarithm of the DOR = D:
D = ln(DOR) = ln[TPR/(1 – TPR)] ×
[(1 – FPR)/FPR]
and logarithm of S, a measure of test threshold:
S = ln[TPR/(1 – TPR)] × [FPR/(1 – FPR)]
D was plotted against S for each study and a line
(D = a + bS) was fitted to the data. Weighted
least-squares was used to fit this regression line.
Although extensions to this model exist
(incorporating other factors to explain
heterogeneity in the DOR) and more complex
models have been suggested utilising Bayesian
methods, this model seems appropriate, avoiding
unnecessary complexity particularly with relatively
small sample sizes.
The regression model used to fit the SROC curve
was used to test for potential threshold effects.
The logarithmically transformed DORs (lnDOR)
will be symmetrical around the line sensitivity =
specificity where studies are homogeneous, so any
variation in these end-points between studies can
be attributed to a threshold effect. 
Where there were three or fewer studies for a
particular test, SROC analysis was not presented
graphically; however, AUC values are still reported
in the text if this mode of analysis is most
appropriate (i.e. where sensitivity and specificity
are correlated).
Publication bias
Meta-analytic systematic reviews must assess the
magnitude of publication bias. There is
considerable emphasis on ‘significant’ (p < 0.05)
in academic journals, so studies which lack the
statistical power to detect a clinically important
effect may remain unpublished. Additionally, trials
of lower quality may yield exaggerated estimates
of diagnostic accuracy. The existence of
publication bias was examined graphically by the
use of funnel plots of log odds ratio (OR). These
were only presented for meta-analyses with four or
more studies, as visualisation of asymmetry is
difficult with a small number of studies. The Begg
and Mazumdar adjusted rank correlation test for
publication bias was used to assess statistical
evidence of publication bias; this estimate was
recorded for all meta-analyses.42 p-Value estimates
from the more powerful Egger’s test43 were also
presented.
Rapidity
There are two important aspects when evaluating
the rapidity of new diagnostic tests. Primarily, they
must detect a pathogen significantly faster than
the standard method. In addition, the hands-on
time requirement for technicians working with the
Systematic review methods
20assay should ideally be shorter than current
practice. The purpose of calculating ‘hands-on’
time was to allow separate calculation of
technician activity required and therefore the
accurate estimation of labour costs.
Where quantitative time estimates were reported,
these were extracted and used to derive summary
data, based on median values for time to detect
and hands-on time for each test method. For all
studies, qualitative assessments of detection time
and technician time requirements were provided.
Although many different testing algorithms 
could be assessed, this research is based on a
representative assessment of time taken to identify
each pathogen.
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The titles and abstracts of 1853 papers were
screened for eligible studies, the full text of 153
papers were retrieved for more detailed evaluation
and 87 studies of test accuracy were ultimately
included. Figure 3 shows a flowchart of the study
selection process. The reasons for exclusion of
studies are provided in Appendix 5.
Almost all relevant studies evaluated tests for E. coli,
Campylobacter or Salmonella. Very few studies
evaluating clinical diagnostic tests for intestinal 
C. perfringens, B. cereus and S. aureus were identified. 
Non-English language papers
The standardised search strategy identified 211
foreign language papers. A more stringent
inclusion criterion was applied to non-English
language papers. In an effort to review
comparable test methods, only papers which
evaluated assays and provided sufficiently
comparable data such as evaluation of commercial
tests were reviewed. Full translation was not
carried out on tests which were developed in-
house or are no longer commercially available. In
total, six non-English language articles were
included in the review.
Main test methods studied
Twenty-eight of the accepted studies concentrated
on antibody-based serological methods. Thirty-two
evaluated nucleic acid-based method and five
evaluated improvements to the traditional culture
technique. (This review may not be a reliable
indication of the volume of nucleic acid-based
tests being developed. Several studies were
identified in the search describing a new nucleic
acid-based test method; however, they were not
evaluated against any reference standard. These
studies make up a large proportion of excluded
studies, detailed in Appendix 5, and it is highly
likely that many more nucleic acid-based tests have
been developed without an assessment of
diagnostic effectiveness, which therefore would
have been missed by the search strategy.) Less
frequent test methods included oligonucleotide
assay, DNA hybridisation and hydrophobic grid
membrane filters (HGMFs), results of which have
been assessed in a narrative evaluation.
Setting and population
The study setting was not always reported, but
where it was, studies were conducted in either
hospital laboratories or publicly funded research
institutions. Five studies were produced from
collaborations between a number of laboratory
centres, the results of which may be more valid
than single-location evaluations, as reproducibility
and repeatability of test methods can be 
measured.
A limited number of clinical studies were found
from developing countries, most of which did not
meet the criteria of comparison against a gold
standard. Many of these assays were
technologically out of date. The review group
decided that it was inappropriate to use these for
the UK setting.
Study design
Given the low isolation rates for the organisms
studied, designing prospective evaluations of novel
rapid methods may prove prohibitively expensive
for some laboratories. The majority of studies
identified have been evaluated retrospectively,
using banked reference strains which have been
inoculated into healthy stools. Nucleic acid-based
detection methods in particular use this study
design. Seventeen prospective study designs were
identified – these involved large-scale, relatively
long-term evaluations, usually being sponsored or
partly funded by the manufacturer of the test
product involved.
The review of studies on clinical isolates was
restricted to the detection of enteric pathogens in
faecal samples, but there has been some research
carried out on the detection of antibodies from
saliva.44
Quality of included studies
The information gained in quality assessment is
important in determining the strength of
inferences. Quality differences may explain
heterogeneity in study results. The majority of
studies were retrospective. Problems with the
quality of data from diagnostic test papers are
compounded by how poorly they are reported.
Health Technology Assessment 2007; Vol. 11: No. 36
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Database search:
MEDLINE
EMBASE
BIOSIS
Web of Science
CINAHL
Additional searching: 
Handsearching of key journals; 
author contact.
Abstract appraisal: 
1853 papers Rejected: 1700 papers
Selection criteria not met
Rejected (insufficient 
information for assessment): 
 68 papers
10 review articles identified; 
15 studies selected for background
information, e.g. novel test 
methods introduced
Full article appraisal: 
153 papers
Data extraction: 
87 papers
Campylobacter
ID = 149
DEx = 26
Inc =13
PCR = 9
ELISA = 4
E. coli O157
ID = 961
DEx = 39
Inc = 27
PCR = 7
ELISA = 17
Salmonella
ID = 768
DEx = 26
Inc = 21
PCR = 8
ELISA = 7
Culture = 3
Bio ID = 3
B. cereus
ID = 56
DEx = 17
Inc = 9
Emetic = 5
Diarrhoeal = 4
PCR = 2
ELISA = 5
Other = 2
S. aureus
ID = 866
DEx =27
Inc = 7
PCR = 3
ELISA = 2
Other = 2
C. perfringens
ID = 89
DEx = 18
Inc = 10
PCR = 3
ELISA = 4
RPLA = 3
Abbreviations:
ID = total identified from search strategy, handsearching and author contact
DEx = undergone data extraction
Inc = included in this review
FIGURE 3 Flow diagram of the study selection processHealth Technology Assessment 2007; Vol. 11: No. 36
25
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
T
A
B
L
E
 
4
Q
U
A
D
A
S
 
s
c
o
r
e
s
 
f
o
r
 
i
n
c
l
u
d
e
d
 
s
t
u
d
i
e
s
A
l
l
 
A
l
l
 
A
l
l
A
l
l
 
A
l
l
 
A
l
l
 
C
a
m
p
y
l
o
b
a
c
t
e
r
 
E
.
 
c
o
l
i
 
S
a
l
m
o
n
e
l
l
a
B
.
 
c
e
r
e
u
s
S
.
 
a
u
r
e
u
s
 
C
.
 
p
e
r
f
r
i
n
g
e
n
s
p
a
p
e
r
s
 
p
a
p
e
r
s
 
p
a
p
e
r
s
p
a
p
e
r
s
 
p
a
p
e
r
s
 
p
a
p
e
r
s
 
(
n
=
 
1
3
)
(
n
=
 
2
4
)
(
n
=
 
2
0
)
(
n
=
 
1
0
)
(
n
=
 
6
)
(
n
=
 
1
5
)
W
a
s
 
t
h
e
 
s
p
e
c
t
r
u
m
 
o
f
 
p
a
t
i
e
n
t
s
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
 
o
f
 
t
h
e
 
p
a
t
i
e
n
t
s
 
w
h
o
 
w
i
l
l
 
8
1
8
1
2
1
0
6
r
e
c
e
i
v
e
 
t
h
e
 
t
e
s
t
 
i
n
 
p
r
a
c
t
i
c
e
?
W
e
r
e
 
s
e
l
e
c
t
i
o
n
 
c
r
i
t
e
r
i
a
 
c
l
e
a
r
l
y
 
d
e
s
c
r
i
b
e
d
?
9
1
1
1
2
0
0
5
I
s
 
t
h
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
 
l
i
k
e
l
y
 
t
o
 
c
o
r
r
e
c
t
l
y
 
c
l
a
s
s
i
f
y
 
t
h
e
 
t
a
r
g
e
t
 
c
o
n
d
i
t
i
o
n
?
1
1
2
4
1
9
1
3
6
I
s
 
t
h
e
 
p
e
r
i
o
d
 
b
e
t
w
e
e
n
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
 
a
n
d
 
i
n
d
e
x
 
t
e
s
t
 
s
h
o
r
t
 
e
n
o
u
g
h
 
4
1
8
1
4
1
3
0
t
o
 
b
e
 
r
e
a
s
o
n
a
b
l
y
 
s
u
r
e
 
t
h
a
t
 
t
h
e
 
t
a
r
g
e
t
 
c
o
n
d
i
t
i
o
n
 
d
i
d
 
n
o
t
 
c
h
a
n
g
e
 
b
e
t
w
e
e
n
 
t
h
e
 
t
w
o
 
t
e
s
t
s
?
D
i
d
 
t
h
e
 
w
h
o
l
e
 
s
a
m
p
l
e
,
 
o
r
 
a
 
r
a
n
d
o
m
 
s
e
l
e
c
t
i
o
n
 
o
f
 
t
h
e
 
s
a
m
p
l
e
,
 
r
e
c
e
i
v
e
 
1
3
2
1
2
0
1
4
6
v
e
r
i
f
i
c
a
t
i
o
n
 
u
s
i
n
g
 
a
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
 
o
f
 
d
i
a
g
n
o
s
i
s
?
D
i
d
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
 
t
h
e
 
s
a
m
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
 
r
e
g
a
r
d
l
e
s
s
 
o
f
 
t
h
e
 
1
3
2
4
2
0
2
2
3
i
n
d
e
x
 
t
e
s
t
 
r
e
s
u
l
t
?
W
a
s
 
t
h
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
 
i
n
d
e
p
e
n
d
e
n
t
 
o
f
 
t
h
e
 
i
n
d
e
x
 
t
e
s
t
 
(
i
.
e
.
 
t
h
e
 
1
3
2
1
1
7
3
3
6
i
n
d
e
x
 
t
e
s
t
 
d
i
d
 
n
o
t
 
f
o
r
m
 
p
a
r
t
 
o
f
 
t
h
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
)
?
W
a
s
 
t
h
e
 
e
x
e
c
u
t
i
o
n
 
o
f
 
t
h
e
 
i
n
d
e
x
 
t
e
s
t
 
d
e
s
c
r
i
b
e
d
 
i
n
 
s
u
f
f
i
c
i
e
n
t
 
d
e
t
a
i
l
 
t
o
 
1
1
1
9
1
1
9
5
8
p
e
r
m
i
t
 
r
e
p
l
i
c
a
t
i
o
n
 
o
f
 
t
h
e
 
t
e
s
t
?
W
a
s
 
t
h
e
 
e
x
e
c
u
t
i
o
n
 
o
f
 
t
h
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
 
d
e
s
c
r
i
b
e
d
 
i
n
 
s
u
f
f
i
c
i
e
n
t
 
8
1
8
1
0
3
4
2
d
e
t
a
i
l
 
t
o
 
p
e
r
m
i
t
 
i
t
s
 
r
e
p
l
i
c
a
t
i
o
n
?
W
e
r
e
 
t
h
e
 
i
n
d
e
x
 
t
e
s
t
 
r
e
s
u
l
t
s
 
i
n
t
e
r
p
r
e
t
e
d
 
w
i
t
h
o
u
t
 
k
n
o
w
l
e
d
g
e
 
o
f
 
t
h
e
 
1
2
1
8
1
7
1
0
1
7
r
e
s
u
l
t
s
 
o
f
 
t
h
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
?
W
e
r
e
 
t
h
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
 
r
e
s
u
l
t
s
 
i
n
t
e
r
p
r
e
t
e
d
 
w
i
t
h
o
u
t
 
k
n
o
w
l
e
d
g
e
 
1
3
1
8
1
0
1
0
0
3
o
f
 
t
h
e
 
r
e
s
u
l
t
s
 
o
f
 
t
h
e
 
i
n
d
e
x
 
t
e
s
t
?
W
e
r
e
 
t
h
e
 
s
a
m
e
 
c
l
i
n
i
c
a
l
 
d
a
t
a
 
a
v
a
i
l
a
b
l
e
 
w
h
e
n
 
t
e
s
t
 
r
e
s
u
l
t
s
 
w
e
r
e
 
i
n
t
e
r
p
r
e
t
e
d
 
1
0
1
8
7
0
0
5
a
s
 
w
o
u
l
d
 
b
e
 
a
v
a
i
l
a
b
l
e
 
w
h
e
n
 
t
h
e
 
t
e
s
t
 
i
s
 
u
s
e
d
 
i
n
 
p
r
a
c
t
i
c
e
?
W
e
r
e
 
u
n
i
n
t
e
r
r
u
p
t
i
b
l
e
/
i
n
t
e
r
m
e
d
i
a
t
e
 
t
e
s
t
 
r
e
s
u
l
t
s
 
r
e
p
o
r
t
e
d
?
8
1
7
7
5
5
1
W
e
r
e
 
w
i
t
h
d
r
a
w
a
l
s
 
f
r
o
m
 
t
h
e
 
s
t
u
d
y
 
e
x
p
l
a
i
n
e
d
?
2
8
1
1
0
0
1Evidence of clinical effectiveness
26
Few studies report any detailed information about
the patients being tested, or how reliable and
reproducible the test is among different
populations.
An analysis of papers using the QUADAS tool is
presented in Table 4.
Analysis of hands-on and total
time 
As stated earlier, the specific methods used in
various assays differed significantly. Table 5 reports
pooled estimates of the average hands-on time
and total time for rapid and traditional culture
methods from included studies. The actual time
taken to perform each individual assay differs
considerably. Therefore, these data are 
presented to illustrate the potentially shorter 
time required for rapid assays in general rather
than to give an accurate comparison of the
methods. 
Campylobacter
Number of studies
A total of 149 studies relating to rapid diagnostic
tests for Campylobacter food poisoning were
identified from the initial search strategy.
Following abstract appraisal, relevant data 
were extracted from 26 studies, and 13 of 
these were included in this review. Basic
information for all included studies is provided 
in Table 6.
Methodological quality of studies 
Quality of reporting was high (QUADAS >11) for
six studies and medium (QUADAS 6–10) for the
remaining seven studies included in this review.
However, data was extracted from several studies
(n = 12) which did not report full diagnostic
accuracy information and were of poor
methodological quality. These papers were
excluded from analysis (see Appendix 5). 
Correlation between sensitivity and
specificity, and tests for heterogeneity
Table 6 shows a very high correlation between
sensitivity and specificity for all rapid assays
evaluated for the diagnosis of campylobacterosis.
In view of this, summary estimates of 
sensitivity and specificity were not generated 
using meta-analysis. Where appropriate, 
pooled DORs and the AUC of an SROC 
curve are shown. 
There were three sets of studies with sufficient
data to allow meta-analysis. These evaluated the
antibody-based ProSpecT Campylobacter microplate
assay, PCR detection using 16s rRNA primer and
PCR detection using hippuricase gene (HipO). For
each of these three groups of studies, a single,
large study accounted for more than half of the
combined sample. As a result, pooled accuracy
measures link very closely with results from the
largest included study. 
Meta-analysis
Nucleic acid-based test methods
The majority of studies identified evaluated PCR
assays for Campylobacter food poisoning. Ten
studies reviewed NAA tests compared with a
suitable reference test and provided enough
diagnostic accuracy information to permit a meta-
analysis of results. PCR tests for Campylobacter were
comprised mainly (9/10 studies) of in-house-
designed assays.
Of evaluated PCR assays, the housekeeping 16s
rRNA gene was the predominant target for
Campylobacter species, with HipO gene regularly
used for the more specific detection of C. jejuni. A
summary of diagnostic accuracy values for 16s
rRNA Campylobacter PCR is shown in Table 7,
Figure 4 (forest plot of sensitivity and specificity)
and Figure 5 (forest plot of DORs). A fixed-effect
model was used to pool the DORs from each
group of PCR assay studies.
SROC analysis
Figure 6 shows a symmetrical SROC curve
(|b| < 0.001, p = 0.999) for PCR assays using the
16s rRNA primer to detect Campylobacter. A total
of 4495 samples were tested. The homogeneous
AUC from the SROC curve was 0.987 (95% CI
0.984 to 0.989).
HipO PCR for C. jejuni
Nucleic acid-based detection specifically for
C. jejuni targeted the hippuricase (HipO) genes. A
summary of diagnostic accuracy from individual
studies of HipO Campylobacter PCR is shown in
TABLE 5 Average hands-on and total time
Mean (standard deviation)
(hours)
Total time rapid methods 38.70 (20.90)
Hands-on time rapid 1.16 (0.50)
Total time traditional 72.00 (22.80)
Hands-on time traditional 0.88 (0.23)Health Technology Assessment 2007; Vol. 11: No. 36
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TABLE 7 Correlation between sensitivity and specificity, and tests for heterogeneity for studies evaluating rapid assays for the diagnosis
of Campylobacter food poisoning
Correlation Heterogeneity
Test No. of studies Spearman’s  p ( = 0) OR Pearson 2 pI 2 statistic (%)
16s rRNA PCR 6 0.714 0.111 1.05  0.958 0
HipO PCR 3 –1.000 – 2.41 0.300 17
ProSpecT EIA 4 0.738 0.262 3.93  0.270 23.6
 1.0
Maher 2003
0.90 (0.74 to 0.97)
0.88 (0.66 to 0.97)
0.94 (0.72 to 0.99)
0.89 (0.86 to 0.92)
1.00 (0.82 to 1.00)
0.94 (0.74 to 0.99)
hipO
La Gier 2004 1.00 ( 0.92 to 1.00)
Lawson 1998 0.81 (0.57 to 0.93)
Linton 1997 1.00 ( 0.82 to 1.00)
other
Amar 2004 0.83 (0.44 to 0.97)
Best 2003 0.98 (0.98 to 0.98)
Iijima 2004 0.84 (0.62 to 0.94)
Study
16s rRNA
Collins 2001
Kulkarni 2002
Lawson 1998
Lawson 1999
Linton 1997
Effect size
(95% CI)
Effect size
(95% CI)
Effect size (a)
Maher 2003
hipO
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Lawson 1998
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other
Amar 2004
Best 2003
Iijima 2004
Study
16s rRNA
Collins 2001
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Lawson 1998
Lawson 1999
Linton 1997
Effect size (b)
0.5 0.6 0.7 0.8 0.9 1.0
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  Odds ratio
 0.01  1.0 100 1000 10,000
 Study
Odds ratio
(95% CI)
 16s rRNA
 Collins 2001 322.14 (15.75 to 6587.09)
 Kulkarni 2002 481.50 (86.25 to 2687.92)
 Lawson 1998 905.00 (88.62 to 9242.49)
 Lawson 1999 327.51 (226.97 to 472.57)
 Linton 1997 377.40 (17.09 to 8334.06)
 Maher 2003 555.33 (54.52 to 5656.63)
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 Lawson 1998 261.44 (47.93 to 1425.96)
 Linton 1997 2035.00 (38.64 to 1.1 × 105)
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 other
 Amar 2004 425.00 (23.04 to 7839.64)
 Best 2003 2768.96 (167.70 to 45719.14)
 Iijima 2004 102.86 (24.17 to 437.78)
 Subtotal 291.54 (96.77 to 878.30)
FIGURE 5 Forest plot of DORs for PCR assays for Campylobacter food poisoning 
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FIGURE 6 SROC curve for PCR assays using the 16s rRNA primer
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FIGURE 7 Begg’s funnel plot of log DOR of PCR assay studies with 16s rRNA primer, with pseudo 95% CIs
Table 7. A heterogeneous AUC (b = 1.001,
p = 0.032) for the SROC curve for PCR 
targeting the HipO gene was 0.997 (95% CI 0.997
to 0.998).
Other PCR assays
Two other studies evaluated PCR assays for
Campylobacter. A commercially available PCR 
test kit, RealArt Campylobacter PCR kit, produced
by Artus45 was found to detect Campylobacter
in five out of six samples positive by culture 
and in one additional sample. It was negative 
in all 86 other samples. The test performed 
well with the small number of samples on 
which it was tested; however, the kit is produced
for research use only, and is not available for
routine diagnostic use. In another study,46 11
previously developed PCR assays for C. jejuni, C.
coli and C. lari were reviewed. Although accuracy
values were not explicitly recorded, the specificity
of assays varied from 84 to 100% and the
sensitivity ranged from 88 to 100%. No assay 
was 100% accurate; tests that yielded amplicons
from all C. jejuni strains proved to be the least
specific. 
Publication bias
Figure 7 shows the funnel plot for PCR studies with
16s rRNA primers. The adjusted Kendall’s score
obtained from Begg’s test for publication bias was
1.0 (p = 0.851) and 1.0 (p = 0.602) and the
Eggers test results were 202.17 (p = 0.139) and
2533.76 (p = 0.276) for 16s rRNA and HipO PCR
studies, respectively, indicating no evidence of
significant publication bias.
Antibody-based test methods
Only one commercial antibody-based test for
Campylobacter was identified in clinical studies.
Four studies evaluating the ProSpecT Campylobacter
microplate assay (Remel) provided enough
diagnostic accuracy information to be included in
meta-analysis.
Figures 8 and 9 show the results of studies
evaluating this assay. The estimates of sensitivity
were high and the minimum specificity from the
studies was 0.98. The pooled DOR was 462 (95%
CI 228.4 to 934.9) from a fixed-effect model
(Figure 9).
SROC analysis
A symmetrical SROC curve (|b|< 0.001,
p = 0.188) for the ProSpecT Campylobacter
microplate assay is shown in Figure 10. The AUC
of the SROC curve was 0.862 (95% CI 0.568 to
1.000). There did not appear to be uncertainty
over false positive results for these antibody-basedtests, such as those which may hinder
understanding of nucleic acid-based test
effectiveness. Culture methods, in this instance,
appear to be a suitable gold standard.
Publication bias
There was no statistical evidence of publication
bias (Begg’s test, Kendall’s score = –2, p = 0.624)
(Figure 11) and Eggers test results (slope 1270,
p = 0.333).
Discussion
The majority of tests for Campylobacter focus on the
detection of the two most common species,
C. jejuni and C. coli. However, various evaluation
studies suggest that that the prominence of
C. jejuni and C. coli over other species may be
exaggerated. A major drawback of culture
methods for Campylobacter, on epidemiological
grounds, is that the pre-enrichments necessary to
detect C. jejuni and C. coli eliminate the other
Health Technology Assessment 2007; Vol. 11: No. 36
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 Effect size (a)
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 Hindiyeh 2000 1.00 (0.99 to 1.00)
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  Odds ratio
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 Study Odds ratio (95% CI)
 Dediste 2003 1353.13 (168.3 to 40.89)
 Endtz 2000 1229.92 (12.34 to 4285.19)
 Hindiyeh 2000 1218.00 (207.78 to 7139.78)
 Tolcin 2000 2712.00 (240.17 to 30623.78)
 Overall 1462.04 (228.35 to 934.88)
FIGURE 9 Forest plot of DORs for PCR assays for Campylobacter food poisoning
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FIGURE 10 SROC curve for the ProSpecT Campylobacter microplate enzyme immunoassayspecies. A number of studies using PCR detection
methods12,47,48 predict that C. upsaliensis and
C. hypointestinalis are being missed in routine
culture. 
The overall sensitivity for 16s rRNA PCR was
lowered considerably by one study,48 a large-scale
collaborative trial of UK laboratories which
constituted the largest NAA-based evaluation study
performed on Campylobacter to date. The authors
reported that the time lag of 10 days between
culture and PCR detection may have artificially
reduced the sensitivity of nucleic acid-based
methods. It is therefore likely that in a routine
investigative circumstance, when samples 
would not sit for so long before testing, the
sensitivity of the test would be higher. This would
increase the summary estimate of 16s rRNA test
sensitivity.
It is important to note that although the numbers
of studies providing full evaluation with a
reference test are limited, a large number of
studies describe novel assays in development
which have not yet been validated by comparing
diagnostic accuracy with another test method.
These studies have been excluded from the final
review (Appendix 5). One excluded study49
developed a rapid duplex rtPCR assay for
speciation of C. jejuni and C. coli directly from
culture plates. This was a very large study
(involving over 6000 samples), but evaluation
against culture was not performed, and negative
samples were not included. 
Salmonella
Number of studies
The original search strategy identified 768 studies
relating to rapid diagnostic tests for Salmonella.
The majority of these were eliminated by
reviewing titles and abstracts. Most studies
identified on methods for Salmonella detection are
focused on food or veterinary samples. Following
appraisal of abstracts, 26 studies were subjected to
full text review and data extraction. Twelve clinical
studies, primarily describing PCR assays for
Salmonella detection, were excluded (Appendix 5).
Twenty-two studies were ultimately included in this
review. Basic information for all included studies is
provided in Table 8.
Methodological quality of studies 
The methodological quality of studies evaluating
Salmonella detection methods was high. Nine
studies scored QUADAS >10 (out of 14) and the
remaining 11 scored QUADAS 6–10. None of the
studies evaluating tests of Salmonella scored
QUADAS of 5.
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.Correlation between sensitivity and
specificity, and tests for heterogeneity
Where there is evidence of correlation (Spearman’s
 > 0.5), sensitivity and specificity estimates from
each study were presented but not pooled. Table 9
shows Spearman’s  and Pearson’s 2 test results
for rapid diagnostic assays for Salmonella infection.
Correlation was evident in PCR and Wampole
Bactigen results, therefore meta-analyses were
carried out for these assays, including AUC of a
SROC curve analysis. Due to the presence of
significant heterogeneity (Table 9) for all assays
based on the 2 test (and the exact test 
where appropriate), random-effect models 
were used.
Meta-analysis
Nucleic acid-based test methods 
In total, there were seven in-house-designed PCR
assays for use on clinical samples with sufficient
data for meta-analysis. The characteristics of
studies evaluating these assays are summarised in
Table 8. Four were reported to perform worse than
culture, one was equivalent and in two studies
authors concluded that PCR assays performed
significantly better than the traditional culture
method. More research is required to determine
whether the additional cases detected by PCR are
indeed true isolates. 
Figure 12 shows forest plots of sensitivity and
specificity of Salmonella studies with a random-
effect model. The pooled estimate of sensitivity
was 0.85 (95% CI 0.75 to 0.97) and the specificity
was 0.98 (95% CI 0.96 to 1.00). One study50 had
very low specificity, and the PCR assay by Luk and
colleagues51 had the lowest sensitivity. Both studies
were good-quality studies based on the QUADAS
score (Table 8). The Luk assay was developed to
detect Serogroup D Salmonella only, so although a
high proportion of false negatives were reported,
the assay succeeded in its more specific objective.
Such a narrow focus is not appropriate in the
routine diagnostic laboratory. Although the quality
of the Chiu study was high (QUADAS = 11), it
had a notably small sample size (n = 57). 
Figure 13 shows the DORs from these studies. The
DOR values for PCR were the most varied,
reflecting the greatest variation in sample sizes for
these studies (range 57–1204). All the studies had
very high DORs.
Publication bias
There was no statistical evidence of publication
bias (Figure 14, Begg’s test, Kendall’s score = 7,
p = 0.293; Egger’s test bias = 1063, p = 0.714).
Non-molecular-based methods 
The characteristics of the studies evaluating non-
molecular-based tests are summarised in Table 8.
Wampole Bactigen
The Wampole Bactigen latex agglutination test
was evaluated in four studies. All these studies
were carried out in the late 1980s in the USA, and
the current UK availability of this kit remains
unclear. The kit is used as an early screen for
Salmonella and Shigella, with negative samples
eliminated within 24 hours, and a further
24 hours needed to identify positive samples
biochemically. All studies concluded that the
Salmonella test may be useful as an enrichment
broth screening test to detect Salmonella spp.;
however, given the low positive predictive value of
the kit, parallel primary plating of samples is
used. The sensitivity and specificity estimates are
shown in a forest plot (in Figure 15). The
sensitivities and specificities of the assay from each
study were very high. The summary estimate of
sensitivity was 0.932 (95% CI 0.850 to 1.015) and
that for specificity was 0.967 (95% CI 0.950 to
0.985) using a random-effects model. A pooled
estimate of the DOR (264.3, 95% CI 116.9 to
597.6) was determined (Figure 16). 
Publication bias
Begg’s test for Wampole Bactigen assays produced
a Kendall’s score of 6 (p = 0.089), and Eggers test
produced bias 1653 (p = 0.303), hence no
publication bias was evident. 
Wellcolex Colour Salmonella test
The Wellcolex Colour Salmonella test is a rapid latex
agglutination test designed to detect Salmonella
antigens in stool enrichment broth or from culture
plates. Latex particles are colour coded with
antibodies specific for Salmonella serogroups A–E
and G, and Vi antigen, which makes it more specific
than other commercial latex test systems. This
review found that the above test was most commonly
assessed following enrichment in selenite F broth,
and compared with traditional culture methods.
Measures of diagnostic accuracy from each of the
three evaluative studies are shown in forest plots
(Figures 15 and 16). The summary DOR was 2951
(95% CI 710.9 to 12,000) using a fixed-effect model
(no evidence of heterogeneity, I2 = 0%). The
Wellcolex Colour Salmonella test produced the
highest pooled DOR. SROC analysis was not carried
out because there are only three eligible studies.
AutoMicrobic Enteric Pathogen Screen cards
Three studies evaluated the AutoMicrobic EPS
system against a reference standard of
Evidence of clinical effectiveness
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TABLE 9 Correlation between sensitivity and specificity, and tests for heterogeneity for studies evaluating rapid assays for the diagnosis
of Salmonella infection
Correlation Heterogeneity
Test No. of studies Spearman’s  p ( = 0) OR Pearson 2 pI 2 statistic (%)
PCR 7 0.296 0.518 45.66 0.001 86.9
MUCAP 4 0.889 0.111 4.38 0.223 31.5
Wellcolex 3 0.500 0.667 0.45 0.797 0
AutoMicroBic 3 –0.500 0.667 15.40 0.001 87.0
Wampole Bactigen 4 0.105 0.895 4.4 0.221 31.5
FPR, false positive rate; TPR, true positive rate.
   Effect size (a)
0.5 0.6 0.7 0.8 0.9 1.0
 
0.5 0.6 0.7 0.8 0.9 1.0
 Study   Effect size (95% CI)
 Alvarez 2004   0.93 (0.79 to 0.98)
 Amar 2004   0.75 (0.30 to 0.95)
 Chiu 1996   0.91 (0.72 to 0.97)
 Farrell 2003   1.00 (0.91 to 1.00)
 Iijima 2004   0.82 (0.52 to 0.95)
 Luk 1997   0.57 (0.48 to 0.64)
 Malorney 2003   0.96 (0.94 to 0.97)
 Overall   0.86 (0.75 to 0.97)
   Effect size (b)
 Study   Effect size (95% CI)
 Alvarez 2004   1.00 (0.96 to 1.00)
 Amar 2004   1.00 (0.96 to 1.00)
 Chiu 1996   0.49 (0.33 to 0.64)
 Farrell 2003   1.00 (0.98 to 1.00)
 Iijima 2004   0.96 (0.92 to 0.98)
 Luk 1997   1.00 (0.94 to 1.00)
 Malorney 2003   0.99 (0.98 to 1.00)
 Overall   0.98 (0.96 to 1.00)
FIGURE 12 Forest plots of studies showing (a) the sensitivity and (b) the specificity of evaluating PCR assays for Salmonella detectionEvidence of clinical effectiveness
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Odds ratio
0.01  1.0  100  1000  10,000
 Study   Odds ratio (95% CI)
 PCR
 Alvarez 2004   2063.40 (96.23 to 44245.99)
 Amar 2004   413.00 (14.14 to 12059.32)
 Chiu 1996   9.44 (1.91 to 46.66)
 Farrell 2003   13614.33 (545.01 to  3.4 × 105)
 Iijima 2004   108.00 (19.03 to 612.99)
 Luk 1997   152.01 (9.22 to 2506.70)
 Malorney 2003   2293.16 (967.28 to 5436.46)
 Subtotal   406.16 (50.87 to 3243.00)
FIGURE 13 Forest plot of DORs for PCR assays for Salmonella
FIGURE 14 Begg’s funnel plot of log DOR for studies evaluating the PCR detection of Salmonella, with 95% CIs
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15conventional biochemical test media.52–54 (Notably,
all studies retrieved for EPS were carried out in
the late 1980s. The system is still commercially
available in the UK from BioMerieux-Vitek, but
several modifications may have taken place since
then. Unfortunately, evaluations of current systems
used on clinical samples could not be found. It
would be useful to know if the level of false
positive results has improved since these studies
took place.) This system is able to detect
Salmonella, and also the less common pathogens
Shigella, Yersinia enterocolitica and Edwardsiella spp.
A preliminary diagnosis can be achieved within
6 hours of incubation, allowing correct clinical
decisions to be made the next day from receiving
samples (24 hours earlier than conventional
methods). The sensitivity and specificity estimates
from these studies are summarised in Figure 15.
Figure 16 shows the meta analysis of DORs (365.5,
95% CI 30.2 to 4421.1) from the three included
studies. Due to the limited number of studies, an
SROC analysis was not carried out.
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  (a) Effect size
0.5 0.6 0.7 0.8 0.9 1.0
 Study  Effect size (95% CI)
 AutoMicroBic
 Geers 1989   0.87 (0.68 to 0.95)
 Imperatrice 1993   0.99 (0.97 to 1.00)
 Villasante 1987   0.99 (0.96 to 1.00)
 MUCAP Test
 Abdalla 1994   1.00 (0.86 to 1.00)
 Aguirre 1990   0.79 (0.60 to 0.91)
 Manafi 1994   0.77 (0.59 to 0.88)
 Munoz 1993   1.00 (0.98 to 1.00)
 Wampole Bactigen
 Fedorka 1989   1.00 (0.82 to 1.00)
 Geers 1988   1.00 (0.84 to 1.00)
 McGowan 1989   0.86 (0.78 to 0.91)
 Metzler 1988   0.86 (0.69 to 0.95)
 Wellcolex
 Bouvet 1992   0.98 (0.95 to 0.99)
 Hansen 1993   1.00 (0.91 to 1.00)
 Rohner 1992   0.87 (0.73 to 0.94)
   Effect size (b)
0.5 0.6 0.7 0.8 0.9 1.0
 Study  Effect size (95% CI)
 AutoMicroBic
 Geers 1989   0.85 (0.82 to 0.88)
 Imperatrice 1993   0.90 (0.82 to 0.95)
 Villasante 1987   0.91 (0.87 to 0.94)
 MUCAP Test
 Abdalla 1994   0.58 (0.39 to 0.74)
 Aguirre 1990   1.00 (0.96 to 1.00)
 Manafi 1994   1.00 (0.94 to 1.00)
 Munoz 1993   0.92 (0.90 to 0.94)
 Wampole Bactigen
 Fedorka 1989   0.94 (0.92 to 0.95)
 Geers 1988   0.99 (0.98 to 1.00)
 McGowan 1989   0.97 (0.97 to 0.98)
 Metzler 1988   0.97 (0.95 to 0.97)
 Wellcolex
 Bouvet 1992   1.00 (0.74 to 1.00)
 Hansen 1993   0.98 (0.97 to 0.99)
 Rohner 1992   1.00 (0.99 to 1.00)
FIGURE 15 Forest plots of studies showing (a) the sensitivity and (b) the specificity of the Wellcolex Colour, MUCAP , Wampole
Bactigen and AntiMicrobic EPS assays for SalmonellaMUCAP test
The MUCAP test is a rapid method for the
presumptive detection of Salmonella spp. which
can potentially reduce the work and material
involved in testing by selecting samples requiring
further assessment. A total of eight comparisons
were carried out on the MUCAP test. Figure 15
shows estimates of sensitivity and specificity from
each study, all of which are high except the study
by Abdalla and colleagues,55 where the specificity
was 0.58 (95% CI 0.39 to 0.74). A high pooled
DOR of 543.8 (95% CI 95.5 to 3097.2) was
obtained (Figure 16).
Publication bias
There was no statistical evidence of publication
bias using Begg’s test (Wellcolex test Kendall’s
score = –1, p = 0.602, MUCAP test Kendall’s 
score = 2, p = 0.805, and AutoMicrobic EPS
Kendall’s score = 1, p = 0.602,). Egger’s test was
similarly not significant for Wellcolex test (–857.5,
p = 0.835), MUCAP test (0.0051, p = 0.067) and
AutoMicrobic EPS (3704.1, p = 0.257).
Culture-based methods
A large proportion of studies focusing on
Salmonella detection compared different culture-
based methods, as opposed to evaluating ‘rapid’
methods such as PCR or immunoassays. This
review identified at least 10 studies evaluating
commercially available chromogenic agar plates
(see Appendix 5). These assays use a combination
of chromogenic substrates and conventional
biochemical tests, and are more specific than
traditional culture methods. Chromogenic agar
plates can reduce the workload with regard to
unnecessary examination of suspect colonies,
saving time, supplies and money; however, they do
not reduce the time needed to detect isolates by
more than 1 day, and therefore cannot be
considered ‘rapid’.
Discussion
In view of the high prevalence and strong media
attention given to Salmonella infections, it is
surprising that evaluative studies for rapid
diagnostic test methods are relatively scarce. This
review identified three key latex agglutination kits,
evaluations of which had all been carried out in
the late 1980s. Studies evaluating nucleic acid
detection methods have been published more
frequently in recent years, but the number of
developmental, non-evaluative studies far
outweighs those in which the PCR assay has been
evaluated against a suitable reference test. The
most well developed and methodologically sound
Evidence of clinical effectiveness
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Odds ratio
0.01  1  100  1000  10,000
 Study Odds ratio (95% CI)
 AutoMicroBic
 Geers 1989   39.20 (11.34 to 135.59)
 Imperatrice 1993   1669.88 (205.21 to 13588.65)
 Villasante 1987   949.90 (222.73 to 4051.13)
 Subtotal   365.49 (30.21 to 4421.06)
 MUCAP Test
 Abdalla 1994   66.04 (3.63 to 1202.68)
 Aguirre 1990   719.73 (38.23 to 13550.93)
 Manafi 1994   416.73 (22.90 to 7582.06)
 Munoz 1993   3963.84 (244.14 to 64355.71)
 Subtotal   543.77 (95.47 to 3097.20)
 Wampole Bactigen
 Fedorka 1989   502.33 (29.79 to 8469.92)
 Geers 1988   4168.33 (217.07 to 80043.72)
 McGowan 1989   216.42 (116.81 to 401.00)
 Metzler 1988   174.51 (57.86 to 526.33)
 Subtotal   264.28 (116.87 to 597.59)
FIGURE 16 Forest plot of DORs for non-molecular based assays for Salmonella. Studies evaluating the Wellcolex assay are not
presented in this figure because they were pooled using a fixed-effect model.research on Salmonella detection relates to
improvements in culture methods, which,
although useful to a laboratory user, do not
significantly improve the speed of microbiological
detection.
Escherichia coli O157 and other
shiga toxin-producing E. coli
Number of studies
A total of 916 studies relating to rapid diagnostic
tests for E. coli were identified from the initial
search strategy. Of these, 123 related specifically to
the E. coli O157 strain and 153 focused on all
shiga toxin-producing E. coli (STEC) strains.
Following appraisal of abstracts, 40 published
articles were reviewed as background information
only, relevant data were extracted from 39 studies
and 27 of these were included in this review. Basic
information for all included studies is provided in
Table 10.
Of the 27 studies included in this review, 10 used
PCR methods and 12 used antibody-based
techniques. PCR and antibody-based tests were
compared in five studies. Fourteen studies were
suitable for meta-analysis. 
Methodological quality of studies 
The methodological quality of studies evaluating
E. coli rapid assays was relatively high compared
with that for other pathogens. Seventeen of the 26
studies were of ‘high’ quality (QUADAS >11)
quality, seven were of medium quality (QUADAS
= 6–10), and only two were of poor quality
(QUADAS <5).
Correlation between sensitivity and
specificity, and tests for heterogeneity
Significant correlation between sensitivity and
specificity was observed except for Premier EHEC
(Table 11). The sensitivity and specificity of studies
evaluating Premier EHEC assay were therefore
pooled. Random effects models were used for the
meta-analysis where appropriate because the
studies all showed significant evidence of
heterogeneity.
Meta-analysis
Nucleic acid amplification tests
PCR diagnosis of E. coli was predominantly
centred on detection of shiga toxin genes, often
referred to as stx1 and stx2 present in STEC. The
review identified 12 studies in which novel assays
were developed around stx1 and stx2: eight of
these contained sufficient comparative statistical
data to enable meta-analysis. PCR for the
detection of the eae gene was additionally
evaluated in four studies.
Figure 17 shows forest plots of sensitivity and
specificity of E. coli O157 studies with random-
effect model. 
A total of 4746 samples were tested with stx PCR
assays. Further details are provided in Table 10.
Sensitivity estimates for EHEC studies were
consistently high (lowest 0.82); however, they had
wide 95% CIs. Of the three test methods
evaluated, PCR assays provided the highest
sensitivity value and narrowest 95% CI. 
Figure 18 shows DORs from these studies. There
was some variation in DOR values for PCR assays
for EHEC. The lowest DOR value was observed in
the study by Paton and colleagues,56 with a sample
size of 183, whereas the very large study by
Welinder-Olsson and colleagues57 had a DOR of
290,000. This illustrates the problem of using
DOR as a summary estimate when specificity is
very high and sample sizes vary widely.
The SROC curve (Figure 19) is symmetrical
(|b|< 0.001, p = 0.141). Therefore, a
homogeneous estimate of the AUC was calculated.
The AUC of the SROC curve was 0.996 (95% CI
0.990 to 1.000).
Publication bias
Meta-analysis of studies evaluating the PCR
detection of stx genes in E. coli shows evidence of
asymmetry (Figure 20). Begg’s test found
statistically significant evidence of publication bias
(Kendall’s score = 15, p = 0.024). In contrast, the
result of Egger’s test was not significant (87,824,
p = 0.771).
Antibody-based tests
This review identified 17 shiga-like toxin ELISAs
that are commercially available in kit form. Of
these, five were evaluated against a suitable
reference test. 
Tests of pure isolates show that the specificities of
the various stx ELISAs are in close agreement 
with the results of Vero cell cytotoxicity assays
(VCAs), the most appropriate reference test for the
detection of STEC. On clinical samples, ELISAs
were generally less sensitive than VCAs. Broadly
comparing all immunoassay tests included in the
meta-analysis, testing almost 4000 clinical samples,
individual sensitivities ranged from 0.824 to 1.000
and specificities ranged from 0.667 to 1.000.
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   Effect size (a)
0.6 0.7 0.8 0.9 1.0 0.5
 Study   Effect size (95% CI)
 Belanger 2002
 Beutin 2002
 Paton 1998
 Paton 2005
 Ramotar 1995
 Welinder-Olsson 2000
 Welinder-Olsson 2004
  1.00 (0.87 to 1.00)
  1.00 (0.93 to 1.00)
  1.00 (0.83 to 1.00)
  0.89 (0.83 to 0.93)
  0.94 (0.82 to 0.98)
  1.00 (0.93 to 1.00)
  1.00 (0.70 to 1.00)
   Effect size (b)
0.5 0.6 0.7 0.8 0.9 1.0
 Study   Effect size (95% CI)
 Belanger 2002   0.92 (0.65 to 0.99)
 Beutin 2002   0.96 (0.91 to 0.98)
 Paton 1998   1.00 (0.98 to 1.00)
 Paton 2005   1.00 (0.76 to 1.00)
 Ramotar 1995   1.00 (0.96 to 1.00)
 Welinder-Olsson 2000   1.00 (1.00 to 1.00)
 Welinder-Olsson 2004   0.96 (0.87 to 0.99)
FIGURE 17 Forest plots of studies showing (a) the sensitivity and (b) the specificity of stx PCR for E. coli detection
TABLE 11 Correlation between sensitivity and specificity, and tests for heterogeneity for studies evaluating rapid assays for the
diagnosis of E. coli food poisoning
Correlation Heterogeneity
Test No. of studies Spearman’s  p ( = 0) OR Pearson 2 pI 2 statistic (%)
stx PCR 7 0.647 0.116 15.2 0.019 60.5
Premier EHEC 5 0.177  0.776 7.28 0.122 45.1
VTEC Screen 5 –0.671 0.215 14.7 0.005 72.8Health Technology Assessment 2007; Vol. 11: No. 36
45
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Odds ratio
0.01 1 100 1000 10,000
 Study   Odds ratio (95% CI)
 Belanger 2002   406.33 (15.37 to 10740.28)
 Beutin 2002   2239.59 (127.21 to 39427.92)
 Paton 1998   12831.00 (247.57 to  6.7 × 105)
 Paton 2005   195.51 (11.13 to 3433.58)
 Ramotar 1995   2359.80 (110.43 to 50428.98)
 Welinder-Olsson 2000    2.9 × 105 (11606.45 to 7.1 × 106)
 Welinder-Olsson 2004   368.60 (16.36 to 8305.62)
FIGURE 18 Forest plot of DORs for stx PCR assays for E. coli food poisoning
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FIGURE 19 SROC curve for stx PCR tests for E. coliForest plots for sensitivity, specificity and DORs 
for antigen-based tests for EHEC are provided 
in Figures 21 and 22). Sensitivity estimates for
Premier EHEC and VTEC Screen assays were
generally high (lowest estimate 0.82). There 
was one notable outlier in specificity for 
EHEC non-molecular assays. Chart and
colleagues,64 evaluating VTEC Screen assay, 
had a specificity estimate of 0.67, which is 
0.25 lower than the second lowest. The quality 
of this study was medium (QUADAS = 9);
however, it had a very small sample size 
(n = 15).
Premier EHEC (Meridian Diagnostics)
Meridian Diagnostic’s Premier EHEC test kit was
evaluated against SMAC culture and a Vero cell
cytotoxicity assay in six studies.32,33,58–61 Based on
evidence of its diagnostic performance, the
Premier EHEC kit provides an alternative test
method when cytotoxin assay or PCR is neither
feasible nor accessible. A total of 4741 samples
were tested in the four studies. Pooled estimates 
of sensitivity and specificity were calculated 
using random-effect models. The pooled 
estimate of sensitivity and specificity for this assay
were 0.926 (95% CI 0.867 to 0.985) and 0.998
(95% CI 0.996 to 1.001), respectively. The pooled
DOR was similarly high (3755.0, 95% CI 795.5 to
17726.2). 
VTEC Screen (Denka Seiken)
Five studies evaluating Denka Seiken’s VTEC
Screen were identified.58,62–65 This commercial test
kit uses reversed passive latex agglutination to
detect shiga-like toxins. The reference test used
was verocell cytoxicity, and in some cases
additional stx gene-specific PCR. Promising in
terms of ease of use and performance, the VTEC
Screen test kit has considerable potential to
improve STEC detection and isolation rates in
routine clinical diagnostic laboratories, especially
for non-O157 STEC and sorbitol-fermenting
E. coli O157. The VTEC Screen assay was
evaluated in five studies (Table 10). The pooled
DOR was high [1224.1 (95% CI 117.5 to 13,000)].
A symmetrical SROC curve (b = 0.172, p = 0.906)
was plotted (Figure 23) and a homogeneous AUC
of the SROC curve was calculated [AUC = 0.994
(95% CI 0.982 to 1.000). There was no statistical
evidence of publication bias (Begg’s test Kendall’s
score = 2, p = 0.624).
Assays ineligible for meta-analysis
ProSpecT Shiga Toxin E. coli
The ProSpecT Shiga Toxin E. coli microplate
(Oxoid) was evaluated in one study. Gavin and
colleagues66 conducted a large-scale prospective
evaluation of this commercial ELISA kit over two
consecutive summers. They concluded that the kit
Evidence of clinical effectiveness
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FIGURE 20 Begg’s funnel plot of DORs for stx PCR assays, with 95% CIscould detect equal numbers of E. coli O157 as
SMAC culture, with the potential to detect twice as
many non-O157 STEC. This study recommends
adoption of virulence factor-based tests such as the
ProSpecT kit for routine diagnostic use.
ImmunoCard STAT! O157:H7
The ImmunoCard STAT! (ICS) test (Meridian
Diagnostics) attempts to detect E. coli by targeting
O157:H7 strains only, which are most commonly
associated with severe secondary illnesses such as
HUS. In this sense, the most appropriate
reference test to use is culture with SMAC, as this
method also attempts to isolate the O157 strain to
the exclusion of others. Authors have evaluated
the ICS test accordingly. The test kits performed
equally well as culture;67,68  however, in a larger
retrospective component, the sensitivity of the test
was relatively low (81%) compared with other
methods.
Health Technology Assessment 2007; Vol. 11: No. 36
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   Effect size (b)
0.5 0.6 0.7 0.8 0.9 1.0
 Study  Effect size (95% CI)
 Premier EHEC
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FIGURE 21 Forest plots of studies showing (a) the sensitivity and (b) the specificity of non-molecular assays for E. coli detectionEvidence of clinical effectiveness
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FIGURE 22 Forest plot of DORs for antibody tests for E. coli food poisoning
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FIGURE 23 SROC curve for studies evaluating the VTEC Screen (Denka Seiken) for the detection of E. coliImmunochromogenic assays
The most comprehensive investigation of the
efficacy of the IMS method for the isolation of
E. coli O157 is that of Karch and colleagues.69 This
method involves a selective enrichment step using
O157-specific antibodies attached to paramagnetic
particles to enhance detection. Thirty children with
HUS were examined. EHEC O157 strains were
isolated from stool samples of 18 patients and non-
O157 EHEC strains were isolated from five
patients. The IMS method detected EHEC O157 in
all 18 samples compared with seven using sorbitol
SMAC and cefixime–tellurite SMAC. However, this
method did not detect non-O157 E. coli strains.
Duopath Verotoxin
Illustrating the potential benefits of applying
methods from the food industry to clinical practice,
Park and colleagues70 evaluated the clinical use of
Duopath Verotoxin, an immunochromographic
test developed for confirmation of STEC strains
from food products. Clinical stool samples were
retrospectively and prospectively tested by the
Premier EHEC assay as the reference test for
determination of the performance of the Duopath
Verotoxin test. Concordance between the two
methods was very high.
Real-time versus conventional PCR: concordance
To test the comparability of results between rtPCR
and conventional PCR assays, Reischl and
colleagues71 developed two duplex assays (stx1 and
stx2; eae and E-hly) for use with the LightCycler
instrument. From 622 reference strains,
concordance with conventional equipment was
observed in all but 10 specimens, which were not
of human origin. By automating the methods,
time requirements were reduced by an estimated
4–4.5 hours.
ELISA versus conventional PCR versus rtPCR
Pulz and colleagues22 compared the diagnostic
accuracy of a novel PCR assay using LightCycler
instrumentation to that of both conventional PCR
and immunoassay in a prospective evaluation of
295 faecal samples. rtPCR performed slightly
better than the conventional methods. Comparing
both PCR methods with the immunoassay
(RIDASCREEN Verotoxin ELISA, R-Biopharm),
significantly more STEC-positive stool specimens
were identified by the nucleic acid-based
techniques.
Discussion
Considerable controversy exists as to whether
SMAC culture methods are appropriate for the
detection of E. coli.72 The selective enrichment
involved with SMAC is designed predominantly
for the O157 strain, and may have an inhibitory
effect on other (non-O157) strains producing
shiga-like toxins. In choosing a rapid test to detect
E. coli, it is important for policy makers to
ascertain the significance of these non-O157
strains.73 For example, Karch and colleagues69
found that sole reliance on SMAC agar would
underdetect 28% of STEC, and sole reliance on
enzyme immunoassay (EIA) would underdetect
11% of E. coli O157:H7 organisms. The choice of
a rapid test for E. coli depends on the significance
and prevalence of non-O157 strains. Within the
UK, serious complications, and subsequent media
coverage, have largely been associated with E. coli
O157 strains. There is, however, evidence from
some other European countries that non-O157
strains may be equally harmful. In Germany,
Gunzer and colleagues74 recovered 44 isolates of
shiga-like-toxin (SLT) producing non-O157 E. coli
strains and only 18 isolates belonging to serogroup
O157 from 668 diarrhoeal stool specimens. Given
the low sensitivity associated with SMAC for non-
O157 strains, it is likely that several of these may
have been missed in routine investigation, leaving
the true prevalence hard to estimate. New test
methods with improved detection of non-O157
strains may have the potential to bridge this gap in
knowledge, delivering not only faster diagnosis,
but increasing the likelihood of pathogen detection
in routine investigation.
Some of the studies included have a number of
limitations. For instance, Kehl and colleagues
sought toxins on frozen stools.32 Due to freezing
and thawing potentially liberating toxin, and the
lack of use of freezing and thawing in the
protocols of currently used tests, this study was
excluded in a sensitivity analysis but the overall
results remain stable. Some studies, such as that of
Park and colleagues,70 did not perform a rapid
test on stool. Stool samples were inoculated into
broth, and the broth was subsequently tested for
the presence of shiga toxin. These assays may not
be truly ‘rapid’ because standard culture could also
be positive that day, and a rapid antigen test on a
suspect sorbitol non-fermenting colony
(identifying E. coli O157:H7) could obtain the
same information as the toxin assay.
The incidence of E. coli, and hence the isolation
rate in routine culture, are considerably lower than
for other food-borne pathogens, such as
Campylobacter, Salmonella and Yersinia. Occasionally,
research has prompted the use of testing strategies
when stool samples are submitted for culture, such
as only testing for E. coli in infant samples or if
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appear attractive in terms of laboratory resource
use and labour requirements, it is unclear if this
would prove cost-effective in the long run. If more
expensive rapid test methods are adopted, the use
of triage may be advisable. 
Clostridium perfringens
Illness due to C. perfringens results from ingestion
of large numbers of vegetative cells, which
subsequently produce an enterotoxin (cpe) after
sporulating in the gut. Spore count should be
interpreted with caution and the presence of
enterotoxin may be more informative.75
C. perfringens enterotoxin is not usually produced
in foods; therefore, assays for cpe in foods are not
very meaningful.
Number of studies
The initial search strategy identified 89 studies
evaluating rapid detection tests for C. perfringens
in clinical specimens. Following abstract appraisal,
19 were subjected to full critical appraisal and data
extraction. Ten of these have been included in this
review. Basic information for all included studies is
provided in Table 12.
Contemporary research on C. perfringens detection
has focused on environmental and veterinary
testing.76,77 There has been scarce published
research on clostridial food poisoning in clinical
laboratories in the last decade. Of the 10 studies
included in this review, three developed PCR
assays and seven investigated serological methods.
Four studies evaluated the rapid tests with a
reference standard and six could measure
diagnostic accuracy through the use of known
reference strains.
Methodological quality of studies
Studies evaluating rapid detection of C. perfringens
enterotoxin were of varying quality. Only four
studies were identified in the review in which a
rapid assay was evaluated against a suitable
reference standard using a reasonably large
sample size (>100). A number of studies which
did not include a full diagnostic comparison are
included in this review, to allow a fuller
understanding of research in the area.
Antibody-based tests
Commercial kits identified to test for C. perfringens
enterotoxin include PET-RPLA (Oxoid), which
uses RPLA, and the TechLab C. perfringens test,
based on an EIA technique.
TechLab immunoassay was evaluated, using an in-
house ELISA test previously designed by the Food
Safety Microbiology Laboratory (FSML) as a
reference.78 The authors found the commercial kit
to be significantly less sensitive than the in-house
method (33.9% compared with 100%). No other
evaluations of this product were identified, and its
performance characteristics have not been
established.
Oxoid’s PET-RPLA was compared with an in-
house designed ELISA in one study,79 testing 131
faecal specimens from food poisoning outbreaks.
A high (94%) concordance rate was reported
between the two methods, with discrepancies
ascribed to either a low toxin concentration or
non-specific interference in the PET-RPLA. The
same authors later tested 392 faecal specimens
from food poisoning outbreaks by Vero cell assay,
PET-RPLA and in-house ELISA methods.79 The
Vero cell assay was the least sensitive and
reproducible method, detecting only 30.00% of all
enterotoxins. ELISA and PET-RPLA sensitivity
rates were only slightly better, detecting 40% and
42% of all enterotoxins, respectively. In a
subsequent study,80 PET-RPLA was compared with
a Vero cell assay in a case–control study of a
C. perfringens food poisoning outbreak in Italy. The
Vero cell assay detected only 8/15 (53.30%) of
PCR-confirmed cases, whereas the PET-RPLA
could detect 13/15 (86.70%).
C. perfringens enterotoxin is only produced in
sporation, therefore it may be difficult to attain in
usual culture media. This has led to some
uncertainty regarding the accuracy of the SET-
RPLA. Mpamugo and colleagues81 used the Oxoid
RPLA kit to establish the incidence of cases of
sporadic diarrhoea associated with C. perfringens,
using a previously designed ELISA test82 for
confirmation over a 2-year period. The authors
concluded that an evaluation of diagnostic
accuracy for PET-RPLA is needed, although no
further studies have been identified which do this.
The lack of any well-defined reference test makes
it hard to evaluate the PET-RPLA fully, but a
number of studies suggest that it may fail to detect
a considerable proportion (21.00–45.00%) of
enterotoxigenic cells. The preferred method
currently used at FSML is the in-house-designed
ELISA test reviewed here.82
Four in-house-designed immunoassay tests were
identified testing for C. perfringens type A
enterotoxin.82–85 Results from all studies could be
read within 24 hours of sample delivery. The
largest investigation82 tested 515 faecal and 21
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.food samples in a multi-centred investigation
throughout the UK. The authors highlighted the
importance of fast delivery to the laboratory to
ensure that enterotoxins were still viable in the
specimen, as the ELISA assay detected 228/294
(78%) of specimens tested within the first 2 days of
C. perfringens outbreaks. However, for samples
collected later than this, the test detection rate
dropped to 74/233 (32%). When results from the
ELISA assay were compared with double gel
diffusion and counter-immunoelectrophoresis, the
ELISA was recorded as detecting significantly
more than its comparators (ELISA sensitivity 89%
compared with 68% and 66% of 44 positive
enterotoxin samples tested).
PCR assays
Only three of the six nucleic acid-based detection
studies identified compared the assay with a
suitable reference test. Most PCR detection targets
either the entertoxin gene (cpe) or phospholipase
C (plc) genes.
An early PCR-based assay was developed by Saito
and colleagues;86 however, as their methods
required 48 hours of pre-enrichment of each
sample, this was not considered a rapid test. Kato
and Kato87 evaluated their in-house PCR assay
with a combination of banked reference strains
and clinical isolates, reporting one false positive
and no missed strains from a total of 107 isolates.
Fach and Popoff 88 evaluated an in-house-designed
duplex PCR against an in-house-designed slide
latex agglutination assay. Testing 23 human faecal
samples, they concluded the latter assay produced
one false negative and one false positive compared
with PCR. The PCR, targeting the plc and cpe
genes, was presented as a very useful test for both
faecal and food samples. The method was
repeated by Augustynowicz and colleagues,89,90
who reported that at least one of the two PCR
targets (plc and cpe) were detected in all 30 stool
samples, whereas the PET-RPLA method detected
only 16 C. perfringens-positive stool samples. A
similar duplex PCR has since been developed in
Japan by Tansuphasiri and colleagues,91 who
found that all reference strains with previously
known enterotoxigenicity produced the expected
results. The same group has recently reduced the
pre-enrichment time for this assay to 4 hours,
which increases its appeal in the investigation of
clostridial food poisoning.92
Discussion
The volume of research attributed to diagnostic
test methods for C. perfringens is substantially less
than that for Campylobacter, Salmonella and E. coli
assays. The reason for this may include the natural
history of the disease, limited duration of ill
health and low complication rate of disease due to
C. perfringens. 
Problems associated with artificially growing
C. perfringens enterotoxin on plating media have
resulted in ambiguous results for many serological
assays. The use of PCR may alleviate this issue, but
due to a lack of comparison of the two methods
this has not been established. More comparative
research is required against a well-established
reference standard.
Screening for enterotoxigenic C. perfringens
isolated from primary faecal spore isolation
cultures may increase the knowledge base for this
pathogen, and lead to improved patient outcomes,
particularly in elderly patients with food-borne
diarrhoea.
Bacillus cereus
Number of studies
The standardised search strategy identified 56
clinical studies for B. cereus. After initial abstract
appraisal, nine studies reporting detection
methods for either emetic or diarrhoeal forms of
B. cereus were included in this review. Basic
information for all included studies is provided in
Table 13.
Methodological quality of studies
Studies evaluating B. cereus detection methods on
prospectively collected human stool samples could
not be found. All tests were used on banked strains
of the pathogen, and the sample size for each
study did not exceed 14. Due to the small number
of studies which evaluated rapid detection
methods against a suitable reference test, the
reviewers were unable to assess the effectiveness of
the majority of assays described. The results of the
remaining seven studies without a comparator are
also reported. Similarly, rigorous quality
assessment could not be applied due to the
limited information available.
Diarrhoeal strains
Rapid detection methods for diarrhoeal strains of
B. cereus were the focus of five identified studies
(Table 13). Two commercially available serological
kits were identified, the BCET-RPLA (B. cereus
enterotoxin-reverse passive latex agglutination,
Oxoid) and VIA (Tecra). Both were developed to
test food samples, but have since been applied in
clinical practice. These kits do not detect the same
Evidence of clinical effectiveness
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.antigen, and comparisons between them have led
to mixed conclusions. The two were given parallel
evaluations in four studies.28,93–95 BCET-RPLA
(Oxoid) is the most commonly cited test method
for diarrhoeal B. cereus, identified in 12 evaluative
and non-evaluative studies in the wider search.
Fletcher and Logan95 compared the BCET-RPLA
(Oxoid) and BDE-VIA (Bacillus diarrhoeal
enterotoxin, Tecra) with an improved McCoy cell
culture cytotoxicity assay. They found the
cytotoxicity assay was more sensitive than the
Oxoid kit and, unlike the Tecra kit, did not give
false positive results. Beecher and Wong 93 were
similarly unclear as to the usefulness of the two
commercial kits, although Day and colleagues94
suggested that the Tecra kit is more reliable,
having detected 87.5% (14/16) strains, compared
with the Oxoid kit, which detected only 43.75%
(7/16). Another study which examined foods and
faeces using Tecra EIA detected the enterotoxin in
seven out of 34 foods and 10 out of 15 faecal
specimens from outbreaks of food poisoning. One
normal faecal specimen also gave a positive
result.96 The Chinese hamster ovary (CHO)
cytotoxicity assay97 is a common detection
technique for diarrhoeal B. cereus strains; however,
as results become available only after 3 days, this is
not considered a ‘rapid’ method.
Emetic strains
Of the toxins produced by B. cereus, the emetic
toxin is likely the most serious but, due to lack of a
suitable assay, the least well known.28 In this
review, no commercial kits for the detection of
emetic toxin were identified. This review identified
six novel assays developed for emetic (cereulide-
producing) strains; however, none of these were
compared with a suitable reference test. One
study98 assessed a novel PCR assay to detect
emetic strains of B. cereus. Using banked bacterial
isolate, the assay was found to be accurate with 30
cereulide-producing (i.e. emetic) strains correctly
identified, whereas all 148 non-cereulide
producing strains gave no PCR signal. This
appears to be a high-performance diagnostic tool
for emetic strains of B. cereus; however, a larger,
prospectively designed study is required. Other
detection methods which were developed, but not
fully evaluated, include liquid chromatography99
and MMT assay.100 In addition, tests developed to
test food samples include PCR101 and bioassay.102
Discussion
There is currently insufficient evidence to assess
the diagnostic accuracy of rapid methods in the
detection of B. cereus. The main diagnostic process
with B. cereus in practice relies on clinical history.
As the duration of illness for both emetic and
diarrhoeal strains of B. cereus does not usually
exceed 24 hours, it is reasonable to suggest that
the urgency for rapid tests of B. cereus is somewhat
diminished, in comparison with potentially more
serious infections such as with E. coli or
Campylobacter. Although comparisons with
reference tests were not performed, results from
the studies suggest that to measure the food
poisoning risk of B. cereus, the toxin content must
be measured. From the evidence identified in this
systematic review, the diagnostic accuracy of test
methods has not been fully assessed. Current
provision of tests for B. cereus may underestimate
the role of emetic strains, due to the lack of a
suitable assay. In an epidemiological profiling
investigation to determine the aetiology of food-
borne outbreaks in which no pathogen was
isolated by routine laboratory testing, Hall and
colleagues103 used pathogenic-specific profiles and
estimated that as many as 18.8% of all reported
food-borne outbreaks in the USA between 1982
and 1989 were caused by either B. cereus or
S. aureus vomiting toxin outbreaks. From a
research perspective, there may be additional
value in exploring novel assay techniques for
emetic strains further, to assess the level of under-
reporting of these pathogens. 
Staphylococcus aureus
Number of studies
The initial standardised search strategy identified
2593 studies relating to detection of S. aureus.
When an attempt was made to limit methicillin-
resistant strains [focusing on methicillin-resistant
S. aureus (MRSA) and hospital-acquired infection],
727 were eliminated. Several MRSA-related papers
were subsequently eliminated in the abstract
appraisal process, suggesting that the electronic
search lacked specificity. Twenty-seven studies were
considered potentially eligible and data was
extracted using the standard proforma. Of these,
only four provided summary statistics of diagnostic
accuracy when testing on faecal samples. Basic
information for all included studies is provided in
Table 14.
Methodological quality of studies
The methodological quality of studies evaluating
diagnostic tests for S. aureus was considerably low. 
Most S. aureus studies were not excluded on
grounds of insufficient quality or data, but rather
that they were not directly linked to staphylococcal
food poisoning. The review identified several
Evidence of clinical effectiveness
54studies developing novel detection techniques for
blood cultures, including DNA hybridisation104
and fibre-optic-based biosensors.105 Application to
faecal samples (i.e. pertaining directly to intestinal
toxins) used agglutination, immunoassay (three
studies) or PCR (six studies) techniques.
Very few of the studies assessed were ultimately
included in this review. As discussed in an earlier
section of this report, S. aureus is ubiquitous in the
environment, and enterotoxigenic forms of the
organism account for only a small fraction of its
species. As such, most of the current research on
its detection does not concentrate on staphylococcal
enterotoxins. Very few studies evaluated the rapid
method against a suitable reference test. However,
some non-evaluative studies have been included in
this review to identify potentially relevant assays to
assess the availability of rapid assays to improve
the identification of S. aureus. Some of the
molecular assays included utilise isolates grown
from non-faecal samples. In addition, none of the
studies was carried out directly on faecal samples.
PCR assays
The characteristics and results of studies
evaluating PCR assays for the detection of
S. aureus are summarised in Table 15. Two
multiplex PCR assays were developed and
evaluated against the current standard phenotypic
test, SET-RPLA (Oxoid). Klotz and colleagues106
recorded their in-house-designed PCR as being
more sensitive than SET-RPLA, with the reference
test detecting only 75.9% of toxins detected by
PCR. Sharma and colleagues107 found similarly
favourable results for nucleic acid-based detection
of all staphylococcal enterotoxins in the same
multiplex assay, unusually without the need for
bacterial pre-enrichment of samples, with results
available within 3–4 hours. Using a mixture of
environmental and clinical strains, they reported
that the SET-RPLA produced two false negative
results (sensitivity 98.7%) whereas PCR detected
all toxin types. This PCR multiplex assay was
subsequently adapted by Letertre and
colleagues,29 to include seg to sej. They found that
compared with both rtPCR and conventional PCR,
SET-RPLA missed 13 out of 68 enterotoxigenic
strains of S. aureus, with sensitivity at 80.8%,
whereas PCR techniques were found to be fully
reliable. In previous non-evaluative studies, Tsen
and colleagues108 and Monday and Bohach109
developed individual PCR assays for each of the
staphylococcal enterotoxin groups A–E. Given the
expanding number of enterotoxin groups being
discovered, the development of multiplex assays is
a considerable progression.
Antibody-based tests
This review identified three studies in which EIAs
were used to detect S. aureus enterotoxins, only
one of which was evaluated against a reference
test. Guardati and colleagues110 developed a novel
ELISA assay for the identification of S. aureus
strains of human and animal origin, and found
that although it missed no positive strains, the
commercial kits against which it was compared
rated poorly, detecting between 90.2% (Bactident
Staph) and 96% (Bacto Staph Latex) of isolates.
The ELISA also produced 100% specificity,
compared with a range of 90.8% (Staphyslide Test
and Sero-StTAT Staph) to 93.7% (Pastorex Staph).
Fukuda and colleagues111 developed a
bioluminescent EIA in which detection of protein
A-bearing S. aureus is possible within 7 hours,
including culture. Kijek and colleagues112
developed a rapid IMS–electrochemiluminescence
assay to detect staphyloccocal enterotoxin B, using
the ORIGEN Immunoassay System (IMS) (Igen,
Rockville, MD, USA). Both studies concluded that
the methods were successful in detecting the
specific toxins of interest (sea and seb). However, as
staphylococcal food poisoning may be due to a
wide range of toxins, it is unlikely that these assays
would be applied in routine practice.
Four studies113–116 compared commercial
agglutination tests designed for the identification
of S. aureus; however, the strain collections for
these evaluations rarely came from faecal samples. 
Discussion
Studies evaluating tests for the identification of
S. aureus are limited and of poor quality. It is not
possible to make any evidence-based
recommendations for practice based on the
limited nature of the available data. Further
studies to develop rapid assays for S. aureus and
subsequent evaluation in trials are recommended.
Assays detecting multiple
organisms
One of the limitations of the many test formats is
that for the majority of assays, users must test for
each bacterial species separately. The development
of nucleic acid-based methods in which probes for
multiple organisms may be used in the same
reaction tube signals significant advances in
detection technology. Testing for a wide range of
pathogens in a single reaction is likely to result in
long-term cost saving, in terms of technician time
and reagent use, compared with plating for
multiple organisms on individual selective agars.
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nResearch is broadly centred on two techniques:
multiplex PCR and microarray technology. A
limited number of studies were identified using
these techniques for the detection of food-borne
pathogens. These are outlined below.
Multiplex PCR
Iijima and colleagues117 reported a multiplex assay
demonstrated using 161 clinical stool samples,
with the ability to detect S. enterica, Vibrio
parahaemolyticus, C. jejuni and STEC infections in a
single reaction. Unusually, this rtPCR assay did
not require sample pre-enrichment, so results were
available within 3 hours from receipt of sample.
Comparing PCR detection with conventional
culture results, the authors found the PCR to be
more sensitive than its reference standard for
S. enterica and V . parahaemolyticus, but slightly less
sensitive for C. jejuni. No STEC isolates were
found.
Fukushima and colleagues118 developed a 
20-primer rtPCR assay to detect 17 species of
food- and water-borne pathogens in faecal
samples. They reported that eight species could be
detected without pre-enrichment, making results
available within 2 hours or less; however, for
pathogens with an infective dose of 104 cfu g–1, an
overnight enrichment step is still required.
In the food industry, multiplex testing has been
developed more widely. Gilbert and
colleagues119,120 developed a multiplex PCR assay
for the simultaneous detection of C. jejuni,
Salmonella and E. coli O157 in raw and ready-to-
eat foods, by successfully combining the methods
from separately published PCR assays for each of
the organisms. Similar multiplex assays have also
been developed for Salmonella and STEC121 and
for Salmonella, Listeria monocytogenes, and S.
aureus.122 Hence the simplex assays discussed in
this review may potentially be combined to allow
the cost-effective detection of all three bacterial
pathogens in one reaction tube.
Microarray technology
Microarray technology is a powerful tool that can
be used for the simultaneous detection of
thousands of genes of target DNA on a glass slide.
Importantly, selecting groups of oligonucleotide
probes for each microarray can allow the detection
of several bacterial species without significantly
increasing the complexity or cost, so a wide range
of pathogens may be tested for using a single
microarray slide. As this is still very much at the
development stage, studies tend to have very small
sample sizes, with specimens from only two or
three patients (often examined in triplicate to
ensure validity). As yet, no large-scale evaluation
of the methods has been reported for the
detection of food-borne pathogens, but
exploratory research in the area suggests that this
technology shows very promising accuracy. In two
of the larger studies relating to intestinal
pathogens, Hong and colleagues123 described the
rapid detection of 14 common pathogenic bacteria
in food-borne infections using oligonucleotide
array technology, and Chiang and colleagues124
reported a detection rate of more than 98% when
182 randomly selected strains of Bacillus spp.,
E. coli, Salmonella spp., Staphylococcus spp. and
Vibrio spp. were assayed.
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This chapter reviews tests that are designed and/or
currently applied only to food samples and
assesses the potential usefulness for transfer to
clinical testing. It comprises summary descriptions
of methods used for food studies and results by
organism. The analyses reported aim to identify
tests with potential for further study in the clinical
microbiology setting. This chapter is therefore
limited to a simple assessment of the technical
feasibility of the assays and comparison of their
sensitivity with a reference standard where
available. More detailed data are appended.
Methods
A search strategy was constructed for MEDLINE,
EMBASE, Web of Science and Science Citation
Index Expanded (SCI-EXPANDED). The search
strategy was designed to identify studies
describing rapid methods of detection for the six
organisms relevant to this study and having
comparison of the rapid method(s) with a
reference standard. The key groups of search
terms and sequence of filters used to obtain
studies for further consideration are given in
Appendix 1. Searches were not restricted by
language and the search was last updated at the
end of September 2005. 
Selection of papers
All study titles were reviewed by CA to assess the
likely relevance of the study to the review and then
further exclusion was based on abstract appraisal
and publication date if studies:
● were pre-1995 (except B. cereus and
C. perfringens, for which there were few studies)
● were not food-related
● were method reviews
● had no comparison of method performance
with an appropriate reference standard
● could not be considered more rapid than
traditional methods.
Full texts of selected studies were evaluated and
further inclusion and exclusion criteria were
applied. Further studies were excluded if:
● Food matrices were not relevant to this study.
● Data did not fit extraction criteria.
● The study was of poor quality. (Systematic
reviews of food pathogen detection studies 
have only recently emerged, and there is a 
lack of any validated quality assessment
instruments in the food industry. A subjective
decision was taken between CA and GW as to
the quality of study methods, based on several
years of experience in the field of microbial
detection of food-borne pathogens. Notably, all
included studies appear in peer-reviewed
journals.)
In addition, for studies which were described in
more than one paper, e.g. development and
validation, only the most relevant publication was
included. References were managed and stored
using the Reference Manager program
(version 11). An overview of the search results is
provided in Table 15. Data were extracted, stored
and managed using an Excel spreadsheet
proforma (see Appendix 2). 
Quality assurance for search strategy
The AOAC database of Performance Tested
Methods (Microbiological test section) was
searched to determine that all available relevant
publications had been retrieved by the previous
search strategy. This source also indicates that a
test kit’s performance has been reviewed by AOAC
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Chapter 6
Systematic review of studies testing food samples
TABLE 15 Search results for diagnostic studies of food-based assays
Organism Campylobacter Salmonella C. perfringens B. cereus S. aureus VTEC Total
7,073 24,256 2,422 28,358 29,347 5,887 97,343
Filter 1 851 2,834 273 1,885 2,351 842 9,036
Filter 2 140 512 45 75 372 123 1,267
Final 8 22 1 18 3 18 70Research Institute and found to perform to the
manufacturer’s specifications.
Reference methods named or indicated by authors
of the literature under examination were checked
against formal standards obtained from standards
agencies [e.g. International Standards
Organization (ISO), Bacteriological Analytical
Manual (BAM)] to check stated methodology or to
determine unstated methodology.
Reviewers CA and GMW were authors of one of
the papers included in the review.125 CA entered
data from this publication according to the
prescribed procedure.
Summary of analysis for all food-based
studies
For the food-based studies, the following provides
descriptive analyses of the data and data sources
accessed, evidence of the efficacy of tests described
and evidence for the rapidity with which tests can
be conducted. 
In this report, analysis of food-based studies was
carried out separately from clinical studies due
mainly to the difference in priorities of the two
areas. Priorities for food-based studies are, largely,
to determine the absence of a single organism in
an aliquot of a food (which is likely to be either
negative for the target organism or contaminated
at very low concentration), or to identify or
enumerate putative pathogens. Additionally, food
microbiologists may be interested in a particular
phenotypic characteristic, e.g. psychrotolerant
bacillus species126 in, for example, ready meals.
Priorities for clinical studies are to determine the
cause of disease (presence of the likely causative
agent) from matrices positive for a disease agent.
They may also prioritise identifying pathogenic
species by, e.g., nucleic acid analyses of pathogenic
determinants. As a consequence of this, data
extraction (and therefore results) for the food-
based studies analysed in this report is treated in a
slightly different format to that for clinical data. 
It is important to note that data suitable for
statistical analyses for C. perfringens were extremely
limited and therefore are presented as narrative.
One reason for this may be the prioritisation of
strategy and/or funds (and therefore research)
towards a particular pathogen or group of
pathogens. This is well illustrated in the food arena,
where in the relatively recent past there has been
great effort directed towards developing methods
for E. coli O157 (in relative terms, an emerging
pathogen) but minimal effort in developing
methods for detecting C. perfringens (a relatively
well-established pathogen in terms of methodology).
Instead, resources have been directed towards
control of C. perfringens with the development of
predictive models (e.g. the Perfringens Predictor
predictive microbiology programme) and public
information awareness campaigns.
The language of all selected studies was English. 
Study types
The major study types selected for analysis in this
report were those in which one or more methods
were compared (often simultaneously) against a
panel of previously known or unknown sample
types. Methods compared were usually a novel
method (the test method) against a method
considered to be a standard method (the reference
method). Where a number of methods considered
rapid were tested against a pre-evaluated panel of
test materials or bacterial strains without
simultaneous testing using a standard method, the
pre-evaluated panel were assumed ‘true’ or
‘standard-based’ results and the rapid methods were
compared against these. Where a number of rapid
tests were evaluated within a single study, results
were statistically evaluated against each other.
Presentation of results
Methods for each of the six organisms under
evaluation were considered separately. Full
tabulation of results includes identification of the
study by author and year, general method format,
e.g. PCR, ELISA, the target analyte, kit type where
possible, reference method used, study size and
sample type and analyses. For each of the studies
tabulated there is additional information
regarding the test, supplier’s details where
applicable and other relevant comments.
Tests were carried out on a number of different
foods spiked at different concentrations, each of
which is a single ‘record’ (row) in the data
extraction form. Tabulated method details are
given in Appendix 3.
Campylobacter species food studies
One study described an antigen detection method
and nine studies described one or more nucleic
acid-based methods. No other method types were
evaluated. Studies described an antigen detection
method in ELISA format and nucleic acid-based
methods in PCR, multiplex PCR (mPCR), rtPCR
and PCR hybridisation (also sometimes called
PCR–ELISA) format. Analytes for detection
included cell surface antigens, a number of
Systematic review of studies testing food samples
60different genes, conserved DNA and 16S rRNA.
Test materials were mainly poultry-based but also
comprised a wide range of relevant foods, including
red meats, vegetables and dairy products. Two
proprietary methods were evaluated (EiaFoss
ELISA, BAX PCR) and, although proprietary
component(s) were used in several of the methods,
all other methods were considered non-proprietary
at the point of publication of the study. 
Historically, at least in the UK, there has been
little agreement on the way forward for a standard
methodology for the detection or enumeration of
Campylobacter species and this may be reflected in
the fact that only one study utilises the
International Standard method (ISO12072:1995)
for the detection of thermotolerant Campylobacter
species from food and animal feeding stuffs.
Traditional methods are lengthy and complex,
often comprising a non-selective or semi-selective
pre-enrichment stage followed by supplementation
with further selective agents and two phases of
incubation (at different temperatures) for the
initial 48 hours and then plating to two highly
selective agars or one selective and one non-
selective agar (made physically selective via a 
45-µm pore size filter, through which Campylobacter
spp. can selectively migrate) prior to incubation
for up to 3 days under appropriate
microaerophilic conditions. 
Performance
In summary, seven evaluations identified test
methods as equivalent to standard reference
methods using 2 and nine as significantly
different to reference methods (Table 16).
Rapidity
A number of authors described methods as rapid.
Campylobacter detection is a long process by
traditional methods (4–5 days) and a number of
Campylobacter study authors claim to be able to
reduce this time by between 1 and 3 days. Rapid
methods could be performed in 3.9–49.85 hours
(total time to presumptive positive result).
Traditional methods also require substantial
hands-on time with addition of selective
supplements to basal media and in some cases
during incubation.
Salmonella species food studies
Twelve studies described antigen detection
methods, 13 described nucleic acid-based methods
and three described traditional methods. Two
studies described methods dependent on
organism motility127,128 and no studies described
bioassays. Studies described antigen detection
methods in different formats [n = 20, RPLA,
ELISA, IMS, automated IMS (AIMS), PCR-ELISA,
FIA and lateral flow immunoassay (LFIA)] and
nucleic acid-based methods (n = 20, PCR and
rtPCR with or without BAX, VIDAS and Taqman
systems) and the remainder described rapid or
standard traditional-style methods (n =5 ) .
Analytes for detection included Salmonella cells,
cell surface antigens, a number of genes and
ribosomal RNA. Analyses were performed in a
wide range of relevant foods including cake mix,
cheese, coconut, egg, seafood (fish and shrimps)
meat (beef, pork, poultry and frankfurter), milk,
chocolate, peanut butter, flour and yeast. Assay
outcomes were generally lines on gel or on the
basal membrane of LFIA devices, colour
development, fluorescence intensity, analysis of
melting point versus temperature (BAX software),
zone of turbidity [on modified semisolid
Rappaport-Vassiliadis (MSRV) agar] and colonies
on plates.
Performance
The relative performances of assays for the
detection of Salmonella in food are shown in
Table 17.
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TABLE 16 Campylobacter method performance summary for food studies
Significantly different  Not significantly  Significantly different  Total
with fewer presumptive  different with more presumptive 
positivesa positivesb
Antigen detection 0 1 0 1
Nucleic acid-based 3 6 6 15
Traditional 0 0 0 0
All 3 7 6 16
a Inferior: significantly different by 2 and a lower proportion of presumptive positives, p=0.05.
b Superior: significantly different by 2 and a higher proportion of presumptive positives, p=0.05.Rapidity
For rapid methods, pre-enrichment was
performed for all studies (100%) and for reference
methods described pre-enrichment was performed
for all but one (95%, quantitative plating) method.
Standard methods take between 36.45 and
97 hours to presumptive positive detection
(0.45–1.0 hours for hands-on) and rapid methods
described take between 7.55 and 73 hours to
presumptive positive (0.65–2.55 hours for 
hands-on).
Verocytotoxin-producing E. coli
food studies
Fourteen studies described antigen detection
methods (n = 28), 13 described nucleic acid-based
methods [n = 20; one of which was a combined
nucleic acid–antibody based (NA–AB) assay] and
four described traditional (TRAD) or enhanced
traditional (eTRAD) methods. One study
described a bioassay (the Vero cell assay). Studies
described antigen detection methods in four
different formats (ELISA, IMS, LFIA and
IMS–plate) and nucleic acid-based methods in two
basic formats, PCR and rtPCR. Analytes for
detection included E. coli cells, cell surface
antigens [mainly O157 lipopolysaccharide (LPS)],
a number of virulence genes, eae, stx1, stx2, and
verotoxins VT1, VT2 and VT2c. Analyses were
performed in a wide range of relevant foods.
The performance of the methods compared with a
reference method is summarised in Table 18. It
should be noted that much of the work for these
studies was carried out prior to the publication
and wide dissemination of the validated BS EN
ISO 16654 (2001) method for E. coli O157 and
therefore many of the comparative methods are
listed as ANS (appropriate non-standard;
Appendix 3).
Rapidity summary
For rapid methods, pre-enrichment was performed
for all studies (100%) and for reference methods
described pre-enrichment was performed for all but
one (95%, quantitative plating) method. Standard
methods took between 36.45 and 97 hours to
presumptive positive detection (0.45–1.0 hours for
hands-on) and rapid methods described took
between 7.55 and 73 hours to presumptive
positive (0.65–2.55 hours for hands-on).
Clostridium perfringens food studies
Like B. cereus, C. perfringens grows readily (1 day to
presumptive positive; ISO/DIS 7937:2002) in
traditional culture from naturally contaminated
Systematic review of studies testing food samples
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TABLE 17 Salmonella method performance summary for food studies
Significantly different  Not significantly  Significantly different  Total
with fewer presumptive  different with more presumptive 
positivesa positivesb
Antigen detection 12 3 4 19
Nucleic acid-based 1 8 12 21
Traditional 3 0 0 3
All 16 11 16 43
a Significantly different by 2 and a lower proportion of presumptive positives, p = 0.05.
b Significantly different by 2 and a higher proportion of presumptive positives, p = 0.05.
TABLE 18 E. coli method performance summary for food studies
Significantly different  Not significantly  Significantly different  Total
with fewer presumptive  different with more presumptive 
positivesa positivesb
Antigen detection 10 13 4 29
Nucleic acid-based 1 11 4 16
Traditional 1 6 1 7
a Significantly different by 2 and a lower proportion of presumptive positives, p = 0.05.
b Significantly different by 2 and a higher proportion of presumptive positives, p = 0.05.samples, provided that it is handled in an
anaerobic manner. Maximum growth rate in ideal
conditions can be higher than 1.0 log increase per
hour (doubling every 0.3 hours) in meat medium
at 45°C at pH 8.0 (www.combase.cc) (using the
ComBase Predictor Program).
For C. perfringens, it is also important to consider
the route of food-borne infection; it is usually
associated with disease after consumption of
cooked meats. It may be present, usually in low
concentration, in raw meats. A recent survey
indicated that 1.4% of retail raw meats in the USA
were cpe gene, C. perfringens positive. C. perfringens
may be present as vegetative cells or as spores.
Spores can survive thermal treatment given to
some products and may subsequently germinate
and outgrow very rapidly during the cooling
process, giving rise to high numbers of cells and
therefore toxin. For this reason, in recent years, a
large proportion of the UK and US research
budget in this area has been targeted toward
establishing the growth kinetics of C. perfringens
during cooling, and a number of mathematical
models and predictive modelling tools have been
developed (see www.combase.cc).
A number of studies have been carried out on the
detection or enumeration of C. perfringens and its
associated toxins in foods. Results retrieved
indicated that standard methods were developed
and evaluated during the period 1974–85 with
early molecular research in areas such as
identification of genes of virulence factors
reported from the late 1980s (e.g. by Titball and
colleagues237). 
Some early studies evaluated methods for toxin
detection. As an example, Harmon and Kautter238
described a 15-laboratory collaborative study to
estimate C. perfringens population using an indirect
semi-quantitative method for quantifying the
concentration of alpha toxin in cooked beef. This
method was proposed as “adequate for estimating
population levels of C. perfringens in foods
associated with food-borne disease outbreaks” and
was proposed as an improvement to the AOAC
Official First Action Method 41.019–41.023, which
reportedly underestimated numbers from foods
that had been frozen or refrigerated. 
Gene sequences for the four major toxins of
C. perfringens (alpha, beta, gamma and epsilon)
have been published (1989–93) and since then
several PCR methods have been developed. It is
important to note that only the alpha toxin is
implicated in human food-borne illness or gas
gangrene. C. perfringens can grow exceedingly
quickly,239 which may mean that minimal time is
required for pre-enrichment. Where C. perfringens
is implicated in food poisoning, it is usually
present in high numbers in food or faecal
samples. This means that short incubation or even
no pre-enrichment is required.
C. perfringens method performance
summary
Combined results for six studies describe tryptose
sulfite cycloserine (TSC) as superior to lactose
sulphite medium (LS), sulphite cycloserine (SC),
Shahidi-Ferguson perfringens (agar) (SFP) and a
PCR method, equivalent to DNA hybridisation
and iron milk medium (IMM) MPN and inferior
to rapid perfringens medium (RPM). In one study,
RPM is described as superior to perfringens
enrichment medium (PEM) and TSC and in
another as equivalent to LS. LS is suggested 
as a growth medium for its confirmatory qualities
but is found to be poor as a confirmatory 
agent when compared with other confirmatory
methods.
Quantification of cells by toxin presence is unlikely
to be useful, as different strains are now known to
produce different concentrations of toxin in
response to different stimuli.
C. perfringens can be presumptively detected or
enumerated with good accuracy using traditional
methods within a 1-day time frame. Evidence
evaluated suggests that it may be feasible to
provide PCR or ELISA determinations, with a
degree of characterisation, using a 4-hour
enrichment period, within one working day. This
may be beneficial in quality assurance and
positive-release scenarios.
Bacillus cereus food studies
Methods for B. cereus; B. cereus
enterotoxin or species of the B. cereus
group
Four studies described antigen detection methods
and two studies described nucleic acid-based
methods. One study evaluated an enhanced
traditional method and one evaluated a novel
bioassay. Studies described antigen detection
methods in ELISA and RPLA format. Nucleic
acid-based methods were both in PCR format.
Analytes for detection included cell surface
antigens, emetic and diarrhoeal toxins, genes and
16s rRNA. Relevant test materials were mainly dry
products, dairy products, vegetables and spices.
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[BCET-RPLA (Bacillus cereus enterotoxin–reverse
passive latex agglutination), Oxoid; BDE-ELISA
(Bacillus diarrhoeal enterotoxin, or VIA), Tecra;
and Bacillus chromogenic medium (BCM®
Biosynth], and although proprietary component(s)
were used in several of the methods, all other
methods were considered non-proprietary at the
point of publication of the study. Only one study
utilises the International Standard method
(ISO 7932:2004) as a reference standard.
Performance
In summary, six evaluations identified test
methods as equivalent to standard reference
methods, 10 as significantly different to the
reference method, one with fewer presumptive
positives than the reference method and nine with
more (Table 19).
Rapidity
B. cereus detection is a relatively quick process by
traditional methods and presumptive positive
detection/enumeration may be made within
24 hours. A further enrichment of positive isolates
for 18 to 24 hours can result in detection of toxin
using, for example, the RPLA method. There is
no requirement for substantial hands-on time for
detection of this organism or its toxins. However,
some selective supplementation of the media is
required. Simultaneous detection and
characterisation such as those which could be
obtained by PCR may be beneficial.
Staphylococcus aureus food studies
Staphylococcal food poisoning is an intoxication
caused by ingestion of toxins produced in 
foods by S. aureus cells. It may be appropriate,
therefore, to detect either cells or toxin for this
organism.
Broad conclusions are that petrifilm methodology is
equivalent to Baird Parker agar (BPA), as evidenced
in three studies, and RPFA is equivalent to BPA, as
evidenced in two studies. API STAPH is superior to
ID32 STAPH (one study only). The VIDAS SET2
method is superior to VIDAS SET and may be
useful for a wide range of dairy products. Table 20
summarises method performance for all studies
considered statistically.
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TABLE 19 B. cereus method performance summary for food studies
Significantly different  Not significantly  Significantly different  Total
with fewer presumptive  different with more presumptive 
positivesa positivesb
Antigen detection 1 3 7 11
Nucleic acid-based 0 1 2 3
Bioassay 0 1 1
Traditional 0 1 0 1
All 1 6 9 16
a Significantly different by 2 and a lower proportion of presumptive positives, p = 0.05.
b Significantly different by 2 and a higher proportion of presumptive positives, p = 0.05.
TABLE 20 S. aureus method performance summary for food studies
Significantly different  Not significantly  Significantly different  Total
with fewer presumptive  different with more presumptive 
positivesa positivesb
Antigen detection 10 0 0 10
Nucleic acid-based 0 0 2 2
Bioassay 0 0 0 0
Biochemical gallery 1 0 1 2
Traditional 1 6 1 8
All 12 6 4 22
a Significantly different by 2 and a lower proportion of presumptive positives, p = 0.05.
b Significantly different by 2 and a higher proportion of presumptive positives, p = 0.05.Rapidity
RPLA is considered more rapid than BPA.
Petrifilms are considered more rapid than either
of the traditional methods. Toxin analysis by
ELISA is more rapid than cell detection.
Extraction procedures and the confirmation of
colonies should be taken into consideration when
estimating timeliness of a method, especially as
some methods are not highly specific and
therefore require relatively more confirmation.
Assessment of food-based methods
Summary statistics for all methods
Method evaluations (n = 155) described in 67
articles were statistically evaluated and a further
39 studies were used for non-statistical evaluation
of methods. Summary results for all statistically
evaluated methods are given in Table 21. 
The sensitivity and specificity for all methods are
most easily visualised by grouping test methods
according to whether lower or higher presumptive
positive results compared with the reference
method results are obtained. A ‘lower’ result
indicates a <100/100 sensitivity/specificity
scenario, an ‘equal’ result indicates an equivalent
(e.g. 100/100) scenario and a higher result
indicates a 100/<100 scenario.
Results indicate that there were a relatively high
proportion of antigen detection methods in the
‘lower’ category (61.4% compared with 43.2% for all
methods). There appeared to be a higher
proportion of nucleic acid-based tests in the ‘higher’
category (45.9% compared with 32.9%). Traditional
methods were most abundant in the ‘equal’ category.
This result is unsurprising as most of the traditional
or enhanced traditional methods were very similar
to the reference method in format.
Despite the relatively high false positive rate (the
‘higher’ classification), nucleic acid-based methods
display fewer significant differences from standard
methods with respect to disparate results as
detailed by summary statistics (Table 21) for
significant differences identified between test and
reference methods. Antibody-based methods
exhibit a significant difference at p = 0.05 or lower
in 49.9% of tests and nucleic acid-based methods
exhibit difference in 42.6% of tests. Antigen
detection and nucleic acid-based tests showed no
significant difference (34.3 and 45.9%,
respectively; p = 0.05) or 50 and 62.3%,
respectively, at p = 0.01).
Conclusions for the food-based method
review
● Nucleic acid-based methods may be more
valuable for the detection of organisms that are
relatively difficult to culture (e.g. Campylobacter
as opposed to B. cereus). 
● Immunological and nucleic acid-based tests may
be better for ‘multiplexing’ thereby providing
simultaneous speciation or characterisation 
(e.g. Hsu and colleagues129).
● Traditional methods will allow the examination
of the live target organism. However, there is
some evidence that prolonged pre-enrichment
may be counterproductive for some organisms,
for example missed detection of E. coli O157
due to being outcompeted by other
autochthonous flora.130
● Nucleic acid-based and immunological 
methods are, in general, more rapid to
presumptive positive. Some authors indicate
that substantial savings in time to results can be
achieved.129
● Rapid characterisation may be of particular
benefit in the medical arena for rapid
identification of EHEC. This would allow
informed, rapid and appropriate treatment,
thereby reducing the chance of serious kidney
damage or death. 
● For Campylobacter detection, rapid methods
would be of immense benefit, as this organism
is very difficult to culture and sub-type.
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TABLE 21 Method performance summary for all methods and all organisms, identifying number (percentage) of test methods having
lower, equal or higher presumptive positive results compared with reference methods
Lower Equal Higher Total
Antigen detection 43a (61.4) 7 (10) 20 (28.6) 70
Nucleic acid-based 14 (23) 19 (31.1) 28 (45.9) 61
Traditional 7 (35) 10 (50) 3 (15) 20
Other 3 (75) 1 (25) 0 (0) 4
All 67 (43.2) 37 (23.9) 51 (32.9) 155
a Two records are for mixed antibody-nucleic acid tests.W
ith over 800,000 stool tests for gastroenteritis
ordered each year in England, progressive
introduction of new diagnostic technologies could
lead to substantial increases in costs, especially if
new rapid tests were to be used as an ‘add-on’ to
existing culture methods. Furthermore,
widespread implementation of these rapid tests
could have substantial implications for the
organisation of treatment services and training of
laboratory staff. Any introduction of new
diagnostic technologies should include careful
consideration of the costs and benefits of different
testing strategies before their implementation.131
Economic evaluation is crucial to determining
circumstances under which new tests should be
performed, and what level of capital investment is
justified.
It is increasingly recognised that clinical decisions
must take into account the economic costs of a
given intervention. Cost containment must be
balanced with public health objectives, and
attempts to evaluate diagnostic test methods
economically must address multifaceted issues:
● specifying the relevant diagnostic alternatives
● measuring diagnostic accuracy
● measuring diagnostic costs
● specifying the measured outcomes of the
diagnostic process.
If a case is to be made for the cost-effectiveness of
new diagnostic tests, much more work is required
to identify and quantify the potential intermediate
effects and to predict the likely impact on health
outcomes. However, the impact on health
outcomes is extremely difficult to quantify.132 The
measurement of such outcomes would require
large-scale trials, which are unlikely to be feasible,
so a modelling approach is needed to extrapolate
from intermediate outcomes and incorporate
variations in epidemiological, costing and
effectiveness data. A decision analytic model was
constructed to assess the financial costs and
potential clinical benefits gained from
implementing various rapid testing strategies in a
hypothetical NHS microbiology department. Data
on isolation rates for each pathogen and costs of
microbiological examination were based on
published studies, laboratory user information,
manufacturers’ pricing quotations and expert
opinion, where possible. It must be noted that a
high degree of uncertainty in both data input and
model structure is inevitable when assessing new
technologies, so where possible sensitivity analysis
has been applied to account for any problems
encountered in parameter estimations. 
Plan of investigation
For the purpose of this report, the following
assumptions were made:
● Testing period was set at 1 year.
● Analysis is based on the NHS viewpoint,
involving the cost of microbiological
investigation only. As it is unclear how
treatment costs (e.g. antibiotic therapy or
hospital bed days) may change as a result of
rapid diagnosis, there are insufficient data to
model further the impact new testing strategies
may have on these costs and subsequent health
outcomes.
● Testing was carried out Monday–Friday,
9 am–6 pm, for all methods.
● Setting was a hypothetical UK microbiology
laboratory testing 10,000 faecal samples for
enteric pathogens per year.
● For the purposes of the model, testing in the
laboratories during the stated time period will
require a steady flow of samples to be constant.
To account for outbreak scenarios, the isolation
rate can be artificially increased, as would occur
as more of the specimens being sent in would
produce positive results.
● No inconclusive results were recorded, and no
tests were repeated on the same sample.
● The costs of diagnostic tests used within the
economic model are average costs and include
elements of capital and overheads of providing
these services.
● The effect of cases averted due to the
prevention of person to person transmission
was considered minimal for food-borne
pathogens.
Cost-effectiveness analysis of competing test
strategies was twofold. Initially, the majority of
analyses worked on the assumption that the
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Chapter 7
Economic evaluationsensitivity and specificity for the reference test,
bacterial culture, equalled one (i.e. perfect
accuracy). In the second part of decision
modelling, this assumption was relaxed, to
determine the cost per additional case detected
associated with each strategy if culture methods
were sub-optimal. 
Test strategies
It is unlikely that bacterial culture methods will
soon be replaced as the routine diagnostic
procedure for suspected food-borne illness.
Growth of culture has enjoyed a 100-year history
in microbiology laboratories, with reasonable
diagnostic accuracy at a fairly low cost. The
introduction of rapid diagnostic technology would
probably be additive, rather than a substitute for
culture methods, in the first instance. However,
decision analysis can play an important role in
predicting the outcomes associated with 
numerous strategies, irrespective of the likelihood
that they will be adopted. We therefore address the
option that bacterial culture will be fully replaced
by rapid methods, although we acknowledge that
this is an unlikely scenario for the immediate
future.
As discussed earlier in this report, it is impractical
to assume that every incident of food-borne 
illness will undergo microbiological investigation.
Under-reporting by affected individuals is the
primary reason for this, but also GPs may put in
place a system of triage whereby mild cases in
otherwise healthy adults do not need laboratory
analysis. Likewise, it is highly probable that any
decision to order an additional test to enable
faster diagnosis will involve prioritising those cases
for which rapid detection will bring the greatest
benefit. Food-borne illness is an important cause
of cross-infection among certain patient groups,
including neonates and the elderly. For E. coli in
particular, serious infection leading to
hospitalisation is most pertinent with younger
populations.133 There is some empirical evidence
to suggest that children are more susceptible than
adults to O157 strains. In an economic review of
the 1994 outbreak of E. coli O157 in Midlothian,
Scotland, GP and hospital surveys confirmed that
49.3% of all cases (35/71) were aged under 
5 years, accounting for 50% (12/24) of
hospitalisations.134 The need for more prompt
diagnosis and patient management for children
highlights the potential benefits of rapid testing
for this patient group. Consequentially, we have
constructed various testing strategies in which the
detection of microorganisms in high-risk patients
is prioritised. 
Four broad testing strategies were examined
(Table 22), as outlined below.
Status quo – routine culture
Costs and cost-effectiveness of the current testing
strategy were assessed, namely where all samples
are cultured for Campylobacter, Salmonella and
E. coli O157. Enrichment broths and selective
agars used for each organism are in line with those
from UK National Standard Operating
Procedures.
Routine culture combined with additional rapid
tests for high-risk patients
‘High-risk’ patients include pregnant women, aged
under 5 or over 65 years, immunocompromised or
anyone presenting with severe symptoms, such as
bloody diarrhoea. Although there is no clear
evidence that the pathogen isolation rate is higher
for these patients, the consequences of prolonged
undiagnosed food poisoning may be more serious,
such as an increased risk of renal failure. For
modelling purposes, it is assumed 25% of patients
are ‘high risk’. Sensitivity analysis was carried out
to assess the additional cost and cost-effectiveness
outcomes if up to 50% of all samples were deemed
‘high risk’, such as may be the case if a suspected
food-borne outbreak were to occur in a nursing
home or primary school.
Routine culture combined with additional rapid
tests for enterohaemorrhagic E. coli
Given the importance that health professionals
place on E. coli O157, irrespective of its low
prevalence compared with some other enteric
pathogens, various testing strategies were
developed in which only rapid tests for E. coli were
carried out. It is assumed that the rapid test kits
used for E. coli could detect all enterohaemorrhagic
strains, thus potentially reporting more true cases
of infection than SMAC culture methods, which
may miss sorbitol-fermenting non-O157 strains.25
In this instance, additional cases detected can be
used as a suitable outcome measure.
Complete replacement of routine culture with
rapid tests for all samples
The most radical strategies modelled involve the
total replacement of bacterial culture methods
with rapid testing. Although this is unlikely to be
adopted in the very near future, there is evidence
to suggest that new technologies, particularly
involving molecular detection methods, may
evolve and replace existing procedures in the next
few decades. This strategy is a forward-looking
assessment of how microbiological investigation of
food-borne illness may look in the future.
Economic evaluation
68Health Technology Assessment 2007; Vol. 11: No. 36
69
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
T
A
B
L
E
 
2
2
S
u
m
m
a
r
y
 
o
f
 
t
e
s
t
i
n
g
 
s
t
r
a
t
e
g
i
e
s
S
t
r
a
t
e
g
y
T
e
s
t
O
r
g
a
n
i
s
m
s
P
a
t
i
e
n
t
 
T
o
t
a
l
 
T
o
t
a
l
 
r
a
p
i
d
 
D
e
s
c
r
i
p
t
i
o
n
 
o
f
 
s
t
r
a
t
e
g
y
g
r
o
u
p
s
a
m
p
l
e
s
t
e
s
t
s
S
t
a
t
u
s
 
q
u
o
R
o
u
t
i
n
e
 
c
u
l
t
u
r
e
 
o
n
l
y
,
 
n
o
 
r
a
p
i
d
 
t
e
s
t
i
n
g
C
u
l
t
u
r
e
A
l
l
1
0
,
0
0
0
3
0
,
0
0
0
S
t
a
n
d
a
r
d
 
c
u
l
t
u
r
e
 
i
n
 
l
o
c
a
l
 
l
a
b
o
r
a
t
o
r
y
H
i
g
h
-
r
i
s
k
 
p
a
t
i
e
n
t
s
,
 
r
a
p
i
d
C
u
l
t
u
r
e
 
a
n
d
 
r
t
P
C
R
 
f
o
r
 
h
i
g
h
-
r
i
s
k
 
g
r
o
u
p
s
 
o
n
l
y
r
t
P
C
R
A
l
l
H
i
g
h
-
r
i
s
k
2
,
5
0
0
7
,
5
0
0
T
e
s
t
 
h
i
g
h
-
r
i
s
k
 
s
a
m
p
l
e
s
 
f
o
r
 
a
l
l
 
t
h
r
e
e
 
o
r
g
a
n
i
s
m
s
 
b
y
r
t
P
C
R
C
u
l
t
u
r
e
 
a
n
d
 
E
L
I
S
A
 
f
o
r
 
h
i
g
h
-
r
i
s
k
 
g
r
o
u
p
s
 
o
n
l
y
E
L
I
S
A
A
l
l
H
i
g
h
-
r
i
s
k
2
,
5
0
0
7
,
5
0
0
T
e
s
t
 
h
i
g
h
-
r
i
s
k
 
s
a
m
p
l
e
s
 
f
o
r
 
a
l
l
 
t
h
r
e
e
 
o
r
g
a
n
i
s
m
s
 
b
y
E
L
I
S
A
E
.
 
c
o
l
i
 
r
a
p
i
d
 
t
e
x
t
s
C
u
l
t
u
r
e
 
a
n
d
 
r
t
P
C
R
 
t
e
s
t
i
n
g
 
f
o
r
 
E
.
 
c
o
l
i
o
n
l
y
r
t
P
C
R
E
.
 
c
o
l
i
A
l
l
1
0
,
0
0
0
1
0
,
0
0
0
T
e
s
t
 
a
l
l
 
s
a
m
p
l
e
s
 
f
o
r
 
E
.
 
c
o
l
i
b
y
 
r
t
P
C
R
C
u
l
t
u
r
e
 
a
n
d
 
E
L
I
S
A
 
t
e
s
t
i
n
g
 
f
o
r
 
E
.
 
c
o
l
i
o
n
l
y
E
L
I
S
A
E
.
 
c
o
l
i
A
l
l
1
0
,
0
0
0
1
0
,
0
0
0
T
e
s
t
 
a
l
l
 
s
a
m
p
l
e
s
 
f
o
r
 
E
.
 
c
o
l
i
b
y
 
E
L
I
S
A
C
o
m
p
l
e
t
e
 
r
e
p
l
a
c
e
m
e
n
t
 
o
f
 
c
u
l
t
u
r
e
 
m
e
t
h
o
d
s
C
o
m
p
l
e
t
e
 
r
e
p
l
a
c
e
m
e
n
t
 
o
f
 
c
u
l
t
u
r
e
 
w
i
t
h
 
r
t
P
C
R
r
t
P
C
R
A
l
l
A
l
l
1
0
,
0
0
0
3
0
,
0
0
0
T
e
s
t
 
a
l
l
 
s
a
m
p
l
e
s
 
f
o
r
 
a
l
l
 
t
h
r
e
e
 
o
r
g
a
n
i
s
m
s
 
b
y
 
r
t
P
C
R
 
C
o
m
p
l
e
t
e
 
r
e
p
l
a
c
e
m
e
n
t
 
o
f
 
c
u
l
t
u
r
e
 
w
i
t
h
 
E
L
I
S
A
E
L
I
S
A
A
l
l
A
l
l
1
0
,
0
0
0
3
0
,
0
0
0
T
e
s
t
 
a
l
l
 
s
a
m
p
l
e
s
 
f
o
r
 
a
l
l
 
t
h
r
e
e
 
o
r
g
a
n
i
s
m
s
 
b
y
 
E
L
I
S
AThis decision model (Figure 24) concentrates on
the three testing procedures for which a sufficient
level of data is available to establish diagnostic
accuracy and cost estimates. These are bacterial
culture (status quo), antibody-based assays and
PCR. It is assumed that commercial testing kits
will be used in applying rapid methods.
Outcome measures
For the purpose of this report, the cost-
effectiveness of diagnostic tests for food-borne
illness is expressed as cost per case detected. The
cost per case finding is a concept borrowed from
the economic evaluation of screening procedures.
Where clinical evidence can show that the rapid
method is more sensitive than traditional culture
methods, incremental cases detected and cost per
additional case detected have also been calculated. 
Quality of life considerations have not been
incorporated into this analysis because the quality
of life literature with regard to food-borne illness
has not yet been investigated, and is beyond the
scope of this review. As the course of
gastrointestinal illness usually lasts no longer than
1 week, and patients are usually treated
symptomatically, it is unlikely that the quality of
life impact would be significant for the majority of
patients. However, for the small minority of
patients who go on to develop secondary
complications such as HUS or GBS, quality of life
estimates are likely to be significant.134 There is
not enough literature currently available to deduce
the impact that rapid diagnosis would have on the
course of illness in these cases, and therefore it is
unclear what impact quality of life considerations
may have on cost-effectiveness estimates for the
rapid diagnosis of food-borne illnesses. More
research is needed in this area, but the difficulties
in developing such evaluative studies of diagnostic
procedures have been noted.132,135
Review of economic literature and construction
of the model
An attempt was made to collect previously
published cost and cost-effectiveness evidence.
Although considerable investigation has been
carried out on the costs of food-borne
disease,136–139 at the time of writing, no economic
studies were identified on the cost-effectiveness of
test methods for the rapid diagnosis of food
poisoning. Where economic considerations were
mentioned in the included articles, this
information is recorded in the study characteristics
in Appendix 3. In should be noted, however, that
these studies focused only on cost analysis, and as
such, information regarding relative efficiency
could not be gained. Interpretation of these
studies was further complicated as none were
conducted within the UK and baseline years for
cost estimation varied widely.
Decision analytic models are formulated using
three key fields of information:
● effectiveness data
● epidemiological data 
● cost data.
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Sample received
Routine culture
Rapid testing strategy
Total replacement
with rapid methods
Routine culture for all,
additional rapid testing
in some circumstances
Replace culture with
nucleic acid-based tests
(rtPCR)
Replace culture with antibody-
based tests (ELISA)
Rapid testing for high-risk
patients (infants, elderly,
severely symptomatic)
Rapid testing for high-risk
organism (e.g. E. coli  O157)
rtPCR tests for high-risk,
culture for all
ELISA tests for high-risk,
culture for all
rtPCR tests for high-risk,
culture for all
ELISA tests for high-risk,
culture for all
FIGURE 24 Decision tree outline of potential strategiesEffectiveness data
No diagnostic test method is ‘perfect’. The
economic cost of diagnostic errors must be
incorporated into any decision model on clinical
effectiveness. With food-borne illness, the cost of
incorrect positive diagnosis, in particular, may be
extensive when public health measures to prevent
further spread of infection are considered.
Effectiveness data were collected through a
systematic review of evidence evaluating rapid test
methods for Campylobacter, Salmonella, and E. coli
O157. Due to the lack of substantiating evidence
of rapid technologies being applied to toxin-
inducing food-borne pathogens, tests for
C. perfringens, S. aureus and B. cereus were excluded
from the decision analytic model. This is in
keeping with current laboratory practice, as toxin-
inducing food-borne pathogens are usually only
tested for after a specific request from the
clinician.
Rapid diagnosis
An overall summary of clinical effectiveness for
nucleic acid-based (PCR) (as previously described,
there are a number of inherent problems in using
this summary figure; the majority of studies
assessing nucleic acid-based methods were carried
out using in-house-designed PCR, as opposed to
commercially available kits, and, as such, questions
of reproducibility and heterogeneity must be
addressed) and immunological diagnosis was
calculated from the body of evidence reviewed.
Data were derived from pooled sensitivity and
specificity estimates, as reported in forest plots
(Chapter 5). The baseline values for diagnostic
accuracy of PCR and immunoassays for each
pathogen are given in Tables 23 and 24. Due to the
intrinsic uncertainty surrounding these values, a
10% upper/lower confidence range has been
applied for sensitivity analysis.
Traditional culture
Attempts to quantify the diagnostic accuracy of
rapid test methods are confounded by the lack of
a robust reference test. In most cases, traditional
culture methods are assumed to be ‘correct’;
however, a growing body of evidence comparing
culture with new rapid techniques (such as nucleic
acid-based detection) suggests that sensitivity
values are significantly lower than 100%. In
particular, evidence suggests that sensitivity of
culture for Salmonella and EHEC may vary in the
range from 30–80% compared with PCR, ELISA
or full biochemical identification.25 The culture
method is more robust for Campylobacter detection,
with the sensitivity range varying between 83 and
100%. It is probable that these samples include a
mix of under-reporting by culture and
misinterpretation by rapid methods (e.g. due to
PCR contamination); however the impact of
under-reporting may be assessed through
sensitivity analysis. As it is the reference standard
used for the majority of rapid tests, the baseline
value for culture methods was set at 100%
sensitivity and specificity. However, a lower limit of
80% sensitivity was modelled. 
Epidemiological data
Annualised data detailing the number of positive
laboratory results for enteric pathogens are widely
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TABLE 23 Baseline values and sensitivity range for diagnostic accuracy of nucleic acid-based methods (PCR tests)
Organism Baseline values Upper limit (+10%) Lower limit (–10%)
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Campylobacter 0.90 0.97 0.99 1.00 0.81 0.87
Salmonella 0.88 0.98 0.97 1.00 0.79 0.88
E. coli O157 0.99 1.00 1.00 1.00 0.89 0.90
TABLE 24 Baseline values and sensitivity range for diagnostic accuracy of antibody-based methods (ELISA tests)
Organism Baseline values Upper limit (+10%) Lower limit (–10%)
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Campylobacter 0.89 0.98 0.98 1.00 0.81 0.89
Salmonella 0.96 0.96 1.00 1.00 0.86 0.86
E. coli O157 0.95 0.98 1.00 1.00 0.86 0.88available from the Health Protection Agency.
However, without knowing the volume of stool
tests carried out each year, it is impossible to
estimate the isolation rate for each pathogen. It is
notoriously difficult to estimate this value. 
Published evidence
The most comprehensive research carried out on
food-borne pathogens in the UK to date was
commissioned by the FSA in the late 1990s. The
Report of the Study of Infectious Intestinal
Disease in England3 preceded its full investigation
with an enumeration study in 1994, which
estimated the incidence of IID presenting to GPs
and the proportion of samples routinely sent for
microbiological investigation. Data relating to the
volume of tests performed are summarised in
Table 25.
A GP case–control component was also included in
the Study of Infectious Intestinal Disease in
England,3 to assess the incidence of IID
presenting to GPs. The number and proportion of
pathogens isolated from a total of 2893 stool
samples tested are given in Table 26.
Using the information provided by the above
study3 and annual reports from the Health
Protection Agency, the percentage of positive
samples for Campylobacter, Salmonella and E. coli
O157 can be extrapolated to provide the estimates
of the proportion of positive samples given in
Table 27. 
Isolation rates for Campylobacter and Salmonella
appear to have decreased dramatically since the
IID study results were recorded. Given the
importance of accuracy in epidemiological data
for decision analysis, attempts were made to
obtain a clearer picture of the volume of
laboratory tests today, by conducting a small
validation survey.
Validation survey
In order to test the validity of the IID data in
current practice, information was obtained on
faecal workload and positive isolates by sending
questionnaires to randomly selected microbiology
laboratories in England and Wales. There was a
reply from 7/20 (35%) of laboratories. Data were
pooled to increase the statistical power of isolation
Economic evaluation
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TABLE 25 Total number of samples and pathogen detection rate in the Study of Infectious Intestinal Disease in England3
Total stools examined  Total stools positive for  Proportion positive 
in 1994 any target isolate (%)
All laboratories in England (n = 178) 878,247 108,180 12.3
TABLE 27 Estimates of the proportion of positive samples in 2005
Organism Estimated stools  Total laboratory reports  Proportion 
examineda recorded in 2005 positive (%)
Campylobacter 878,247 44,342 5.05
Salmonella 878,247 6,639 0.76
E. coli O157 878,247 946 0.11
a Volume of tests based on value derived in the IID enumeration study.3
TABLE 26 Pathogen detection in stool samples from patients presenting to GPs in the Study of Infectious Intestinal Disease in
England3
Organism Cases of IID presenting to GP
No. identified No. tested Proportion identified (%)
Campylobacter 354 2893 12.2
Salmonella 146 2893 5.0
E. coli O157 3 2893 0.1
Other organisms 1085 2893 37.5
No organism identified 1305 2893 45.1rate estimates, which are given in Table 28 along
with 95% CIs, highest estimates and lowest
estimates.
Statistical significance of summary
estimates
There does not appear to be a statistically
significant variation between the estimated
isolation rates derived from published 2005 data
and actual rate of positive test results recorded
between 2004 and 2005 in replies from
laboratories. 
Summary of epidemiological data
Table 29 details baseline values (generated from
published evidence), along with upper and lower
values for sensitivity analysis (as reported in the
validation survey). Upper and lower values were
used instead of CIs of isolation rates to investigate
the effect of a large outbreak on laboratory
services. The much higher upper value for E. coli
O157 was derived using empirical evidence from
the South Wales E. coli O157 outbreak in autumn
2005. In a subsequent review commissioned by the
Chief Medical Officer for Wales,140 it was reported
that 2100 samples were tested during the
outbreak, with 158 persons (7.52%) positively
identified as infected.
Costing details
This economic evaluation was undertaken from
the perspective of the NHS. Therefore, only direct
medical costs paid for by the NHS bodies and
funding laboratory tests are included. It is unclear
how indirect costs such as time costs incurred by
patients or their over-the-counter medical
treatment costs would change if rapid tests were
implemented, and as such these values are
excluded from analysis.
Initial costs of implementing
programme
A decision model was developed to convey how
rapid test methods could be adopted in a
medium-sized NHS laboratory. Initial one-off 
costs in starting up the programme include
financing additional training in nucleic acid-
based methods.141 A hypothetical training 
scenario was developed, with the estimated 
cost of technician training estimated at £6600,
based on hourly wage rates for laboratory staff
(2005 prices). Results are shown in Appendix 6,
Table 49.
Finding spare capacity within the laboratory
building to accommodate new equipment may be
extremely difficult. For strategies in which tests are
provided in addition to culture, this is likely to
have a significant impact on the overall costs of
developing a rapid diagnostic service. PCR suites,
in particular, may demand a large area of
laboratory space to ensure that contamination will
not lead to false positive reporting. However, these
costs are likely to vary widely between laboratories,
depending on the size and capacity levels in each
centre. To minimise the subjectivity involved in
measuring these start-up costs, these were
excluded from this analysis. Each laboratory
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TABLE 28 Results of a survey of seven hospitals in England and Wales to estimate current workload and isolation rates
Organism Total stools examined  Total stools positive  Proportion Upper value–lower value
in 2004 for isolate positive (%)
Campylobacter 58,964 2562 4.35 16.94–2.98
Salmonella 58,964 584 0.99 7.91–0.65
E. coli O157 58,432 37 0.06 0.51–0.01
Source: Survey of faecal workload and positive isolates in randomly selected laboratories in England and Wales.
TABLE 29 Summary of epidemiological data
Organism Isolation rate (% positive samples) Upper value Lower value
Campylobacter 5.05 16.94a 2.98
Salmonella 0.76 7.91a 0.65
E. coli O157 0.11 7.52b 0.01
a Derived from outlier values reported in the laboratory survey.
b Estimated isolation rate experienced during South Wales E. coli O157 outbreak in 2005.manager should assess their unique laboratory
requirements carefully before deciding if rapid
testing could be implemented. 
Labour costs
Staff costs contribute significantly to the total cost
of running a diagnostic laboratory. Traditional
culture methods, with their time-consuming and
labour-intensive procedures, have relatively high
staff costs. Labour costs include not only the time
taken to perform the test, but also the time for
preparation of the extract, which may include a
lengthy extraction or concentration step.
Under the assumptions of the decision analytic
model, all tests are carried out by a medical
laboratory assistant. Results are read and
interpreted by a biomedical scientist. Salary costs
have been taken from pay scales in effect for
laboratory personnel in 2005, with the time for
analysis, administration and reporting calculated
(Table 30). All calculations are based on a working
week of 37.5 hours, with 17% on-costs included to
estimates.
The hands-on time for each test was calculated
from the commencement of handling the
specimens and controls in the laboratory to the
final absorbance results. Biochemical tests are
required for all culture-positive samples, and staff
time for this was calculated according to the
proportion of culture-positive samples received.
Full staff cost analysis is reported in Appendix 6,
Table 48.
Nucleic acid-based diagnosis
Attempts to attach a singular value to the cost of
nucleic acid-based diagnosis are confounded by
three major issues:
● Conventional PCR tests have a significantly
different cost structure to automated rtPCR
tests.
● A breakdown of costs for in-house-designed
PCR tests is difficult to administer. Once 
the high initial costs of developing the assay
have been accrued, the marginal costs of
routinely using an in-house-designed PCR 
test may be significantly lower than continuing
to purchase commercial kits. There is
insufficient evidence in the published literature
to validate the true costs of molecular assay
development. 
● The total cost per case is dependent on the
throughput per ‘run’ of PCR equipment.
Application of commercial real-time PCR test kits
versus in-house-designed methods
rtPCR tests can either be developed by the testing
laboratory themselves (‘in-house’) or purchased
from a commercial supplier. Good in-house assays
include appropriate controls in order to monitor
their reproducibility and effectiveness, with the
results of validation studies of in-house assays
being submitted for publication in peer-reviewed
journals.
In the absence of reliable information on the costs
of in-house-designed PCR assays, the unit cost
listed for commercially available kits was used.
Although the list price was set at £5.25, substantial
economies of scale are usually available, and
following consultation with the supplier, a price of
£3.75 was agreed.
Problems remain with the use of commercial tests,
including variability between batches; however, for
economic modelling purposes, it is assumed a
commercial rtPCR test kit will be used to detect
pathogens by nucleic acid-based methods.
Justifications for this assumption include:
● The methodologies and primer selection of in-
house-designed PCR tests are very
heterogeneous, and most of the in-house tests
have not undergone sufficient validation which
Economic evaluation
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TABLE 30 Estimates of staff cost using 2005 NHS pay scales
Test method Staff gradea Time taken Staff cost 
per test (£)
Campylobacter test culture  MLA/MLSO to report 8 minutes test plus 10 minutes for positives 1.40
Salmonella test culture MLA/MLSO to report 8 minutes test plus 10 minutes for positives 1.31
E. coli O157 test culture MLA/MLSO to report 10 minutes test plus 10 minutes for positives 1.59
PCR – any organism MLA/MLSO to report 6 minutes test 0.94
ELISA – any organism MLSO  7 minutes test 1.40
MLA, Medical Laboratory Assistant; MLSO, Medical Laboratory Scientific Officer.
a Based on 2005 NHS pay scales.commercial test kits must pass to ensure
reproducibility and efficacy.
● Staff training is considerably reduced when
using commercial test kits compared with in-
house designs, as they are easy to use. If
implementing nucleic acid-based methods in
regional laboratories, the additional training
costs to use the commercial kits would be much
less than training a laboratory scientist how to
replicate an in-house-designed assay.
● There is reduced risk of background DNA
contamination with quantitative rtPCR
methods, as the process is fully automated.
● Quantitative rtPCR technology is expanding at
such a rate that some authors predict that
conventional PCR methods will soon become
obsolete.
Reagent costs per test
Unit costs of commercially available kits vary
widely. Volume buying can reduce the cost by up
to 40% and ‘bundling’ of different kits from the
same manufacturer could result in substantial
discounts. The unit cost of Applied Biosystems
rtPCR kits was valued at £5.25. A discounted price
of £3.75 per test was available to moderate- and
high-volume laboratories (information gained
through direct contact with manufacturer). This
includes sample reaction mixes, positive and
negative control reaction mixes and reagents 
used for quality control. A 25% sensitivity range
was placed on these to account for other
manufacturers’ prices (from the evidence 
available at the time  of analysis, the Applied
Biosystems kits were the lowest cost commercial
rtPCR assays on the market; however, as the
technique becomes more popular, it is likely that
costs may decrease).
Impact of PCR capital equipment throughput on
price per test
Traditional culture and antibody-based testing can
be performed in a laboratory of any size,
irrespective of the throughput of faecal samples
that it may have. Due to the significant start-up
costs of purchasing the necessary equipment, PCR
tests are likely to require development in a larger
laboratory setting.
Nucleic acid-based test methods, particularly
rtPCR, are associated with very high capital costs.
As previously described, thermal cycler machines
are used to amplify DNA for nucleic acid-based
detection. Most have a maximum capacity of
96 wells, which can hold up to 92 samples
(excluding positive and negative controls). The
most up-to-date technology can perform DNA
amplification and interpret results within
40 minutes. It is estimated that to make optimal
use of this expensive equipment, each PCR run
must have a high throughput of tests
administered.
The decision to implement nucleic acid-based tests
must take account of the volume of samples being
sent to the laboratory each day. For example, in
many smaller laboratories, it may not be possible
to achieve adequate economies of scale to justify
the large sunk cost of PCR capital equipment.
Using the testing strategies outlined, the
throughput of tests per day for nucleic acid-based
detection is estimated in Table 31.
Despite the large volume of tests carried out each
year, there may still be sub-optimal usage of rtPCR
equipment. Ideally, given that each thermal cycler
can test 92 samples simultaneously, and three or
four cycles can be run per day, the volume of
testing would be higher. However, the cost of
commercially available reagents would limit usage. 
rtPCR needs a large capital outlay, with fully
automated thermal cyclers costing within the
range £20,000–30,000. NHS procurement of
expensive medical equipment usually permits
substantial reductions in the unit price. Through
discussion with manufacturers, we have assumed
the baseline cost to NHS laboratories to be
£20,000. The cost range for sensitivity analysis
(Table 32) is set at £16,500–23,500 (based on
estimates quoted by Applied Biosystems). The
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TABLE 31 Estimated throughput of tests per day for nucleic acid-based assays
Organisms Patient groups PCR  Annual  Throughput  Throughput  Runs/day
capacity samples (annum) (day)
All All 96 (92) 10,000 30,000 115 1/2
All High-risk (25%) 96 (92) 2,500 7,500 29 0/1
All High-risk  (50%) 96  (92) 5,000 15,000 58 0/1
E. coli All 96 (92) 10,000 10,000 38 0/1equipment is assumed to have a useful lifespan of
either 3 years (minimum value and baseline) or
5 years (maximum value) years (there is no
consensus on the lifespan of medical equipment –
10 years is commonly used, but for rapidly
evolving technologies this can be much shorter; a
3–5-year lifespan was chosen after discussion with
laboratory users regarding the ‘useful lifespan’ of
equipment in their workplaces).
For the six rtPCR testing strategies applied to this
decision analysis, baseline capital costs associated
with each strategy range from £0.22 per test for
full rtPCR replacement, compared with £0.89, if
only samples from high-risk patients are included.
When sensitivity analysis is included, this range
widens from £0.11 to £1.74. This considerable
variation suggests that the throughput of tests is
an important factor when implementing rtPCR
tests for enteric pathogens. Full details of variation
in rtPCR capital costs are given in Appendix 6,
Table 51.
Antibody-based tests: immunoassays
The cost of a test includes the direct costs of
reagents, equipment and labour. The shelf-life of
each test and volume of throughput may affect the
cost per test. Kits with a shorter shelf-life (e.g.
6 months) may not be used before the expiry date
if there is insufficient throughput of specimens.
Similarly, a microtitre format of a batch of eight or
96 will be expensive for testing on a single
specimen. Although it is difficult to quantify how
strongly these may impact the cost per test for
antibody-based tests, as a precautionary measure a
wide upper sensitivity range of 20% is applied to
all costs, while the lower value remains at 10%
(Table 33). 
Culture-based methods
As most UK laboratories now use prepoured plates
to culture food-borne pathogens, costs for culture
are based on this method.
In most hospital laboratories, the use of an
enrichment broth increases the overall cost and
turnaround time of the stool culture. Unfortunately,
conventional approaches are time consuming and
costly. Eliminating culture broths may be one
strategy for reducing these costs; however, it is
likely that the sensitivity of these tests would be
sacrificed as a result.142 Costs used in this economic
model were based on current laboratory costs
computed at a moderately large hospital laboratory,
and through contact with Oxoid, the leading
supplier of bacterial culture reagents in UK.
Breakdown of unit costs for each
testing strategy
A summary of unit costs of tests is given in
Table 34.
A detailed summary of how these costs were built
up is given in Appendix 6, Tables 50–52. In
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TABLE 32 Capital cost (£) of nucleic acid-based detection methods based on different testing strategies
£20,000 over 3 years £16,500 over 5 years £23,500 over 3 years
Annualised capital costs 6,666.67 3,300.00 7,833.33
Capital cost per test
rtPCR replacement strategy 0.22 0.11 0.26
25% high-risk patients, all organisms 0.89 0.37 1.74
50% high-risk patients, all organisms 0.44 0.22 0.52
All samples, E. coli only 0.67 0.33 0.78
ELISA test 0.05 0.03 0.10
Culture 0.02 0.02 0.05
TABLE 33 Cost estimates (£) for antibody-based tests
Baselinea Min. unit cost (–10%) Max. unit cost (+20%)
Campylobacter ProSpecT kit 3.64 3.28 4.37
Salmonella Wellcolex kit 1.41 1.27 1.69
E. coli Premier EHEC kit 3.65 3.28 4.38
a Cost estimates obtained through direct contact with manufacturers.summary, the composite values for each testing
strategy are shown in Figures 25 and 26.
Notably, the unit costs of bacterial culture are
slightly higher than that of full-scale rtPCR
detection or similarly replacement with ELISA
methods. rtPCR assays demand a large capital
outlay, but these costs may be offset by a reduction
in technical staff costs associated with labour-
intensive bacteriological culture methods. It is
worth noting that due to the ability of commercial
rtPCR test kits to automate DNA extraction and
analysis of results, the majority (78%) of staff costs
with PCR occur due to the need for initial pre-
enrichment. Should direct sampling become
available in the future, this would have a dramatic
impact not only on the timeliness of PCR, but also
on labour costs incurred.
Additive costs incurred when testing for all three
pathogens are higher than for those strategies
which test for only E. coli strains. It is important to
assess whether these lower costs relate to more
efficient outcomes. This can be achieved through
cost-effectiveness analysis.
Cost-effectiveness results 
Base-case results
The base-case test parameter values represent the
best estimate of sensitivity and specificity for each
type of test. Because the study designs used to
obtain measured values of sensitivity and
specificity vary widely, and the degree of available
evidence varies across the different types of test
under consideration, reasonable upper and lower
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TABLE 34 Summary of unit costs of tests (£)
Baseline unit costs Min. value Max. value
Campylobacter culture 5.21 4.17 6.25
Campylobacter ELISA 7.54 6.03 9.05
Campylobacter PCR 7.83 6.81 10.13
Salmonella culture 4.81 3.84 5.77
Salmonella ELISA 2.67 2.14 3.20
Salmonella PCR 5.35 4.82 7.15
E. coli O157 culture 4.99 4.00 5.99
E. coli O157 ELISA 5.45 4.36 6.54
E. coli rtPCR 5.67 5.08 7.53
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FIGURE 25 Breakdown of unit costs per sample for each testing strategy: replacement strategies versus status quouncertainty boundaries are specified for the
diagnostic accuracy of each test. The results show
a series of simulations to assess the cost-
effectiveness of various testing strategies (Table 35).
Baseline results from this decision model suggest
that if rapid test strategies were to replace fully
bacterial culture as the standard test, long-run cost
savings may potentially be enjoyed. However, the
implementation of rapid test methods as a
diagnostic adjunct would require significantly
more funding. The use of ELISA test kits is a
marginally less expensive strategy than rtPCR
testing; however, it is likely that rtPCR tests are
available sooner than antibody-based tests. When
diagnostic accuracy estimates are varied in the
model, it is suggested that the greatest uncertainty
surrounds the sensitivity of culture methods. At
the baseline 100% sensitivity, culture may detect
591 cases of food-borne infection in every 10,000
samples (using baseline epidemiological data,
based on 2005 reported cases of Salmonella,
Campylobacter and E. coli O157), but when the
lowest estimate is applied (see Table 35),
potentially 118 cases may be missed. Speed of
diagnosis, rates of diagnostic error and costs of
implementation should be considered
simultaneously when deciding which strategy is
optimal. 
Sensitivity analysis 1: variation in costs
of implementation
To assess the robustness of optimal testing strategies
to potential changes in prices, a 25% sensitivity
range was placed on unit costs for each strategy.
Table 36 shows the unit price of each method.
Sensitivity analysis 2: variation in
isolation rates
Cost-effectiveness results for individual organisms
according to minimum and maximum recorded
isolation rates from laboratory survey are
presented in Tables 37–39.
Sensitivity analysis 3: outbreak of 
food-borne illness
In September 2005, a large outbreak of E. coli
O157 was reported in South Wales, with the
original source implicated identified as a local
school meat supplier. A large-scale investigation
was mounted, with an increased volume of tests
carried out. A report from this investigation stated
that 2100 stool samples were taken, with 158 cases
positively identified. In accordance with this
empirical evidence, an isolation rate of 7.52% was
applied to the economic model to account for a
hypothetical outbreak of E. coli O157, and the
cost-effectiveness of each strategy in this setting
(Table 40).
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.Owing to the similarity in diagnostic accuracy
values and unit costs, the cost per case detected
was remarkably similar for all strategies. However,
as the ‘additive’ strategies convey only the
incremental costs of choosing rapid test methods,
and not the full costs of these in addition to
routine culture costs, these options are
considerably more expensive.
Sensitivity analysis 4: suboptimal
detection with bacterial culture
Implications of routine use of culture
An interesting finding from this review concerns
not just the diagnostic error experienced with new
rapid technologies, but also that of routine
culture. As bacterial culture is the current testing
procedure nationwide, it is likely that the
Economic evaluation
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TABLE 36 Summary unit costs for each test method, by organism (costs per sample)
Strategy Baseline unit costs (£) Min. value (£) Max. value (£)
Campylobacter culture 5.21 4.17 6.25
Campylobacter ELISA 7.54 6.03 9.05
Campylobacter PCR 7.83 6.81 10.13
Salmonella culture 4.81 3.84 5.77
Salmonella ELISA 2.67 2.14 3.20
Salmonella PCR 5.35 4.82 7.15
E. coli O157 culture 4.99 4.00 5.99
E. coli O157 ELISA 5.45 4.36 6.54
E. coli rtPCR 5.67 5.08 7.53
TABLE 37 Cost-effectiveness of different strategies for detecting Campylobacter
Strategy Cost per sample  Baseline isolation –  Lowest isolation –  Highest isolation – 
(£) 5.05% 2.98% 16.94%
Status quo – cost of culture 5.21 158.65 268.79 47.28
rtPCR replacement – all samples 7.38 164.50 278.70 49.03
ELISA replacement of culture 7.59 170.27 288.49 50.75
rtPCR for high-risk patients 7.82 174.23 288.49 51.93
TABLE 38 Cost-effectiveness of different strategies for detecting Salmonella
Strategy Cost per sample Baseline isolation – Lowest isolation – Highest isolation – 
(£) 0.76% 0.65% 7.91%
Status quo – cost of culture 4.81 677.30 787.69 64.73
rtPCR replacement of culture 4.90 755.27 878.36 72.18
ELISA replacement of culture 2.88 411.07 478.06 39.28
rtPCR for high-risk patients 5.34 821.97 955.94 78.55
TABLE 39 Cost-effectiveness of different strategies for detecting E. coli 
Strategy Cost per sample Baseline isolation – Lowest isolation – Highest isolation – 
(£) 0.11% 0.01% 0.51%
Status quo – cost of culture 4.99 5,273.20 56,800.00 1,113.73
rtPCR replacement of culture 5.22 5,025.18 54,128.46 1,061.34
ELISA replacement of culture 5.44 5,405.38 58,223.86 1,141.64
rtPCR for high-risk patients 5.66 5,306.20 58,623.25 1,149.48
ELISA for high-risk patients 5.44 5,343.75 58,223.86 1,141.64
rtPCR for all patients, E. coli only 5.89 5,514.38 60,870.64 1,193.54published epidemiological data underestimates
the identification of pathogens in submitted
samples. The public health implications of these
findings may be considerable, and further research
in this area is warranted.
Implications of under-reporting by culture on
costs per case detected
The most serious implications of diagnostic errors
in culture methods are likely to be experienced
with E. coli infections. Evidence from clinical
effectiveness studies suggests that sensitivity of
SMAC in detecting all EHEC (i.e. including non-
O157 strains) may be as low as 32%,25 when
compared with a ‘gold standard’ of SMAC culture
and cytotoxicity assays. Instead of concentrating
on the biochemical characteristics of the E. coli
O157 strain, rapid detection technologies target
all shiga toxins, and as such can encompass O157
and non-O157 strains equally. It is therefore
possible to estimate the level of under-reporting
for all EHEC associated with the use of SMAC
culture. Keeping rapid test sensitivity values as
estimated from meta-analysis of studies, and
changing the culture sensitivity for EHEC to 80%,
there are considerably more cases detected by
rapid techniques. The cost per additional case
detected, further to what would be found in
culture, is shown in Table 41.
Replacing culture
It is not assumed at present that rapid test
methods will replace bacteriological culture, but
rather that they should be a diagnostic adjunct to
improve patient outcomes when speed of response
is crucial in preventing further outbreak or
worsening of patient conditions. However, with
much research being invested in the development
of rapid methods, these tests may well be viable as
replacements to traditional culture in the future.
This hypothetical analysis illustrates that if
microbiology laboratories were to switch from
bacterial culture to molecular methods, the
increase in costs per sample for rapid methods
compared with culture is not significant.
Summary of cost-effectiveness results
In terms of economic efficiency, strategies to
implement rapid detection methods as a
diagnostic adjunct to culture were strictly
dominated by strategies which fully replace culture
by either serological or nucleic acid-based tests.
However, in the light of the apprehension shared
among many microbiologists over abandoning
bacterial culture, ‘double testing’ strategies
remained in analysis. For ‘adjunct’ strategies, the
implicit cost-effectiveness of carrying out the
additional rapid tests would in most cases be low.
For ‘replacement’ strategies, the cost per case
detected varied widely with sensitivity analysis;
however, the overall costs for each strategy were
relatively similar. Results were most sensitive to
changes in isolation rate. Incremental changes in
cost estimates made a moderate impact on overall
costs. Naturally, implementing rapid detection for
all organisms would cost significantly more than if
performing rapid detection for EHEC only.
However, using cost per case detected as a suitable
Health Technology Assessment 2007; Vol. 11: No. 36
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TABLE 40 Cost per case detected in outbreak scenario (E. coli isolation rate 7.52%)
Strategy Cost/sample (£) Cost/case detected (£) Implementation (£)
Status quo – cost of culture 4.99 68.48 158,100
rtPCR replacement of culture 5.67 71.13 178,966
ELISA replacement of culture 5.45 73.62 162,100
‘Add-on’ rapid strategies
rtPCR for high-risk patients 5.66 add-on 85.23 80,166 add-on
ELISA for high-risk patients 5.45 add-on 75.62 54,365 add-on
rtPCR for all patients, E. coli only 5.89 add-on 79.99 60,188 add-on
TABLE 41 Cost per additional case of EHEC detected by rapid methods compared with bacterial culture
Strategy Cost per sample EHEC cases detected  Cost per EHEC case 
(£) per 10,000 tests detected (£)
rtPCR 5.22 18 2933.91
ELISA 5.44 17 3206.25
Culture 4.99 11 4536.20
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.outcome measure, testing for all three organisms is
associated with much more attractive cost-
effectiveness outcomes. 
One of the initial assumptions of the model was
that the sensitivity and specificity of bacterial
culture equalled unity. Relaxing this assumption
would be expected to lead to improvements in the
cost-effectiveness of rapid detection methods
relative to standard testing. With a culture
underperformance modelled at 80% sensitivity,
both nucleic acid-based and serological assays
could detect an additional seven cases of EHEC
infections per year. Given the severity of illness,
and the speed at which an E. coli outbreak can
spread, switching to an alternative testing strategy
for this pathogen may have substantial benefits. 
A subgroup of high-risk patients (i.e. those with
severe symptoms or the very old and young) were
assumed to account for 20% of all samples
submitted. Two-way sensitivity analysis was
performed to assess the incremental cost-
effectiveness of testing this patient group with
rapid detection methods, assuming that the
isolation rate will now be higher (given the
presence of severe symptoms, e.g. bloody
diarrhoea). It is worth noting, however, that triage
may have a cost to the laboratory. Several
alternative testing algorithms will have to be in
place and any lack of information accompanying
the sample will have to be sought by telephone
before testing strategies can be decided.
Discussion
This modelling exercise relies heavily on knowing
precise data estimates for three key parameters:
isolation rates for each pathogen, costs of
implementation and diagnostic accuracy for each
test. Sensitivity analysis was performed on each of
these parameters to assess the impact that changes
in these estimates may have on outcomes for each.
The model predicts that whereas small changes in
diagnostic accuracy and cost estimates do not vary
the overall cost per case detected for each strategy,
a marginal change in isolation rates results in
relatively large changes in the outcomes.
Outcomes are highly sensitive to the overall
prevalence of each organism, which may explain
why the cost per case detected for Campylobacter,
the most commonly reported food-borne illness, is
substantially lower than that for E. coli, which
occurs rarely, but is given high priority due to the
serious medical complications that may ensue.
The sensitivity of isolation rates will have
widespread implications for these results with
respect to geographical variations in community
prevalence. By using minimum and maximum
isolation rates recorded from a prospective
nationwide laboratory survey, authors have
attempted to account for this regional variability.
However, policy makers should take account of
their localised community prevalence when
assessing the need for rapid test methods. 
Whereas sensitivity analysis to overall diagnostic
accuracy values did not significantly alter
outcomes for each testing strategy, the
implications of diagnostic errors with bacterial
culture had a greater impact. Under-reporting by
culture methods may suggest that the number of
positive cases recorded annually may indeed be
lower than the ‘true’ volume of pathogenic
samples submitted, given the current reliance on
culture methods throughout the UK. Much more
research is required in this area.
Availability of data
Although stringent attempts were made to secure
the most accurate data for this economic
evaluation, there are potential shortcomings with
several of the input values for the model. By using
the most recently published annual figures for
disease incidence, we are confident that the
volume of positive cases is relevant; however, the
only figure we could identify regarding the total
volume of tests carried out per year (used to
measure the isolation rate) was last recorded in
1994. A small-scale laboratory survey was carried
out in an attempt to validate this figure, which
somewhat agreed with the published value;
however, uncertainty still remains around the
actual volume of tests carried out nationally in
current practice.
Applicability to smaller laboratories
One criticism of this hypothetical model may
relate to the moderately large volume of tests
performed annually (10,000 samples). Many
hospital laboratories carry out much fewer tests for
food-borne pathogens each year. However, due to
the substantial equipment costs associated with
nucleic acid-based tests, and the need for a high
throughput of samples to lower the average cost
per test, this level of investment would be
infeasible. One option worth exploration could be
the introduction of a centralised PCR testing
centre in each region, where samples could be sent
for rapid diagnosis. However, it is worth noting
that the cost savings enjoyed from economies of
scale are forgone when additional expenses are
considered, such as delivery charges to the centre.
Economic evaluation
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require meticulous organisation and planning.
These are illustrated in Appendix 6, with a
breakdown of costs in a hypothetical centralised
laboratory testing 50,000 samples annually 
(Table 54). 
Exclusion of latex agglutination tests
from analysis
A notable omission from this cost-effectiveness
model is the role of antibody-based screening
tests. Without adequate diagnostic accuracy data,
these tests could not be included in decision
analysis; however, their merits have been noted.142
The diagnostic accuracy of these tests is fair, with
alternative detection methods performing better,
but at a higher cost. The main cost savings arise
from the potential to eliminate further workup of
pathogens. These assays are faster, cheap, easy to
perform, widely available and can cut down on
staff time. Because 85–99% of the total number of
specimens tested have negative results for specific
organisms, proponents argue that the use of
cheap, fast kits could decrease the expense and
overall turnaround time for most stool cultures
performed. The cost savings include the cost of
subculture plates, biochemical tests used to screen
colonies and technologist time to perform the
assays. Although they are not routinely used in UK
laboratories, other countries have adopted them
for routine testing (for example, the Wellcolex
Colour Salmonella test has been adopted widely in
Germany as a screening device). To appreciate
fully the potential cost savings, it is necessary to
look at the volume of subculture plates that receive
further workup. Usually a high proportion
(50–70%) of biochemical screens are performed on
cultures that eventually have negative results.
McGowan and Rubenstein142 estimated that in
their institution, eliminating the workup of
colonies from Gram negative subculture plates
would result in a media saving of US$124.00 per
100 stool specimens cultured and a time saving of
approximately 20 hours per 100 stool specimens
cultured. 
Cost per case detected as an outcome
measure
Cost per case detected is usually consigned to
evaluations of screening programmes, defined as
when tests are performed on people at risk of
developing a certain disease, even if they have no
symptoms. Screening tests can predict the
likelihood of someone having or developing a
particular disease, and hence the added value of
‘detecting’ one person at risk is an economic result
in itself. However, as previously discussed, using
this cost-effectiveness measure fails to link
diagnostic performance to long-term health
outcomes. There is research potential to
investigate the ‘end-point’ impact of these tests,
possibly through a prospectively designed
randomised controlled trial. 
Although the impact of timeliness is central to the
implementation of new test methods, without
available data on patient outcomes it is unclear
how speed of detection may impact the overall
effectiveness, and subsequent cost-effectiveness, of
each strategy. An assessment of clinicians’
willingness to pay for faster diagnosis may also
contribute to understanding.
Health Technology Assessment 2007; Vol. 11: No. 36
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o develop a valid diagnostic model based on
the reviewed literature and assessment of cost-
effectiveness, it is important to seek a clinical
evaluation of the impact of different testing
options. The qualitative arm of this research
involved exploring disagreement and concordance
of ideas between health professionals involved in
the diagnostic process for food-borne illness.
Following ethical approval, a focus group with
three GPs, four microbiologists and one Consultant
in Communicable Disease Control (CCDC) was
organised, applying the nominal group technique
(NGT). This approach was first described in the
1960s as a procedure to facilitate effective group
decision-making in social psychological
research,143 and has been used in many settings to
gain a ranking of expert views on important
impacts of different strategic interventions.144,145
Its three most typical applications have been
problem identification, development of solutions
and establishing priorities all of which have
relevance to our study aims. 
Nominal group process
The NGT consists of two rounds in which
panellists rate, discuss and then re-rate a series of
items or questions. The meeting was structured as
follows:
● Reviews of the relevant literature are provided
to participants before the meeting.
● Participants spend several minutes writing down
their views about each topic in question.
● Each participant, in turn, contributes one idea
to the facilitator, who records it on a flip chart.
● Similar suggestions are grouped together, where
appropriate. There is a group discussion to
clarify and evaluate each idea.
● Each participant privately ranks each idea
(round 1).
● The ranking is tabulated and presented. 
● The overall ranking is discussed and re-ranked
(round 2).
● The final rankings are tabulated and the results
fed back to the participants.
Alongside the consensus process, we will have a
non-participant observer (research associate)
collecting qualitative data on the nominal group.
This is similar to a focus group. However, the
NGT focuses on a single goal.
Following an overview of research findings from
the study investigator (IA), the NGT facilitator
(AH) addressed participants with three key
research questions:
1. Based on clinical and cost-effectiveness data
provided, would you choose rapid tests for:
● an individual case of food-borne illness?
● a suspected outbreak of food-borne illness?
2. For which organism, if any, should rapid testing
be prioritised?
3. What, if any, testing strategy should be
implemented when ordering or using rapid
tests for food-borne illness?
Clinical aspects
For individual cases of food-borne illness,
participants from all professional groups agreed
that the decision to order rapid testing must
depend on clinical criteria: these criteria were
severity of symptoms and belonging to a ‘high-
risk’ patient group. All participants suggested that
if rapid tests were to be adopted, priority would be
given to test children aged under 5 years. Elderly,
pregnant or immunocompromised patients were
also judged as in greater need of rapid tests than
the wider community. Additionally, one GP
suggested that they would only consider rapid
testing in patients who were clinically very unwell
or with serious illnesses which put them at risk of
sepsis, e.g. diabetes or other chronic disease.
Other priorities were to make diagnostic
distinctions of food-borne illness from other
sources of acute abdominal pain, e.g. appendicitis. 
There was a general consensus among the group
that not all patients would warrant selection for
rapid testing, i.e. that triage of patients would be
advisable. One GP noted that in reality the
decision to order microbiological examinations,
whether rapid or routine, is usually empirically
based. All GPs argued that in terms of patient
outcomes, correct patient management is more
valuable than microbiological identification per se.
Health Technology Assessment 2007; Vol. 11: No. 36
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Chapter 8
Nominal group analysis with cliniciansIt was noted that the decision to order laboratory
tests may rest on funding issues, particularly if
both standard culture and rapid tests are available,
but with a large cost variation, as this would act as
a financial disincentive in spite of apparent clinical
priorities.
Some disagreement was expressed among the
microbiologists regarding the need for rapid tests
in individual case settings, for example between
the benefits of quicker results in terms of excluding
a significant problem, while another microbiologist
was not convinced of the need for rapid tests
except in the context of a specific outbreak. 
Organisms under investigation
Perhaps the most interesting findings from the
NGT session centred around the participants’
perception of which organism held greatest
importance. Having been presented with UK
isolation rates for each organism, costs per
individual test and, crucially, cost per case
detected, most participants still felt that E. coli was
the organism for which rapid testing could bring
about most positive change. Irrespective of the
high cost of detection and low prevalence of the
disease, most participants believed that E. coli
testing must be prioritised due to its severe
secondary complications.
Only one participant (a GP) argued that tests
should be prioritised based on prevalence, that is,
that tests for Campylobacter, Salmonella and then
E. coli should be introduced. The same GP argued
that nearly all GP cases of food poisoning that
were confirmed microbiologically were reported as
Campylobacter; and Salmonella, which has a longer
duration of illness, was also an important
pathogen. Contrastingly, a CCDC did not think
that rapid tests for Campylobacter should take
precedence, due to its self-limiting nature and the
low risk of outbreak. Given the mixed opinions
expressed within this small group of health
professionals, more research is needed to uncover
which pathogens should be prioritised. 
Public health aspects
For suspected outbreaks of food poisoning,
microbiologists would be much more inclined to
use rapid tests than for individual cases. Notably,
however, there was some variation between
professions in what is deemed an ‘outbreak’. GPs
argue that the outbreak setting is important – for
example, outbreaks in old people’s homes are
much more likely to cause serious illness than in
secondary schools, where one can assume subjects
are stronger. If there is a clear causal path of the
outbreak, such as several infected people in the
same restaurant, or perhaps in a non-food-borne
source such as children visiting a petting farm,
rapid tests may also be applied to reveal the scale
of outbreak. For restaurant outbreaks, the CCDC
present believed rapid detection methods may be
useful in citing the source of infection – when
waiting for culture results, the food source is most
likely to be thrown out/finished before
confirmation of infection can be given.
Interestingly, rapid detection as a tool to curbing
secondary infection was not an overly important
issue to any clinicians. The CCDC suggested that
rapid tests may be useful for contacts with high
risk of passing on infection, such as food handlers,
children and people with learning difficulties, but
for the general population participants did not
express the opinion that rapid tests could limit
secondary infection. 
Timeliness issues
A key area of concern for many participants was
organisational factors surrounding implementation
of rapid tests. Participants suggested that rapidity
could be reduced by variations at patient and
service level; for example, patient non-compliance
in returning a specimen to their surgery, or the
time delay between the sample arriving in local
hospital and larger laboratories receiving the
sample. All participants agreed that very careful
planning is required if such a testing strategy was
to be developed, to ensure that any significant
benefits were maintained in ‘real-life’ settings.
Service implementation needs to ensure that the
‘actual’ time from when a patient seeks medical
attention to when results are reported back is
significantly faster – GPs were dubious that this
would always happen unless a very well-organised
delivery/reporting system was developed. There
was agreement among all professional groups
involved that food-borne outbreak control lacks
definitive standards on the duration between
confirmation of laboratory results and reporting to
a clinician. 
Choice of rapid tests
Antibody-based tests did not receive as much
interest from participants as molecular methods.
Nominal group analysis with clinicians
86This outcome was expected, as economic
modelling showed that antibody test kits have
almost equivalent costs to rtPCR kits, but with
longer detection times. The CCDC suggested that
he may choose the ‘cheapest test’ first and, once
this organism is eliminated, would go on to use
the more expensive methods. This view was not
shared among other group members.
All microbiologists observed that molecular
diagnosis is coming to the fore in routine
pathological examination. One suggested that
future developments may include a ‘molecular
suite’ in which any pathogen, irrespective of
taxonomy, may be detected within the same
quantitative rtPCR laboratory, catering for all
infectious diseases, such as sexually transmitted
diseases, meningitis or respiratory infections. The
potential benefits of multiplex testing for food-
borne pathogens were also highlighted by another
microbiologist, who suggested that if it were
possible to test for multiple enteric pathogens in
the one run, rtPCR tests would certainly be useful,
but until these methods are validated, it remains
most crucial to exclude E. coli O157.
With the suggestion that full-scale molecular
detection is foreseeable within the next few
decades, one microbiologist argued that PCR as a
diagnostic adjunct is a very expensive strategy. If
molecular diagnosis were to fully replace culture,
certain measures could still be put in place to keep
a record of epidemiological information or data
on antibiotic resistance. Suggestions included
using rtPCR for all samples, but additionally
culturing the nth stool for reference purposes, or
storing half of a stool sample for 24 hours (until
PCR results are known), then culturing every
positively identified specimen. It is important to
note, however, that this opinion was not shared by
all microbiologists. More research is required to
assess professional opinion on the future
directions of molecular diagnostics.
Ease of use issues
The NGT session highlighted problems around
the technical skills required for microbiological
investigations. One microbiologist discussed how,
in recent years, it has become increasingly difficult
to employ laboratory technicians with adequate
skills to carry out tests. More technically
demanding tests increase the likelihood of human
error, such as missed diagnosis or incorrect
reporting of a disease. Culture is relatively
technically demanding. Antibody-based methods
will rely on culture to a certain extent. In this
microbiologist’s opinion, quantitative rtPCR shows
the greatest potential to be carried out by less
skilled technical staff. The use of commercial kits
may further cut down training required. If the
pattern of skill shortages continues in the future,
healthcare providers may find that simple-to-use,
easy-to-interpret methods such as rtPCR are
necessary to ensure diagnostic accuracy. The
appropriate level of skill in using tests can only be
achieved in two respects: through adequate
training and also through adequate practice. In
this respect, the larger the laboratory, that is, the
higher the throughput, the more likely it will be
that human error will be reduced. 
Key recommendations from
nominal group session
● More research is required to define clinical
guidelines for which rapid tests should be
advocated.
● Any strategy to introduce rapid tests would
require meticulous organisation, particularly if a
centralised nucleic acid-based testing laboratory
was created.
● Ease of use is a very important consideration
with regard to the current shortage of
appropriately skilled laboratory staff. In this
respect, commercially available rtPCR kits,
which eliminate the need for technically
demanding culture, may prove the most
suitable. 
● Most clinicians believe that excluding the most
dangerous pathogens is the greatest concern, as
opposed to those (such as Campylobacter) with
the greatest prevalence.
● The most benefit could be derived from a single
test which could be used to detect all the
possible pathogens simultaneously – that is,
multiplex PCR.
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his research was conducted in an attempt to
synthesise a mixed and heterogeneous body of
evidence regarding the diagnostic accuracy and
cost-effectiveness of rapid diagnostic tests for
bacterial food poisoning. Through a systematic
review of evidence, using meta-analytic techniques
where appropriate, this report is the first
comprehensive evaluation of study results to date
produced in the UK.
Summary of diagnostic accuracy
evidence
Food-borne infections
In general, very good test performance levels of
sensitivity and specificity were observed with 
rapid test methods. From meta-analysis of the
published evidence, nucleic acid-based tests
appear to perform marginally better than the
ProSpecT EIA kit for detection of Campylobacter.
There are no statistically significant differences
between rapid diagnostic accuracy values for any
of the rapid test methods for Salmonella food
poisoning, although adaptions to traditional
methods, namely the use of chromogenic 
medium and automated minaturised bacterial
identification systems, performed less well. From
the available evidence on the diagnostic accuracy
of commercial serological testing kits for E. coli,
the VTEC Screen assay appears to be more
sensitive than the Premier EHEC kit, with
comparable high specificities. Nucleic acid-based
tests outperformed serological kits for all EHEC
strains.
Toxin-induced food poisoning
For toxin-induced food poisoning, this review
could not identify a sufficient number of
comparable studies to warrant meta-analysis. From
a narrative review of methods identified, there is
mixed evidence regarding the potential benefits of
rapid tests. The reference tests in diagnostic
comparisons for C. perfringens, B. cereus and
S. aureus are most commonly the commercially
available RPLA kits marketed by Oxoid. Several
authors note that these may not be optimal
methods. The limited evidence available suggests
that nucleic acid-based detection methods perform
well for C. perfringens, Staphylococcal enterotoxins
and emetic strains of B. cereus, in most cases
detecting more cases of illness than the current
reference methods.
Methodological aspects of review
Search strategy
The pre-piloted search strategy identified a
sizeable number of papers claiming to evaluate
rapid tests; however, despite a variety of
commands to locate evaluative studies, most
studies were eliminated due to a lack of
comparison with a reference test. Lack of
specificity in electronic searches has been
problematic in other reviews of this nature, and
researchers have cited insufficient MESH 
indexing as a common problem with evaluations
of diagnostic technology.146 In addition, 
a small proportion of relevant studies 
subsequently found through handsearching
reference lists and key journals were not 
identified in the standardised search, indicting
sub-optimal sensitivity. These factors made
searching for evaluations difficult and could mean
that some papers are still to be discovered. It is
also likely that some evaluations were presented as
conference posters but the data from these are less
easy to trace.
Inclusion criteria
A stringent study inclusion criteria was developed
using findings from the initial piloted search
strategy. This included the prerequisite that all
included studies must compare the rapid test with
a suitable reference standard. Subsequently, when
it became clear that very few evaluations of rapid
toxin detection methods have been published, this
criteria was relaxed to allow for a more narrative
discussion of developments in rapid diagnosis of
B. cereus, S. aureus and C. perfringens. A systematic
appraisal of the diagnostic accuracy of detection
methods for these enterotoxin-producing
pathogens was not possible due to a lack of
evaluative studies on many occasions. There is a
larger evidence base for food-borne bacterial
infections, namely Campylobacter, Salmonella and
E. coli O157. 
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DiscussionStatistical issues
Availability of data for statistical
analysis
Planned statistical analysis included attempts to
model the variability due to other sources, such as
meta-regression of patient characteristics, study
quality and characteristics such as inclusion
criteria and measurement of outcomes in the
regression model. Due to the small number of
studies in each category, this was not possible with
the data currently available.
Lack of true gold standard
Although traditional culture is the natural
reference test to use for comparative statistical
analysis, on many occasions the rapid test may
outperform culture. A major problem in most
studies concerned the reporting of diagnostic
accuracy in the absence of a true gold standard.
The most accurate verification of disease status in
a faecal specimen uses biochemical identification,
an expensive and labour-intensive method which
is usually only applied to those samples in which
food-borne pathogens are presumptively detected
by culture. Sensitive phenotypic reference tests
were used by some authors, and in many cases
these were collinear with novel rapid techniques to
a greater extent than conventional culture. In
other cases, variation in the choice of bacterial
agar plating may have an impact on results
recorded with culture. The application of different
gold standard methods makes it difficult to assess
whether evaluation results for different tests are
truly comparable. Standard methods and a high-
quality evaluation design need to be applied so
that accurate comparisons can be made.
To complicate further the issue of ‘true’
identification of pathogenic isolates, it is possible
that a significant proportion of microbes detected
by nucleic acid-based methods may indeed be false
positives.50 In view of this possibility, stringent
measures are needed when performing the PCR
assay to avoid false positive reactions. Much
improvement of methodology is needed, as through
the use of an imperfect ‘gold’ standard,147 studies in
this area may be inherently statistically flawed. In
reality, most diagnostic tests are evaluated using
architecture subject to immense bias.
Assessment of heterogeneity
Limitations of the meta-analysis in this review
relate to the lack of appropriate techniques for
pooling the results of diagnostic accuracy studies.
This review utilised the simplest techniques
available to facilitate access to data. A systematic
approach to the choice of meta-analysis method
was taken based on the assessment of correlation
between sensitivity and specificity, evaluation of
heterogeneity with a 2 test and the I2 statistic,
graphical display of results and, where
appropriate, SROC analysis. The SROC analysis
technique used in this review includes the lack of
an average estimate of sensitivity/specificity and
the use of a regression model with the explanatory
variable estimated with error. This makes the
standard error estimated less suitable for assessing
sources of heterogeneity. However, formal
assessment of sources of heterogeneity was either
done through subgroup analyses or not
undertaken due to the limited number of studies
in each subgroup. Alternative models were fitted
in the statistical software SAS and the results were
consistent with the reported results. There is no
consensus as to the standard statistical approach to
use in pooling diagnostic accuracy studies and
investigating heterogeneity. The methods used in
this report were based on the limitations of
available data and the particular clinical question
that the report addressed. 
Quality of included studies
The methodological quality of studies included in
this review varied considerably. The QUADAS
tool,236 was used to assess the quality of diagnostic
accuracy studies included in this systematic review.
Limitations of studies related to poor reporting of
test results and the blinding of their
interpretation. Although most of the selected
studies provided enough data to estimate
sensitivity, specificity and predictive values,
subgroup analysis was not attempted by any
authors, and reproducibility of the test was 
rarely formally assessed. For several studies,
particularly those evaluating nucleic acid-based
assays, the length of time between reference test
and index test was extensive (up to 2 weeks in
some instances), and analysts could not be
reasonably sure that the pathogenic state of 
each specimen did not change between the 
two tests. 
Variability of the results from one study to another
demonstrates the necessity to standardise the
different methodologies in the future. Several
evaluations could benefit from design
improvements. The applicability of
methodological guidance such as the STARD
(standards for reporting studies of diagnostic
accuracy) initiative should be highlighted for
future research.
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As food-borne pathogens are generally associated
with very low (<5%) isolation rates, prospectively
designed studies must include a large sample size
to permit the identification of a sufficient number
of true positive results. This may be prohibitively
expensive for several test centres. Although the
use of a retrospective (‘banked samples’) study
design is not usually encouraged when evaluating
new technologies, in this instance, the resources
needed to conduct sufficiently large prospective
studies are sizeable and may not be justifiable in
view of opportunity costs. The studies reviewed
here were mainly of a retrospective design, with
the notable exception of E. coli diagnostic
evaluations, which may reflect the additional
weight given due to the severity of the illness that
it causes. Only one prospective study was
identified for toxin-inducing food-borne illness.78
The use of banked reference samples may lead to
the test performance appearing better than may
have been experienced using fresh patient
samples. 
Laboratory proficiency
Laboratory proficiency may have a significant
impact on the diagnostic error rate experienced
with relatively complex microbiological testing
methods. It is likely that research teams who have
embarked on developing rapid detection methods
would have adequate experience in the techniques
to minimise any human error. Therefore, the
sensitivity and specificity values reported in these
studies may be higher than what could be
experienced in practice in a smaller, less
experienced laboratory setting. This factor further
highlights the need for easy-to-use, highly
reproducible tests. This requirement could most
likely be met through the use of commercial kits,
as opposed to in-house-designed assays.
Cost and cost-effectiveness
Costing issues
No previous economic evaluations of rapid
diagnostic testing for food poisoning could be
identified from the literature search. Only six of
the clinical studies included in the review
contained any information on comparative costs of
implementing rapid tests, and owing to the wide
variation in country and year of measurement for
these cost data, reliability as an estimate of current
UK costs was limited. 
Economic analysis was further hindered by
difficulties in valuing the costs involved in in-
house-designed tests. Although the large
proportion of included studies were novel assays
which were as yet not commercially available, cost
estimates for these methods are very difficult to
quantify, and are likely to vary widely. Decision
analysis was based on the assumption that
commercially available test kits were used, as unit
costs could be applied to these with greater
confidence. Discrepancy may exist between the
diagnostic accuracy reported with commercial kits
and those from in-house-designed assays. In
particular, for published literature on nucleic acid-
based studies, in-house-designed methods were
more widely reported than evaluations of
commercial kits, and the accuracy of kits may vary
from that reported and used in economic analysis.
However, as PCR reported consistently high
sensitivity and specificity values irrespective of
assay format, and sensitivity analysis around
diagnostic accuracy did not alter the findings to a
large degree, it is unlikely that this will cause a
serious miscalculation of correct diagnoses or alter
subsequent cost per case detected values.
Cost-effectiveness issues
Robustness of cost-effectiveness results
The economic model was most sensitive to
changes in isolation rates and less sensitive to
small changes in costs or diagnostic accuracy. As
community prevalence is likely to vary in different
regions, policy makers must carefully assess the
potential benefits gained from implementing
rapid diagnostic tests in each setting.
Effectiveness data
Effectiveness data for the diagnostic tests came
from the systematic review and meta-analysis. The
results show that the cost per case detected is
robust to changes in diagnostic accuracy. This is
not surprising, considering the very high
sensitivity and specificity values that the review of
published studies identified. More revealing was
the potential impact that suboptimal culture
methods may result in. As the standard detection
method for almost a century, it may have been
taken for granted that bacterial culture produced
‘perfect’ accuracy values. However, with the advent
of completely new detection techniques, this
hypothesis is starting to be challenged. Additional
cases detected of EHEC, Salmonella and
Campylobacter could be substantial. This is an
under-researched area, which could benefit greatly
from a larger prospectively designed study to
validate the emerging theory. However, culture is
useful for other reasons, such as phage typing and
sequencing of genes to identify related clusters
and for antibiotic resistance testing.
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The availability of data to estimate confidently the
cost-effectiveness of each method was limited. As
tests become more widespread, unit prices are
likely to decrease for all methods apart from
culture, where they have been stable for decades.
This analysis is likely to underestimate potential
cost-effectiveness of rapid alternatives as a result.
Diagnostic adjunct versus future PCR
replacement of culture
When modelling cost-effectiveness, costs to test all
with PCR compared with testing all by traditional
culture are equivalent, and when the diagnostic
accuracy of culture methods is measured to be less
than optimal, nucleic acid-based methods may
actually be more cost-effective, despite the high
capital costs involved. Given that PCR results are
available quicker than for culture, and are
equivalent in price, this suggests that PCR could be
a viable replacement to culture in the future. One
method of achieving this would be to keep the
stool sample in storage media until the results of
PCR detection are known, at which point positive
samples can be cultured using standard methods
and the isolate can be retained for reference
purposes. An outline of this is shown in Figure 27.
Outbreak setting
There is insufficient evidence available to assess
the impact of rapid diagnostic testing in an
outbreak situation. The clinical significance of
additional positive results or faster diagnosis
remains unclear. The data presented in this report
Discussion
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FIGURE 27 Alternative methods for the rapid diagnosis of food poisoningdo not conclusively suggest that faster diagnosis
will lead to a better clinical outcome for the
patient. Ideally, in the absence of primary studies,
these potential effects could be assessed using a
mathematical transmission model. However, in the
absence of data to parameterise such a model, it
was not possible to model mathematically how
public health measures may change as a result of
rapid diagnosis. The impact of more prompt
interventions within outbreaks, brought forward
through rapid testing, needs to be examined in
future studies. 
Issues for implementation
Acceptance and application of rapid methods in
the analysis of bacterial food-borne pathogens
have been slow. There are a number of factors to
be considered when determining which testing
system is most effective. These factors include the
initial investment that is required, operating costs,
technician time, range of organisms under
investigation and the ability of the test to identify
correctly food pathogens of interest.
Other testing, such as for viruses and parasites,
may be performed on samples collected from
cases or outbreaks of gastroenteritis. Viral
gastroenteritis is mainly diagnosed using
molecular methods and as such PCR equipment is
already available, expertise in place and training
already performed. Common procedures such as
nucleic acid extraction will reduce the costs of tests
for individual targets.
Improvements to speed apart from
rapid laboratory technologies
To ensure faster reporting of results, it may be
worthwhile investigating the means of collecting,
storing and transporting specimens collected in
the primary sector. UK laboratories currently lack
a means of providing primary care providers with
real-time electronic access to laboratory test
results. Prompt delivery of results relies on
compliance from patients, efficient administration
and well-organised general practice. Electronic
patient records and connecting for health may
improve the timeliness of results in the future.
Seven days per week laboratory service
Another consideration regarding time
management of laboratories involves the
assumption that tests are carried out from Monday
to Friday only. This in itself will leave a significant
proportion (around 20%) of samples left over the
weekend period, and therefore not treated
‘rapidly’. Since 15–30% of results are delayed by
24–48 hours due to reduced laboratory staffing at
weekends, the turnaround time could be improved
if laboratories would offer rapid test services
7 days per week. However, a 7-day working week
may impact the costing model in terms of
overtime charges and additional recruitment
needed to cope with longer opening hours.
Further potential problems may occur if relevant
core staff and medical specialists are not available
at all times during laboratory working hours.
Funding issues 
The initial financial investment required for
introducing rapid methods may be a significant
drawback, particularly for smaller laboratories.
rtPCR requires a quantitative thermal cycler, costing
in the region of £16,000–24,000. In addition, the
cost of educating and training personnel to
familiarise them with new technologies and
procedures may be substantial. Whereas
laboratories with a high volume of throughput may
recover set-up costs quickly through the use of
automated test methods, smaller laboratories may
struggle to fund initial training and capital costs
with their limited budgets.
Further microbiological issues
Drug sensitivity testing in culture
versus rapid methods
Culture methods may hold an advantage over
rapid tests when deducing the best possible
antibiotic course to provide to the patient. With
culture methods, once the organism has been
identified, the growth can be further tested to
determine its sensitivity to the antibiotic
treatments that the clinician may want to
administer. If a pathogen is susceptible to a
particular antibiotic, then it may be used for
therapy. Most standard medical textbooks148 do
not recommend the use of antibiotics for
Salmonella and Campylobacter and there is evidence
that the use of antibiotics in patients infected with
E. coli increases the risk of HUS.149 Restricting
their use contributes to the control of antibiotic
resistance. In the rapid assays evaluated in this
review, sensitivity testing for different antibiotic
treatment options was not integrated. However, as
antibiotic resistance and toxin production are a
consequence of gene expression in bacteria,
specific PCR probes for resistance genes may be
developed. Currently, if rapid assays are used,
culture will still be needed for phage typing and
gene sequencing. This will increase costs in terms
of equipment and labour intensity.
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infections
The identification of multiple pathogens is a
frequent occurrence in population-based studies of
gastrointestinal illness.150,151 As more sensitive
assays are developed, it may become increasingly
difficult to ascertain the true causes of disease. For
example, the presence of PCR evidence of an
organism does not always mean that organism is
causing disease. The importance of additional
positives identified by molecular methods requires
further investigation to ascertain that they are true
positives (using Amplicon sequencing RNA-based
PCR). In addition, the clinical significance of the
detection of multiple pathogens from a patient
requires further investigation. 
Conclusions and implications for
healthcare and research
Emerging test methods
Multiplex PCR detection transferable to clinical
samples should be considered, because the costs of
reagents and the preparation time are less than in
systems where several tubes of uniplex PCR are
used. Faced with a sample which, for example, has
come from a patient with non-organism-specific
gastroenteric symptoms, it seems likely that there
could be large savings in both costs (economic
benefit) and time (clinical benefit) if a single test
could determine which pathogen is causing the
problem, rather than running a number of tests
consecutively to eliminate causes one by one. One
multiple pathogen rtPCR test method was
evaluated in this review.117
This systematic review identified PCR as the key
methodology in nucleic acid-based detection.
However, developments in other molecular
techniques are expected. The microarray method
allows the simultaneous analysis of multiple
genetic characteristics of target organisms in one
experiment.152,153 Unlike PCR methods, the glass
microarray chips analyse several genes, and
several sequences for each gene, simultaneously.
Thus, identification is made on the basis of
multiple genetic characteristics, which limits the
probability of both false positive and false negative
results. A Danish research team headed by
Keramas154,155 has developed a DNA microarray to
detect C. jejuni and C. coli in environmental
samples. Their results thus far indicate very high
diagnostic accuracy, which is likely to be
transferable to clinical samples. Further research
in the area of DNA microarrays for Campylobacter is
recommended. Many similar pieces of work are
under way but no formal trials or assessments have
yet been done, so the currently available data
cannot inform the recommendations of this
report. However, it does seem that considerable
progress is being made and this type of approach
should certainly be assessed again for its
usefulness in the near future.
Rapid diagnostics symbolise a hugely expanding
industry, with potentially faster and more accurate
techniques continually being developed. This
review identified evaluative studies up to
September 2005; however, in subsequent months
several novel assays were described, yet no
independent evaluation was available during the
period of this review. It is likely that systematic
reviews such as this will need to be updated on a
regular basis, to take account of the most up-to-
date techniques and their accuracy compared with
a suitable reference test. 
Point of care testing
As yet, rapid diagnostic tests for enteric pathogens
have not been miniaturised to allow point of care
(POC) or mobile testing. However, POC
diagnostics are advancing at a very fast rate,
notably spurred on by the contemporary threat of
biological warfare. This is likely to be a very
significant advance in the future.9,26,156 As POC
tests evolve, their role in the diagnosis and
management of patients with food-borne illness
and their impact on clinical outcomes will become
better defined. Even if POC tests for enteric
pathogens do become available, health and safety
concerns over handling and disposing of
potentially infected stool samples may limit their
uptake.
Clinical outcomes
Research on the improvement of patient outcomes
from using rapid tests is notably lacking. As most
evaluations have been laboratory based, the follow-
up of patients (as opposed to just their specimens)
is limited. If health authorities were to consider
seriously implementing the rapid methods in
practice, it would be very useful to ascertain the
impact of these tests on clinical outcome.
An important finding from the NGT session was
that GPs would only request a rapid test if there is
clinical evidence to suggest that they improve
patient outcomes. Although we may hypothesise
that faster confirmation would lead to a greater
knowledge base from which to treat patients and
inform outbreak management, there is no specific
evidence, from measuring patient outcomes, that
this is the case. 
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slightly adapting testing strategies for enteric
pathogens may lead to improved clinical outcomes
and greater cost-effectiveness of microbiological
investigation.9,26,156 Positive results from the USA
are contrasted to those from recent randomised
controlled trials carried out in Europe. In The
Netherlands, Bruins and colleagues132 found no
beneficial financial or clinical impact of shortened
microbiological procedures for either hospitalised
patients overall or for patients with bacteraemia.
Although this is not directly linked with food
poisoning, it does highlight the need for full
investigation of outcomes prior to the adoption of
new technology.
Ultimately, the decisions about the cost-effectiveness
of strategies involving rapid diagnostic tests rely on
information not only about diagnostic
performance but also on subsequent costs and
effects on treatment. Relatively robust data can be
obtained on, for example, the incremental cost per
accurate diagnosis. Such data are of limited value
as a basis for decisions about allocative efficiency.
This review has been unable to identify any data
which consider long-term costs and consequences
of faster diagnosis of food-borne illness. Without
this information, it is unlikely that hospital
providers can justify the additional costs incurred
with using both culture and rapid detection
techniques. The diagnostic accuracy and cost-
effectiveness of rapid methods may warrant their
implementation as full replacements to routine
culture; however, it is doubtful that the technology
to support such a policy change will be available in
the near future.
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● Although several rapid tests have been
developed to detect food pathogens in clinical
samples, relatively few compare their results
with an appropriate reference test.
● Significant research has been directed in the
clinical and food industries to develop new
rapid diagnostic tests for Campylobacter,
Salmonella and E. coli O157. For tests which
have been evaluated against an appropriate
reference standard (usually culture), diagnostic
accuracy is generally very high.
● There has been little research to date on
detection methods for Clostridium perfringens,
staphylococcal food poisoning or Bacillus cereus.
What the studies cannot tell us
● Inconclusive evidence exists regarding whether
disparent results are caused by the lack of
sensitivity of bacterial culture or lack of
specificity of rapid test.
● There is inconclusive evidence on the
implications of these rapid assays for clinical
practice, as it is not possible to ascertain the
significance of additional positive samples
identified.
What we can infer from modelling
● There is sufficient epidemiological data to
measure the cost and cost-effectiveness of rapid
diagnostic testing compared with current
methods using annualised estimates of
laboratory activity.
● Although cost-effectiveness results appear
robust to changes in assay costs or diagnostic
accuracy, changes in the isolation rates for each
pathogen will significantly alter the estimated
cost per case detected.
● It is likely that the high capital costs of
implementing NAA testing currently outweigh
the potential benefits of molecular
epidemiology and faster diagnosis. However, as
rtPCR techniques continue to develop and costs
fall, NAA testing may provide a suitable
alternative to bacterial culture.
What we cannot infer from
modelling
● No literature on the effectiveness of rapid
diagnostic tests on the management of
outbreaks was available to allow the assessment
of cost-effectiveness in an outbreak setting.
● It is unclear from the reviewed studies or other
published literature if rapid diagnosis of food
poisoning would prevent deaths in a clinical
setting. It is therefore impossible to estimate the
impact that rapid tests may have on mortality
rates. Any discussion on this aspect would have
to rely on mathematical/transmission models of
outbreaks and be purely hypothetical because of
limited data. The mortality rate for food
poisoning is very low already, and it was not
possible to incorporate mortality factors into
the economic model. 
Implications for health policy
makers
● Costly and time-consuming diagnostic tests are
becoming increasingly difficult to justify, and
not all stool specimens can or should be
processed to screen for all potential pathogens.
Salmonella, Campylobacter and E. coli O157
continue to be pathogens that most clinical
laboratories routinely test for in all stool and
faecal specimens. Less is known about the
benefits of testing for B. cereus, C. perfringens
and S. aureus.
● Evidence from studies shows that PCR is
potentially very successful in identifying
pathogens, possibly more than the number
currently detected through culture. Therefore,
the proportion of infectious intestinal disease
due to food poisoning with no organism
detected is likely to decrease from the current
40%. A limitation of PCR assays is that they do
not detect toxin formation but rather toxin
genes. Only antigen detection methods can
detect the actual toxin protein.
● Cost-effectiveness modelling shows that all
methods of microbiological detection will be
expensive. However, using cost per case
detected as an intermediate outcome, the costs
of total replacement of bacterial culture with
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Chapter 10
Conclusionsrapid tests are not excessive when compared
with current practice, as culture methods also
have a high cost.
● The feasibility of conversion to rapid methods is
dependent on localised considerations,
including the community prevalence rates for
specific pathogens, the skill base and
subsequent training costs for laboratory staff,
and spare capacity available to ensure adequate
laboratory space for new equipment.
● Insistence on retaining bacterial culture
methods will mean that costs for rapid methods
will be artificially raised. It is unlikely that the
implementation of rapid test methods, in
addition to bacterial culture, will be efficient on
a cost per case detected basis; however, more
research is needed to assess the impact of
timeliness of results on patient outcomes.
● Evidence of speed of diagnosis, rates of
diagnostic error and costs of implementation
should be considered simultaneously when
deciding which strategy is optimal.
Implications for research
In order of priority these are as follows:
● Further research is needed on the effectiveness
and cost-effectiveness of emerging rapid
diagnostic procedures in food-borne infection,
particularly those being developed to test for
more than one organism at a time, such as
multiplex PCR and DNA microarray
technologies.
● The hypothesis that nucleic acid and serological
assays can detect more true positive cases of
food-borne infection than traditional culture
methods should be validated through further
research. Specifically, the under-reporting of
non-O157 EHEC by SMAC should be addressed
prospectively.
● Special attention should be paid to new
methods for the detection of Campylobacter
(currently the major cause of food-borne disease
in the UK) because of the technical difficulties
with cultural methods for this organism, and
the high likelihood that newly emerging
potentially pathogenic species such as
C. upsaliensis and C. concisus are missed by
current techniques.
● The role of rapid detection methods for toxin-
induced food-borne illnesses, namely
C. perfringens, S. aureus and B. cereus, remains
unclear. 
● Multiple pathogens will be detected in a
significant number of samples if more sensitive
methods are employed. Therefore, tests to
determine the agent responsible for the
symptoms will need to be developed.
● Due to the large volume of research currently
emerging in the field of rapid diagnostics,
systematic reviews such as this should be
regularly updated to account for potentially
faster, more accurate technologies being
developed.
● Methodological and statistical issues are
profoundly difficult to address when attempting
to evaluate diagnostic tests in the absence of a
true gold standard.
● The implications of rapid techniques, if more
sensitive than current methods, will impact
significantly on burden of disease studies. 
Implications for practice
● Based on the evidence summarised, the
reviewers do not feel it is appropriate to draw a
firm conclusion either recommending the use of
these assays or excluding their use in all cases.
Further studies are needed.
● Economic feasibility of conversion to rapid
methods is dependent on localised
considerations, including the community
prevalence rates for specific pathogens, the skill
base and subsequent training costs for
laboratory staff and spare capacity available to
ensure adequate laboratory space for new
equipment. 
● Adoption of rapid tests in combination with
routine culture is unlikely to be cost-effective;
however, as the costs of rapid technologies
decrease, total replacement with rapid
technologies may be feasible.
Conclusions
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he following sources were searched for studies
relating to diagnostic accuracy for each of the
organisms being evaluated. A range of free text
and subject headings was used, as appropriate.
Details of the search strategies are given below.
Initially the search strategy was not limited by
date. However, at an early stage it became evident
that developments in rapid testing for food
poisoning only really came to the fore since the
early 1990s. It was therefore felt that a date
restriction could be applied relatively arbitrarily at
1985, as diagnostic test methods are rapidly
evolving and it was thought that papers before this
date would not be relevant to current practices in
microbiology. No language restrictions were
applied to the searches.
MEDLINE (1985 to April week 4 2005)
1. exp “sensitivity and specificity” or “evaluation
studies”.sh or ("false positive" or "false
negative" or "predictive value").ti,ab,sh.
2. exp diagnosis/ or (detect$ or
diagnos$).ti,ab,sh.
3. 1 or 2
4. time factors.sh. or (rapid$ or fast$ or
quick$).ti,ab,sh.
5. 3 and 4
6. Salmonella.mp
7. Campylobacter jejuni.mp
8. Escherichia coli O157.mp or
enterohaemorrhagic.ti,ab,sh
9. Clostridium perfringens.mp
10. Staphylococcus aureus.mp
11. (resistan$ or Methicillan or
Nosocomial).ti,ab,sh
12. 10 not 11
13. Bacillus cereus.mp
14. 6 or 7 or 8 or 9 or 12 or 13
15. limit 14 to humans
16. 4 and 15
EMBASE (1985 to 2005 week 17) and
CINAHL (1985 to April week 4 2005)
1. exp “sensitivity and specificity” or “evaluation
studies”.sh or ("false positive" or "false
negative" or "predictive value").ti,ab,sh
2. exp diagnosis/ or (detect$ or
diagnos$).ti,ab,sh.
3. 1 or 2
4. (rapid$ or fast$ or quick$).ti,ab,sh
5. 3 and 4
6. Salmonella/
7. Campylobacter jejuni/
8. Escherichia coli/
9. Clostridium perfringens/
10. Staphylococcus aureus/
11. (resistan$ or Nosocomial).ti,ab,sh
12. 10 not 11
13. Bacillus cereus/
14. 5 or 6 or 7 or 8 or 11 or 12
15. limit 14 to humans, 
16. 4 and 15
Web of Science (1945 to 2005)
1. TS=sensitivity
2. TS=compare
3. TS=rapid
4. TS=detect
5. (#1 or #2) and #3 and #4
6. TS=Food Poisoning
7. TS=Salmonella
8. TS=Campylobacter jejuni
9. TS=Escherichia coli
10. TS=E. coli
11. TS=Clostridium perfringens
12. TS=Bacillus cereus
13. TS=Staphylococcus aureus
14. TS=MRSA
15. TS=Methicillin-Resistant Staphylococcus aureus
16. (#6 or #7 or #8 or #9 or #10 or #11 or #12
or #13) not (#14 or #15)
17. 5 and 16
Abstracts selected by search strategy
● MEDLINE – 1279
● EMBASE – 793
● BIOSIS – 17
● Web of Science – 32
● CINAHL – 25
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Appendix 1
Search strategyGeneral Information
ID for reviewer  Source (Journal, Conference)
Author
Article Title
Year of Publication Year of Study
Country of Study Language
Source of Funding Corresponding Author
Patient Characteristics Exposure: Organism(s)
Age Gastrointestinal infection
Co-morbidity Salmonella O
Patient Selection  Campylobacter jejuni O
Test Setting Escherichia coli O157 O
Toxin Induced Food Poisoning
Study Design Staphylococcus aureus O
Bacillus cereus O
Blinded Clostridium perfringens O
Study Design Other (Specify)
Feasible in Local Lab? Analyte/Primer (if applic)
Amplification size (PCR)
Detection: Description of Test Method
Type of Test Nucleic Acid O
Immunoassay O
Agglutination O
Pre-enrichment required? Yes/no
Name Manufacturer
Qualitative/Quantitative Outcome Measure
Threshold Sensitivity
records indeterminate results Positive/Negative control provided
Comparison: Description of Reference Method
Specific Test Details
Name Manufacturer
Outcome Measure Full or partial validation?
Measured Independently? Yes/no Appropriate comparator?
Interpreted Blindly? Yes/no
Accuracy
Calculated: Recorded:
True Positives Reproducibility
True Negatives Repeatability
False Positives Sensitivity
False Negatives Specificity
Positive Predictive Value
Number of Test Materials Negative Predictive Value
Additional notes on concordance
Statistical tests used
Detection Times
Rapid Test Reference Case
Pre-enrichment: time and reagents Hands-on Time
Incubation time Total Time to Results
Amplification time (if PCR)
Hands-on time
Total time to results Difference in reporting times
Additional Information
Notes on costs or cost-effectiveness
Authors’ conclusions
Original Search Strategy Yes/no Likely to include?
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Appendix 3
Study characteristics for clinical studies
Authors (year): Abdalla et al. (1994)55
Journal: British Journal of Biomedical Science
Title: Identification of Salmonella spp. with Rambach agar in conjunction with the 4-methylumbelliferyl
caprylate (MUCAP) fluorescence test
Notes:
Setting: Hospital laboratory, Spain Design: Prospective
Sample size: 50 propylene glycol and -galactosidase-negative strains
Target organism: Salmonella sp.
Rapid test Methods
MUCAP Based on a rapid detection of C8 esterase enzyme by using a fluorogenic 4-methylumbelliferone-
conjugated substrate. Test performed with Rambach cultured strains as described by
manufacturer
Reference test Methods
Standard culture Cultured on Rambach agar using standard methods
Reported accuracy data:
Sensitivity 100 TP 24
Specificity 57.69 FP 11
PPV 68.57 FN 0
NPV 100 TN 15
Agreement  MUCAP test able to detect Salmonellae strains missed by Rambach agar, including S. typi and 
between methods: S. paratypi A. No positive reaction occurred with other members of the family Enterbacteriaceae
Economic evaluation: None provided
What the authors  MUCAP test found to be a useful and fast adjunct to Rambach agar in the identification of all 
conclude: strains of Salmonellae
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Aguirre et al. (1990)30
Journal: Journal of Clinical Microbiology
Title: Rapid fluorescence method for screening Salmonella spp. from enteric differential agars
Notes: Results obtained on different selective media pooled for meta-analysis
Setting: Hospital laboratory, Spain Design:
Sample characteristics:
Sample size: 125 and 307
Target organism: Salmonella spp.
Rapid test Methods
MUCAP Based on a rapid detection of C8 esterase enzyme by using a fluorogenic 4-
methylumbelliferone-conjugated substrate.
Reference test Methods
Standard culture 125 samples cultured on MacConkey agar and 307 cultured on SS agar using standard
methods
Reported accuracy data: Mcconkey agar Reported accuracy data: SS agar
Sensitivity 79.17 TP 19 Sensitivity 66.66 TP 60
Specificity 100 FP 0 Specificity 98.16 FP 4
PPV 100 FN 5 PPV 93.75 FN 30
NPV 95.28 TN 101 NPV 87.65 TN 213
Economic evaluation: None provided
What the authors  The MUCAP test is an easy, rapid, and sensitive method for the screening of colonies 
conclude: suspected of being Salmonella spp, reducing the number of biochemical tests needed
Assessment of authors’  Appropriate conclusions
conclusions:
Authors (year): Alvarez et al. (2004)157
Journal: Journal of Clinical Microbiology
Title: Development of a Multiplex PCR Technique for Detection and Epidemiological Typing of
Salmonella in Human Clinical Samples
Notes:
Setting: University laboratory, Spain Design: Prospective
Sample characteristics: Consecutive human stool samples obtained from Spanish hospital
Sample size: 120
Target organism: Salmonella
Rapid test Methods
PCR  Selenite–cystine broth incubated for 4 hours at 37°C.  DNA extracted
Reference test Methods
Culture and AB 120E XLD, MacConkey and Hektoen agars inoculated in selenite–cystine broth. Salmonella
colonies confirmed with triple sugar iron agar, API 20E strips and serotyped  (Kauffma–White
scheme)
Reported accuracy data:
Sensitivity 98.93 TP 28
Specificity 95.76 FP 9
PPV 87.68 FN 2
NPV 99.66 TN 81
Economic evaluation: None provided
What the authors  Simple, inexpensive, and sensitive and enables the quick and precise detection of most 
conclude: prevalent serotypes of Salmonella in human clinical samples
Assessment of authors’  Appropriate conclusions. High-quality paper; larger scale investigation may be beneficial
conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
117
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Authors (year): Andersson et al. (1998)102
Journal: Applied and Environmental Microbiology
Title: A novel sensitive bioassay for detection of Bacillus cereus emetic toxin and related
depsipeptide ionophores
Notes:
Setting: National Reference Laboratory Design: Assay development
Sample characteristics: Reference B. cereus strains obtained from various laboratories
Sample size: 2 emetic strains, 3 non-emetic strains and other bacteria
Target organism: B. cereus emetic strain
Rapid test Methods
Bioassay for detection of the emetic mitochondrial toxin, by all criteria identical with
cereulide based on the loss of motility of boar spermatozoa
Reference test Methods
No comparison with another assay
Economic evaluation: No economic data presented
What the authors  The test is a sensitive, inexpensive and rapid bioassay for detection of the emetic toxin of 
conclude: B. cereus
Assessment of No comparison group, therefore diagnostic accuracy for this assay is not available. 
authors’ conclusions:
Authors (year): Amar et al. (2004)45
Journal: European Journal of Clinical Microbiology and Infectious Diseases
Title: Blinded application of microscopy
Notes:
Setting: PHLS Laboratory, UK Design: Blinded, multicentre trial
Sample characteristics: Unselected faecal samples (age range 0.8–81 years), submitted between 24 July 2002 and 
25 October 2002
Sample size: 92
Target organism: Wide range, including Campylobacter, Salmonella and Clostridium perfringens
Rapid test Method
PCR  Salmonella detected by rtPCR using ABI PRISM Sequence detector 7700 and RealArt
Salmonella TM PCR Kit (Artus). Campylobacter detected using ABI PRISM Sequence detector
7700 and RealArt Campylobacter TM PCR Kit (Artus). A gel-based duplex PCR performed for
detection of C. perfringens phospholipase C and enterotoxin genes
Reference test Methods
Culture Standard operating procedures of PHLS were followed
Reported accuracy data: Salmonella Reported accuracy data: C. jejuni
Sensitivity 75.00 TP 3 Sensitivity 83.33 TP 5
Specificity 100.00 FP 0 Specificity 98.84 FP 1
PPV 100.00 FN 1 PPV 83.33 FN 1
NPV 98.88 TN 88 NPV 98.84 TN 85
Clostridium perfringens 3 positive by both methods – equivalence
Major confounders or  Low-sensitivity results for Salmonella and Campylobacter may be attributable to low 
bias: numbers of positive isolates. For rarer pathogens, including Cryptosporidium and non-EHEC
forms of E. coli, PCR was considerably more sensitive
Economic evaluation: None provided
What the authors  The results of the present study demonstrate the potential for PCR to improve the 
conclude: detection of enteric pathogens in the faecal sample from patients with diarrhoea
Assessment of  Well-executed small study. One of the few studies reviewed to discuss multiple pathogens 
authors’ conclusions: and asymptomatic infectionAppendix 3
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Authors (year): Araj and Atamian (1997)113
Journal: Laboratory Medicine
Title: Reliability of rapid kits for Staphylococcus aureus identification
Notes:
Setting: University hospital laboratory, Lebanon
Design: Diagnostic comparison study
Sample characteristics: Various clinical specimens – not all faecal
Sample size: 240 S. aureus and 127 coagulase-negative stapylococci (CNS) clinical isolates
Target organism: Staphylococcus aureus
Rapid test Methods
Comparison of various  Slidex Staph-Kit (BioMerieux, France); Avistaph (Omega Diagnostics, UK); Staphylase 
commercial kits, using  (Oxoid, UK); Pastorex Staph-Plus (Sanofi Diagnostics Pasteur, France) all used according to 
banked samples.  manufacturers’ instructions. Agglutination scored as positive (+), equivecol (±) 
No reference test 
provided
Reported accuracy data:
Slidex Avistaph Staphylase Staph-Plus
Sensitivity 96.60 Sensitivity 96.60 Sensitivity 96.60 Sensitivity 96.60
Specificity 91.00 Specificity 67.00 Specificity 94.00 Specificity 94.00
PPV 96.00 PPV 86.00 PPV 97.00 PPV 97.00
NPV 99.00 NPV 99.00 NPV 99.00 NPV 99.00
Uninterpretable 1.60 Uninterpretable 2.70 Uninterpretable 3.00 Uninterpretable 0.30
Economic evaluation: Not provided
Authors (year): Augustynowicz et al. (2002)90
Journal: Journal of Medical Microbiology
Title: Detection of enterotoxigenic Clostridium perfringens with a duplex PCR
Notes:
Setting: Reference laboratory, Poland Design: Assay development
Sample characteristics: 64 isolates, 30 of which were stool samples
Target organism: Clostridium perfringens
Rapid test Methods
PCR Two sets of primers designed to detect Clostridium perfringens phospholipase C (plc) and
enterotoxin (cpe) genes in a single PCR reaction 
Reference test Methods
RPLA Oxoid PET-RPLA used according to manufacturer’s instructions
Reported accuracy data: 
Sensitivity 100.00 TP 16
Specificity NA FP 14
PPV 100.00 FN 0
NPV NA TN 0
Economic evaluation: None provided
What the authors  Duplex PCR for diagnosis of enterotoxigenic C. perfringens from vegetative cultures can be 
conclude: a useful tool as fresh isolates often sporulate poorly or not all, giving rise to the possibility of
false negative results by serological analysis
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Bartholomew et al. (1985)82
Journal: Journal of Clinical Pathology
Title: Development and application of an enzyme linked immunosorbent assay for Clostridium
perfringens type A enterotoxin
Notes:
Setting: National reference laboratory, UK
Design:  Interlaboratory collaborative trial
Sample size: 515 faecal samples, 12 food samples from outbreaks of C. perfringens food poisoning.
44 known positive samples 
In order to compare ELISA technique with other standard immunological tests a group of 44
specimens were assayed for toxin by ELISA, double gel diffusion and
counterimmunoelectrophoresis
Target organism: Clostridium perfringens
Rapid test Methods
ELISA Double antibody ELISA. In-house design using rabbit antienterotoxin IgG
Reference test Methods
Double gel diffusion and  Citation to earlier description of methods. 79 faecal specimens from control groups tested. 
counterimmuno- Blinded
electrophoresis
Reported accuracy data: sandwich ELISA vs double gel infusion:
Sensitivity 100.00 TP 30
Specificity 35.71 FP 9
PPV 76.92 FN 0
NPV 100.00 TN 5
Sensitivity vs reference  Assay confirmed 47 of 50 (94%) of outbreaks compared with 32 of 48 (67%) confirmed by 
method: serotyping
Turnaround time vs  Performed within 24 hours
reference method
Economic evaluation: None provided
What the authors  The ELISA is recommended as a valuable tool in the investigation of C. perfringens 
conclude: food-borne illness
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Beecher and Wong (1994)93
Journal: Applied and Environmental Microbiology
Title: Identification and analysis of antigens detected by two commercial Bacillus cereus diarrhoeal
enterotoxin immunoassay kits
Notes:
Setting: University laboratory Design: Evaluation of two commercial assays
Sample characteristics: B. cereus strains obtained from various laboratories
Sample size: 2 B. cereus strains 
Target organism: B. cereus 
Rapid test Methods
Commercial immunoassays (Bacillus cereus Enterotoxin-Reverse Passive Latex Agglutination
kit from Oxoid and Bacillus Diarrhoeal Enterotoxin Visual Immunoassay from Tecra)
Reference test Methods
Comparison with each other
Reported accuracy data:
Sensitivity TP
Specificity FP
PPV FN
NPV TN
Agreement between  The study aimed to determine the antigen detected by each assay and determine if they are 
methods: part of a diarrhoea-causing enterotoxin
Economic evaluation: No economic data presented
What the authors  The Oxoid BCET RPLA kit detects the L2 component of haemolysin BL enterotoxin while 
conclude: the Tecra assay detects two other proteins that are not part of the enterotoxin
Assessment of  The results of this paper highlight the need to validate commercial assays before they are 
authors’ conclusions: adopted for widespread use. It is unclear whether the proteins detected by the Tecra assay
have a role in diarrhoea
Authors (year): Belanger et al. (2002)158
Journal: Journal of Clinical Microbiology
Title: Rapid detection of shiga toxin-producing bacteria in faeces by multiplex PCR with molecular
beacons on the Smart Cycler
Notes:
Setting: Hospital laboratory, Canada Design: Diagnostic comparison
Sample characteristics: In patients
Sample size: 38 faecal samples from 27 patients
Target organism: EHEC
Rapid test Methods
rtPCR rtPCR for the detection of stx1 and stx2. Prior to clinical evaluation, the assay was tested on
23 STEC strains and 20 non-STEC to ensure adequate sensitivity and specificity
Reference test Methods
SMAC culture Culture on SMAC agar. Sorbitol-negative colonies were then tested for the O157 antigen by
VTEC-RPLA (Denka Seiken)
Reported accuracy data:
Sensitivity 100 TP 26
Specificity 92 FP 1
PPV 96 FN 0
NPV 100 TN 11
Economic evaluation: Not carried out
What the authors  This is a simple, rapid, sensitive and specific method and allows detection of all shiga toxin-
conclude: producing bacteria directly from faecal samples, irrespective of their serotypes
Assessment of  Assay requires validation with a larger pool of clinical samples; details of sources of bias not 
authors’ conclusions: givenHealth Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Berry et al. (1988)79
Journal: Journal of Clinical Pathology
Title: Evaluation of ELISA, RPLA and Vero cell assays for detecting Clostridium perfringens
enterotoxin in faecal specimens
Notes:
Setting: PHLS Laboratory, UK Design:
Sample characteristics:
Sample size: 392 faecal specimens 
Target organism: Clostridium difficile and Clostridium perfringens
Rapid test Methods
TechLab EIA Performed according to manufacturer’s instructions. Optical density read at 450 and 620 nm.
All specimens that gave equivocal or positive readings were repeated
Rapid test Methods
Vero cell assay 96-well microtitre tray seeded with suspension of Vero cells in Eagle’s minimal essential
medium and incubated overnight at 37°C. Faecal extracts prepared and added. Plate covered
and incubated overnight at 37°C, then cell cultures examined for cytotoxicity
Reference test Methods
In-house ELISA PHLS FSML in-house EIA performed as prescribed by Bartholomew et al.82
Reported accuracy data: TechLab EIA Reported accuracy data: Vero cell 
Sensitivity TP 21 Sensitivity TP 11
Specificity FP 0 Specificity FP
PPV FN 41 PPV FN
NPV TN 781 NPV TN
Major confounders or bias: RPLA = good sensitivity, problems with specificity
Economic evaluation: Approximate cost (UK£ 1988)
What the authors  In-house FSML EIA and RPLA tests are both more sensitive than Vero cell assays for 
conclude: detection of C. perfringens
Assessment of authors’  ELISA is a much more sensitive technique than Vero cell assay
conclusions:
Authors (year): Bettelheim (2001)62
Journal: Letters in Applied Microbiology
Title: Development of a rapid method for the detection of verocytotoxin-producing Escherichia coli
(VTEC)
Notes:
Setting: University research laboratory Design: Retrospective evaluation
Sample characteristics: Reference strains only
Sample size: 239 isolates: results reported here correspond to all 111 from human sources
Target organism: EHEC
Rapid test Methods
VTEC Screen  Only parts of the VTEC screen were used, including polymyxin B solution, dilutent, 
(Denka Seiken) sensitised latex, control latex and positive control. Same-day results (2–4 h) reported with
>98% accuracy
Reference test Methods
Standard culture Strains previously isolated by culture
Reported accuracy data (results from human sources only)
Sensitivity 100 TP 55
Specificity 98.21 FP 1
PPV 98.21 FN 0
NPV 100 TN 55
Major confounders  Use of reference strains, instead of fresh clinical samples, may not accurately measure how 
or bias: the test works in routine practice
Economic evaluation: None provided
What the authors  Result available on same working day
conclude:
Assessment of  Appropriate conclusions – reducing time for incubation before performing RPLA test should 
authors’ conclusions: be investigated furtherAppendix 3
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Authors (year): Beutin et al. (2002)63
Journal: Diagnostic Microbiology and Infectious Disease
Title: Evaluation of the VTEC-Screen ‘Seiken’ test for detection of different types of shiga toxin
(verotoxin)-producing Escherichia coli (STEC) in human stool samples
Notes:
Setting: National reference laboratory, Germany Design: Diagnostic comparison
Sample characteristics: Stool samples analysed at national centre from collaborating laboratories over 1 year from
patients with gastrointestinal disease, including four samples from HUS patients
Sample size: 234 samples
Target organism: EHEC
Rapid test 1 Methods
VTEC Screen  VTEC Screen (Denka-Seiken) performed according to manufacturer’s instructions. Positive 
(Denka Seiken) and negative controls provided.
Rapid test 2 Methods
PCR for stx1 and stx2 genes Following previously published methods developed by Lin et al.240
Reference test Methods
SMAC culture 1, culture on SMAC media; 2, VCA assay
Reported accuracy data: VTEC Screen Reported accuracy data: PCR
Sensitivity 89.83 TP 53 Sensitivity 93.2203 TP 55
Specificity 99.43 FP 1 Specificity 95.43 FP 8
PPV 98.15 FN 6 PPV 87.3 FN 4
NPV 96.66 TN 174 NPV 97.66 TN 167
Economic evaluation: Not carried out
What the authors  The test was found to be accurate, rapid and easy to perform, thus being suitable for the 
conclude: routine screening of clinical stool specimens for STEC
Assessment of  Large study. Characteristics of study population not given. Assessment of study quality 
authors’ conclusions: hampered by lack of details
Authors (year): Bouvet and Jeanjean, (1992)159
Journal: Journal of Clinical Microbiology
Title: Evaluation of two coloured latex kits, the Wellcolex Colour Salmonella Test and the
Wellcolex Colour Shigella Test, for serological grouping of Salmonella and Shigella species
Notes: Reporting only Salmonella results
Setting: National reference laboratory, France Design: Retrospective diagnostic comparison study
Sample characteristics: Mixed samples/strains
Sample size: 193 randomly chosen pure cultures received at a reference laboratory – human, veterinary,
and miscellaneous sources
Target organism: Salmonella
Rapid test Methods
Wellcolex Colour  Coloured latex kit performed on non-lactose-fermenting colonies growing in primary 
Salmonella culture on selective media. Based on agglutination of antibody-coated coloured latex particles
in the presence of homologous antigens. Performed to manufacturer’s instructions. Positive
controls supplied with kit
Reference test Methods
Standard culture Details not provided
Reported accuracy data:
Sensitivity 98.35 TP 179
Specificity 100 FP 0
PPV 100 FN 3
NPV 78.57 TN 11
Economic evaluation: Not provided
What the authors  Easy to perform, accurate and easy to interpret when pure cultures were tested
conclude:
Assessment of  Suitable conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Brett et al. (1992)75
Journal: Journal of Clinical Pathology
Title: Detection of Clostridium perfringens and its enterotoxin in cases of sporadic diarrhoea
Notes:
Setting: Hospital laboratories, UK Design: Intercollaborative trial
Sample characteristics: All sporadic cases of diarrhoea submitted between September and December 1988. Age
range 3 months to 89 years (most patients over 60 years)
Sample size: 818 samples
Target organism: Clostridium perfringens
Rapid test Methods
Oxoid RPLA kit with  Methods used similar to those by Berry et al.79 Positive extracts referred to national 
ELISA confirmation reference laboratory for confirmation by ELISA
Reference test Methods
Confirmation of positive  ELISA performed in reference laboratory using standard methods. Pure cultures of 
samples with ELISA C. perfringens isolated from enterotoxin-positive faeces serologically typed using set of 143
antisera
Reported accuracy data:
Sensitivity unclear TP 56
Specificity unclear FP 8
PPV 0.875 FN unclear
NPV unclear TN unclear
Economic evaluation: None provided
What the authors  Diagnostic laboratories should perhaps consider screening for C. perfringens enterotoxin in 
conclude: cases of sporadic diarrhoea, particularly in elderly patients
Assessment of  High-quality epidemiological investigation study. Focus on non-food-related diarrhoea; 
authors’ conclusions: however, test could successfully be applied with suspected food-borne infection also
Authors (year): Buchanan and Schultz (1994)28
Journal: Letters in Applied Microbiology
Title: Comparison of the Tecra VIA kit, Oxoid BCET-RPLA kit and CHO cell culture assay for the
detection of Bacillus cereus diarrhoeal enterotoxin
Notes:
Setting: Reference laboratory Design: Comparison of three assays
Sample characteristics: B. cereus strains obtained from various laboratories
Sample size: 11 B.cereus strains and 1 B. thuringiensis
Target organism: B. cereus 
Rapid test Methods
Commercial immunoassays (Bacillus cereus Enterotoxin-Reverse Passive Latex Agglutination
kit from Oxoid and Bacillus Diarrhoeal Enterotoxin Visual Immunoassay from Tecra) and the
Chinese Hamster Ovary Cell Cytotoxicity assay
Reference test Methods
Comparison with each other
Reported accuracy data:
Sensitivity TP
Specificity FP
PPV FN
NPV TN
Agreement between  The study aimed to evaluate the efficacy of the Tecra assay and compare it with the Oxoid 
methods: kit and CHO cell assay. Tecra assay correlated better with the CHO assay
Economic evaluation: No economic data presented
What the authors  The CHO assay provided more accurate results for assaying cultures for B. cereus
conclude: enterotoxin, both in sensitivity and its direct relationship with biological activity
Assessment of authors’  Further limitations of the two commercial assays were identified by this study
conclusions:Appendix 3
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Authors (year): Carroll et al. (2003)58
Journal: European Journal of Clinical Microbiology and Infectious Disease
Title: Comparison of a commercial reversed passive latex agglutination assay to an enzyme
immunoassay for the detection of shiga toxin-producing Escherichia coli
Notes:
Setting: Paediatric hospitals, USA Design: Prospective
Sample size: 554 diarrhoeal stool samples
Target organism: EHEC
Rapid test 1 Methods
VTEC Screen  Reagents added according to manufacturer’s instructions. Incubation for at least 16 hours. 
(Denka Seiken) Agglutination patterns read manually
Rapid test 2 Methods
Premier EHEC  Performed according to manufacturer’s instructions using the positive and negative controls 
(Meridian Diagnostics) supplied in kit
Reference Test Methods
SMAC culture Inoculated to sorbitol MacConkey agar plates according to standard microbiology
procedures. Incubated at 35°C and read at 24 and 48 hours for presence of sorbitol non-
fermenters
Reported accuracy data: VTEC Screen Reported accuracy data: Premier EHEC
Sensitivity 100.00 TP 4 Sensitivity 100.00 TP 4
Specificity 97.82 FP 12 Specificity 98.36 FP 9
PPV 75.00 FN 0 PPV 69.23 FN 0
NPV 100.00 TN 538 NPV 100.00 TN 541
Additional statistical  99% agreement between VTEC Screen and Premier EHEC ( = 0.823)
analysis:
Major confounders  VTEC screen results delayed by 1 day compared with Meridian EHEC assay
or bias:
Economic evaluation: VTEC screen costs less than current toxin kits marketed in USA, hence some laboratories
may implement routine shiga toxin screening in the future
What the authors  VTEC screen test is easy to perform and does not require special equipment. Results were 
conclude: comparable with those of Premier EHEC, but there were more unconfirmed positives
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Chiu and Ou (1996)50
Journal: Journal of Clinical Microbiology
Title: Rapid identification of Salmonella serovars in faeces by specific detection of virulence genes,
invA and spvC, by an enrichment broth culture–multiplex PCR combination assay
Notes:
Setting: Paediatric hospital, Taiwan Design: Prospective
Sample characteristics: Faecal specimen from 57 children with mucoid and/or bloody diarrhoea were admitted to a
Taiwanese hospital
Sample size: 57 samples
Target organism: Salmonella
Rapid test Methods
Multiplex-PCR 6 hours pre-enrichment, multiplex PCR targeting spvC and invA genes. Amplified DNA
fragments in gel were visualised and photographed under UV illumination
Reference test Methods
Culture Growth on xylose–lysine–sodium deoxycholate agar (Difco), Salmonella–Shigella agar
following enrichment in Gram-negative broth
Reported accuracy data:
Sensitivity 90.91 TP 20
Specificity 48.57 FP 18
PPV 52.63 FN 2
NPV 89.47 TN 17
Agreement between  PCR more sensitive than culture. From 40 banked positive samples, PCR detected 38 
methods: whereas culture methods reported only 24
Economic evaluation: Not carried out
What the authors  A sensitive, rapid and efficient test that will cause only an incremental increase in the cost 
conclude: of stool processing
Assessment of  Clearly highlights the potential increased sensitivity when using PCR rather than culture; 
authors’ conclusions: however, no discussion is provided on the potential for PCR to produce false positivesAppendix 3
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Authors (year): Collins et al. (2001)160
Journal: Journal of Clinical Microbiology
Title: Evaluation of a PCR/DNA probe colorimetric membrane assay for identification of
Campylobacter spp. in human stool specimens
Notes:
Setting: University microbiology laboratory, Ireland
Design:
Sample characteristics: Specifically selected stool specimens from community and inpatient cases of acute diarrhoeal
disease
Sample size: 42–30 culture positive stool specimens,12 culture-negative
Target organism: Campylobacter jejuni and Campylobacter coli
Rapid test Methods
PCR, post-PCR  DNA extraction using QIAamp DNA stool minikit, followed by post-PCR hybridisation to 
hybridisation and  DNA probes specific for Campylobacter genus, C. jejuni and C. coli in a colorimetric 
colorimetric membrane  membrane assay. Can be achieved in same working day
assay
Reference test Methods
Standard culture Cultured on modified CCDA. 48 hours to identify to genus level, which must be followed by
additional biochemical tests to identify species
Reported accuracy data:
Sensitivity 90.00 TP 27
Specificity 100.00 FP 0
PPV 100.00 FN 3
NPV 80.00 TN 12
Major confounders  Selection of samples for PCR detection was not random. However, as this was a small 
or bias: preliminary study, this may be justified
Economic evaluation: None provided
What the authors  Focus of paper not with ‘rapid’ tests but with sensitivity of PCR after stool has been sitting 
conclude: around for a long time. Authors appear to suggest that culture is ‘gold’ standard for
immediate testing, but if test is carried out 2 days later, PCR method is likely to ‘rescue’
additional positive results that culture will miss
Assessment of  1. Although this technique provided good sensitivity and specificity when compared with 
authors’ conclusions: traditional culture methods, the labour intensity of the method would limit this to
research use only, and routine laboratory use is unlikely.
2. Results recorded in data set relate to Set A (culture positive, tested immediately) and 
Set C (originally culture negative) as this would best represent practice in a non-research
environmentHealth Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Cudjoe et al. (1991)83
Journal: International Journal of Food Microbiology
Title: Detection of Clostridium perfringens type A enterotoxin in faecal and food samples using
immunomagnetic separation (IMS)–ELISA
Notes:
Setting: Research laboratory, Norway Design: Assay development
Sample characteristics: 12 spiked faecal samples, 12 healthy faecal samples, one faecal sample from suspected case
of C. perfringens
Sample size: 25 faecal samples
Target organism: Clostridium perfringens
Rapid test Methods
IMS-ELISA IMS–ELISA developed for detection and quantitation of C. perfringens type A enterotoxin
from faecal and food extracts. Minimal 3 hours coating of immunomagnetic particles
(Dynabeads M-280). Specificity was confirmed by both crossed immunoelectrophoresis and
Western immunoblotting techniques
Reported accuracy data: Not reported
Economic evaluation: Not provided
What the authors  A simple, rapid and sensitive immunoassay
conclude:
Assessment of  Full evaluation needed with appropriate comparator
authors’ conclusions:
Authors (year): Davis et al. (2003)161
Journal: Abstracts from the General Meeting of American Society of Microbiologists
Title: An evaluation of the BAX system for rapid screening of stool specimens for Salmonella
species and E. coli O157:H7
Notes: Data derived from published abstract and contact with corresponding author (J Fontana)
Setting: Public health laboratory, USA
Design: Prospective case–control
Sample characteristics: Fresh human stool samples
Sample size: 78 samples tested for Salmonella – 18 of these also tested for E. coli
Target organism: Salmonella species and E. coli O157
Rapid test Methods
BAX system  Overnight enrichment in tethrathionate broth for Salmonella and MacConkey broth for 
(Dupont Qualicon) E. coli O157 samples 
Reference test Methods
Culture Conventional culture methods used
Reported accuracy data: Salmonella results Reported accuracy data: E. coli O157 results
Sensitivity 100 TP 5 Sensitivity 100 TP 4
Specificity 98.6 FP 1 Specificity 100 FP 0
PPV 83.3 FN 0 PPV 100 FN 0
NPV 100 TN 72 NPV 100 TN 14
Economic evaluation: None performed
What the authors  If the BAX system is validated for screening of Salmonella spp. and E. coli O157:H7 from 
conclude: stool samples, it will reduce the time to implement outbreak control measures by at least
2 days
Assessment of  This is one of the few studies in which a well-recognised commercial test developed for the 
authors’ conclusions: food industry has been applied for testing on clinical samples. Results from this small study
suggest the BAX system could successfully be used on stool specimensAppendix 3
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Authors (year): Day et al. (1994)94
Journal: Journal of Applied Bacteriology
Title: A comparison of ELISA and RPLA for detection of Bacillus cereus diarrhoeal enterotoxin
Notes:
Setting: Reference laboratory, USA Design: Comparison of two commercial assays
Sample characteristics: B. cereus strains obtained from various laboratories
Sample size: 14 B.cereus strains
Target organism: B. cereus 
Rapid test 1 Methods
Oxoid BCET-RPLA Commercial immunoassays (Bacillus cereus Enterotoxin-Reverse Passive Latex Agglutination
kit from Oxoid and Bacillus Diarrhoeal Enterotoxin Visual Immunoassay from Tecra) 
Rapid test 2 Methods
Tecra ELISA Comparison with each other
Reported accuracy data: Oxoid RPLA Reported accuracy data: Tecra ELISA
Sensitivity 43.75 TP 6 Sensitivity 87.50 TP 13
Specificity NA  FP NA  Specificity NA  FP NA
PPV NA  FN 8 PPV NA  FN 1
NPV NA  TN NA  NPV NA  TN NA
Agreement between  The study aimed to evaluate both assays for diarrhoeal toxin in cultures of B. cereus isolated 
methods: from food-borne outbreaks. Of 14 samples, 12 cultures were positive by the Tecra ELISA
and six by RPLA. One was negative to both
Economic evaluation: No economic data presented
What the authors  Tecra ELISA assay is a more reliable indicator of diarrhoeaogenic enterotoxin of B. cereus 
conclude: than Oxoid BCET-RPLA
Assessment of  Limitations of the two commercial assays were discussed. Properly designed diagnostic 
authors’ conclusions: evaluation studies are required
Authors (year): Dediste et al. (2003)162
Journal: Clinical Microbiology and Infection
Title: Evaluation of the ProSpecT Microplate assay for the detection of Campylobacter: a routine
laboratory perspective
Notes:
Setting: Hospital laboratory, Belgium Design: Consecutive 
Sample characteristics: All samples over a 4-month period from non-hospitalised and HIV-positive adult and
paediatric patients
Sample size: 1205
Target organism: Campylobacter
Rapid test Methods
ProSpecT Microplate  Commercial enzyme immunoassay (Alexon-Trend, USA), performed according to 
ELISA assay instructions of the manufacturer. Plates read both visually and spectrophotometrically.
Positive and negative controls provided
Reference test Methods
Culture Culture on Mueller Hinton agar supplemented with cefoperazone, rifampicin and
amphotericin B. Plates incubated for 3 days at 25°C in a micro-aerobic atmosphere and
examined daily.
Reported accuracy data:
Sensitivity 89.10 TP 90
Specificity 97.70 FP 25
PPV 78.26 FN 11
NPV 98.99 TN 1079
Additional statistical  Standard errors calculated for accuracy data. The 2 test was used to compare performance 
analysis: of EIA between stools preserved in Cary–Blair transport medium and fresh stool specimens
Economic evaluation: Not carried out
What the authors  A rapid 2-hour assay. Best used for patients requiring antibiotic therapy, cases of prolonged 
conclude: illness, in pregnancy and for immunocompromised patients
Assessment of  Very clear presentation of diagnostic accuracy statistics. Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Dylla et al. (1995)163
Journal: Journal of Clinical Microbiology
Title: Evaluation of an immunoassay for direct detection of Escherichia coli O157 in stool specimens
Notes:
Setting: Hospital microbiology laboratory Design: Diagnostic comparison
Sample characteristics: Stool samples from inpatients and outpatients seen at Mayo Clinic 
Sample size: 185 samples from 161 patients
Target organism: E. coli O157
Rapid test Methods
ELISA (LMD laboratories)
Reference test Methods
Culture on SMAC agar and 5% sheep blood agar
Reported accuracy data:
Sensitivity 98.86 TP 9
Specificity 100 FP 0
PPV 100 FN 2
NPV 81.82 TN 174
Economic evaluation: Not carried out
What the authors  An accurate, easy-to-read screening method for the detection of E. coli O157 in faecal 
conclude: specimens
Assessment of  Appropriate conclusions
authors’ conclusions:
Authors (year): Ehling-Schulz et al. (2004)98
Journal: FEMS Microbiology Letters
Title: Identification of emetic toxin producing Bacillus cereus strains by a novel molecular assay
Notes:
Setting: Reference laboratory Design: Development of a new assay
Sample characteristics: Reference B. cereus strains obtained from various laboratories
Sample size: 178 bacterial isolates include 100 B. cereus isolates from various sources
Target organism: B. cereus emetic strain 
Rapid test Methods
PCR  PCR assay for emetic strain of B. cereus. Not truly rapid, requires 24 hours after isolation
Reference test Methods
No comparison with another assay
Reported accuracy data:
Sensitivity 30/30 (100%) TP NA
Specificity NA  FP NA
PPV NA  FN NA
NPV NA  TN NA
Economic evaluation: No economic data presented
What the authors  This simple and rapid PCR assay represents an attractive alternative for the detection of the 
conclude: emetic toxin via cytotoxicity assay, HPLC–MS and using a sperm-based bioassay
Assessment of  This appears to be a sensitive and test strain specific molecular assay for the detection of 
authors’ conclusions: emetic strain of B. cereus, but there was no comparison test in the study.Appendix 3
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Authors (year): Endtz et al. (2000)164
Journal: European Journal of Clinical Microbiology and Infectious Diseases
Title: Evaluation of a new commercial immunoassay for rapid detection of campylobacter jejuni in
stool samples
Notes:
Setting: Hospital laboratory, The Netherlands Design: Diagnostic comparison
Sample characteristics: 30 consecutive culture-positive for Campylobacter stool specimens, submitted between
January and April 1999. 30 Campylobacter culture-negative specimens and 18 Salmonella
culture-positive samples were used to test specificity
Sample size: 78
Target organism: C. jejuni and C. coli
Rapid test Methods
ProSpecT Campylobacter Commercial enzyme immunoassay (Alexon-Trend, USA), performed according to 
microplate assay  instructions of the manufacturer
Reference test Methods
Culture on modified CCDA Not reported
Reported accuracy data:
Sensitivity 80.00 TP 24
Specificity 100.00 FP 0
PPV 100.00 FN 6
NPV 88.89 TN 48
Major confounders  Significant time delay between culture test and EIA may have affected sample.  Blinding not 
or bias: possible
Economic evaluation: Not carried out
What the authors  A rapid, easy-to-perform test to detect C. jejuni in stool samples
conclude:
Assessment of  Data suggest that the test’s sensitivity and specificity are promising, but this needs to be 
authors’ conclusions: confirmed in a larger, prospective study
Authors (year): Fach and Guillou (1993)165
Journal: Journal of Applied Bacteriology
Title: Detection by in vitro amplification of the alpha-toxin (phospholipase C) gene from Clostridium
perfringens
Setting: Research laboratory, France Design: Assay development
Sample characteristics: Strains only
Sample size: Unclear
Target organism: Clostridium perfringens
Rapid test A gel-based duplex PCR performed for detection of C. perfringens phospholipase C and
enterotoxin genes. Method first used by Saiki and colleagues241
Reference test Assay development only: No comparator
Reported accuracy data: Not provided
Economic evaluation: Not provided
What the authors  This PCR satisfies the criteria of specificity, sensitivity and rapidity required for a useful tool 
conclude: in epidemiology and for the diagnosis of C. perfringens as it may be used directly on stool
samples
Assessment of  Methods clearly reported; however, full evaluation with suitable comparator necessary
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Farrell (2003)242
Journal: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Title: Prospective validation of real time PCR detection of Salmonella in culture from clinical stool
specimens
Notes: Poster presentation only
Setting: Hospital laboratory, USA Design: Prospective
Sample characteristics: All bacterial colonies from stool samples screened for Salmonella between 6 January 2003
and 6 May 2003
Sample size: 298 colonies (from 170 patients)
Target organism: Salmonella enterica
Rapid test Methods
rtPCR for the prgK gene LightCycler platform used.  Study states real-time PCR performed in 3–4 hours
Reference test Methods
Culture Cultured on lysine iron agar and triple sugar iron agar.  Study states conventional screening
and identification protocols require 2–3 days
Reported accuracy data:
Sensitivity 99.62 TP 38
Specificity 100 FP 1
PPV 97.44 FN 0
NPV 100 TN 259
Economic evaluation: None reported
What the authors PCR equivalent to culture-based methods of detecting and identifying Salmonella; however, 
conclude: real-time PCR identification can be performed in 3–4 hours, as opposed to conventional
screening and identification protocols, which require 2–3 days
Assessment of  Methods appear correct
authors’ conclusions:
Authors (year): Fedorka et al. (1989)166
Journal: Diagnostic Microbiology and Infectious Disease
Title: Increased efficiency of stool culture for the detection of Salmonella and Shigella
Notes:
Setting: Research laboratory, USA Design: Diagnostic comparison
Sample size: 822 consecutive stool samples
Target organism: Salmonella and Shigella
Rapid test Methods
Wampole Bactigen Wampole Bactigen Salmonella–Shigella latex agglutination test. Three reagents used: 
(1) coated with goat antibodies to more than 80 common Salmonella serogroups;
(2) layered with rabbit antibodies to Shigella group B and D; (3) bears rabbit antibodies to
Shigella groups A and C.
Reference test Methods
Standard culture SS culture with subculture of selenite broths
Reported accuracy data:
Sensitivity 100 TP 17
Specificity 93.54 FP 52
PPV 24.64 FN 0
NPV 100 TN 753
Economic evaluation: None provided
What the authors  The (Wampole) SSLA test is a useful screening test for Salmonella. By eliminating unnecessary 
conclude: subcultures of selenite broth, it reduces turnaround by 24 hours for negative stool cultures
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Finlay et al. (1999)100
Journal: Applied and Environmental Microbiology
Title: Semiautomated metabolic staining assay for Bacillus cereus emetic toxin
Notes:
Setting: University laboratory Design: Development of a new assay
Sample characteristics: Reference B. cereus strains obtained from various laboratories
Sample size: 13 B.cereus strains
Target organism: B. cereus emetic strain
Rapid test Methods
Metabolic staining assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) conversion 
Reference test Methods
Comparison with Hep-2 cell assay
Reported accuracy data: Not given
Major confounders  None examined
or bias:
Economic evaluation: No economic data presented, but authors state it is cheaper than the reference standard
What the authors  A significant improvement on current methods of emetic toxin assay as it is cheaper and 
conclude: considerably less labour intensive than animal challenge assays, requires no specialised
laboratory apparatus, eliminates personal visual assessment and appears to be specific for 
the B. cereus emetic toxin
Assessment of  The lack of comparison data limits the assessment of this assay
authors’ conclusions:
Authors (year): Fletcher and Logan (1999)95
Journal: Letters in Applied Microbiology
Title: Improved cytotoxicity assay for Bacillus diarrhoeal enterotoxin
Notes:
Setting: University laboratory Design: Evaluation of a new assay
Sample characteristics: Reference B. cereus strains obtained from various laboratories
Sample size: 71 B.cereus strains
Target organism: B. cereus diarrheoal strains
Rapid test Methods
McCoy cell-based assay
Reported accuracy data: Not given
Agreement between  O14 food poisoning samples, 10 were positive on ICA, 13 on Tecra and 7 on Oxoid
methods:
Economic evaluation: No economic data presented
What the authors  The cytotoxicity assay is more sensitive than the Oxoid kit and unlike the Tecra kit did not 
conclude: give false positive results with supernatant samples heat treated to destroy the toxin
Assessment of  This assays appears to be as good as the commercial kits available
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Forward et al. (2003)78
Journal: Journal of Medical Microbiology
Title: Detection of Clostridium difficile cytotoxin and Clostridium perfringens enterotoxin in cases of
diarrhoea in the community
Notes:
Setting: PHLS Laboratory, UK Design: Diagnostic comparison
Sample size: 843 cases of diarrhoea in the community between November 1999 and April 2000
Target organism: C. difficile and C. perfringens
Rapid test Methods
TechLab EIA Performed according to manufacturer’s instructions. Optical density read at 450 and 620 nm.
All specimens that gave equivocal or positive readings were repeated
Rapid test Methods
Vero cell assay 96-well microtitre tray seeded with suspension of Vero cells in Eagle’s minimal essential
medium and incubated overnight at 37°C. Faecal extracts prepared and added. Plate covered
and incubated overnight at 37°C, then cell cultures examined for cytotoxicity
Reference test Methods
In-house ELISA PHLS FSML in-house EIA performed as prescribed by Bartholomew et al.82
Reported accuracy data: TechLab EIA Reported accuracy data: Vero cell
Sensitivity 100.00 TP 21 Sensitivity TP 11
Specificity 33.87 FP 41 Specificity FP
PPV 95.01 FN 0 PPV FN
NPV 100.00 TN 781 NPV TN
Economic evaluation: Not provided
What the authors  TechLab EIA was less sensitive than FSML EIA. A Vero cell assay for CPE is too insensitive 
conclude: for routine use
Assessment of  Appropriate conclusions
authors’ conclusions:
Authors (year): Fukuda et al. (2000)111
Journal: Letters in Applied Microbiology
Title: Rapid detection of Staphylococcus aureus using bioluminescent enzyme immunoassay
Notes:
Setting: Commercial research laboratory (Kikkoman Corp, Japan)
Target organism: S. aureus
Rapid test Methods
Checklite BH  Bioluminescent enzyme immunoassay (BLEIA) for detecting protein A-bearing S. aureus
Staphylococcus aureus using biotylinated firefly luciferase. Stored strains in broth were subjected to the assay. The 
screening test (Kikkoman) test was not carried out directly on stool samples
Reference test Positive/negative  Blinding
controls
Test performed on known S. aureus-positive samples NA No
Reported accuracy data:
Sensitivity 100 TP 24
Specificity 86 FP 50
PPV – FN 0
NPV 100 TN –
Turnaround time vs  Detection of protein-A bearing S. aureus is possible within 7 hours including culture
reference method:
Economic evaluation: Not provided
What the authors  This system could be adapted to detect other food-borne pathogens or toxins using 
conclude: appropriate immunological reagents
Assessment of  Given the increased speed of detection associated with the BLEIA, further research 
authors’ conclusions: regarding its use with other food-borne pathogens may be justifiedAppendix 3
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Authors (year): Gavin et al. (2004)66
Journal: Journal of Clinical Microbiology
Title: Evaluation of performance and potential clinical impact of ProSpecT shiga toxin Escherichia
coli microplate assay for detection of shiga toxin-producing E. coli in stool samples
Notes: Included due to availability of economic analysis
Setting: Reference laboratory, USA Design: Partial prospective diagnostic accuracy study
Sample characteristics: Fresh human stool samples collected over two consecutive summers
Sample size: 2060 samples tested using ProSpecT kit. 543 of these also routinely tested using SMAC
culture, remainder only colonised if ProSpecT kit produced positive result
Target organism: Shiga toxin E. coli
Rapid test Methods
ProSpecT Shiga toxin  Microplate immunoassay using rabbit polyclonal anti-Shiga toxin 1 and 2 capture antibodies 
E. coli (Alexon Trend) and a horseradish peroxidase-labelled monoclonal mouse anti-Shiga toxin 1 and 2 conjugate.
Assay performed according to manufacturer’s instructions
Reference test Methods Positive/negative  Blinding
controls
SMAC Both Yes
Reported accuracy data: full validation (pilot sample) Reported accuracy data: partial validation 
(larger sample) 
Sensitivity 100 TP 7 Sensitivity 100 TP 27
Specificity 100 FP 0 Specificity 100 FP 2
PPV 100 FN 0 PPV 93.1 FN 0
NPV 100 TN 536 NPV 100 TN 2031
Economic evaluation: Materials and labour cost of ProSpecT assay calculated at $16 per test, based on list price for
the assay and average labour cost of $20/hour. Over the two summers, screening 2060 stool
specimens for the presence of Shiga toxins by ProSpecT assay cost $32,960
What the authors  ProSpecT assay demonstrated 100% sensitivity and specificity for detection of O157 
conclude: serotype STEC. Lack of true gold standard for non-O157 serotypes prohibits evaluation of
ProSpecT for all other STEC
Assessment of  Study highlights under-reporting of non-O157 strains resulting from reliance on SMAC 
authors’ conclusions: cultureHealth Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Geers and Backes (1989)52
Journal: American Journal of Clinical Pathology
Title: Evaluation of two rapid methods to screen pathogens from stool specimens
Notes:
Setting: Hospital laboratory, USA Design: Retrospective
Sample size: 125 Salmonella, Shigella or Yersinia isolates and 81 non-enteric pathogens tested with EPS
card; 300 stool cultures with suspicious colonies tested with TSI–urea screens
Target organism: Salmonella, Shigella or Yersinia
Rapid test Methods
AutoMicroBic EPS Enteric Pathogen Screen cards of the AutoMicroBic system (Vitek Systems)
Rapid test Methods: Bactigen Salmonella–Shigella latex agglutination
Bactigen Salmonella-Shigella Three reagents used: (1) coated with goat antibodies to more than 80 common Salmonella
latex agglutination serogroups; (2) layered with rabbit antibodies to Shigella group B and D; (3) bears rabbit
antibodies to Shigella groups A and C
Reference test Methods
Biochemical test media Triple sugar iron and urea agar.  Indole tests performed on organisms displaying characteristic
reactions on these media. Definitive identification achieved with AMS Gram-negative
identification cards and confirmed by sera testing
Reported accuracy data: EPS Reported accuracy data: Bactigen SS latex
agglutination
Sensitivity 86.96 TP 20 Sensitivity 100 TP 20
Specificity 85.47 FP 67 Specificity 98.25 FP 4
PPV 22.99 FN 3 PPV 83.33 FN 0
NPV 99.24 TN 394 NPV 100 TN 457
Economic evaluation: Not provided
What the authors  Because the (Wampole) LPA method is faster, eliminates more clinically irrelevant organisms 
conclude: from further testing and does not require the use of an expensive identification system, the
authors believe that it is better suited for direct screening for Salmonella and Shigella for
most clinical laboratories
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Germani et al. (1990)84
Journal: Research in Microbiology
Title: Competitive erythroimmunoassay for detecting Clostridium perfringens type a enterotoxin in
stool specimens
Notes:
Setting: Research laboratory, France Design: Prospective
Sample characteristics: Retrieved from children’s hospital where patients suffering from diarrhoea. Causes were
food-borne intoxication (5 cases) or antibiotic-associated colitis or unknown (95 cases)
Sample size: 100 samples
Target organism: C. perfringens
Rapid test Methods
Competitive  Immunoassay technique which assesses erythrocyte attachment to wells as assessed by eye.  
erythroimmunoassay (ERIA) Methods described previously
Reference test Methods
ELISA Sheep anti-CPE Ig in a 1:400 dilution in carbonate buffer, incubated overnight at room
temperature.  Washing process takes place over 5.5 hours
Reported accuracy data:
Sensitivity 100 TP 3
Specificity 93.8 FP 6
PPV 33.3 FN 0
NPV 100 TN 91
Sensitivity vs  ELISA reported two false negatives – therefore cannot be assumed as best reference. ERIA 
reference method: as sensitive as other serological assays and more sensitive than the ELISA
Turnaround time vs  Authors claim ERIA is quicker than ELISA
reference method:
Economic evaluation: Authors claim ERIA is cheaper than ELISA, but no evaluation provided
What the authors  ERIA recommended in diagnosis for poorly equipped laboratories
conclude:
Assessment of  Quality of methods sounds; however, evaluation may be dated
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Guardati et al. (1993)110
Journal: Journal of Clinical Microbiology
Title: Rapid methods for identification of Staphylococcus aureus when both human and animal
staphylococci are tested: comparison with a new immunoenzymatic assay
Notes:
Setting: University laboratories, Switzerland and Italy
Sample characteristics: Of human and animal origin
Sample size: 275 S. aureus and 380 non-S. aureus reference strains
Target organism: S. aureus
Rapid test Methods
Immunoassay Based on monoclonal antibody Mab C1-10/11, prepared against SaG, an enzyme produced
by all isolates of this species
Reference test:
Six commercially available:  Staphaurex (Wellcome Diagnostics), Pastorex Staph (Diagnostic Pasteur), Staphyslide test
(bio Merieux), Sero-STAT (Scott Laboratories), Bacto Staph Latex (Difco) and Bactident
(Merck)
Reported accuracy data: Immunoassay Reported accuracy data: Staphaureux (one of 6
commercial kits evaluated)
Sensitivity 100 TP 275 Sensitivity 92 TP 253
Specificity 100 FP 0 Specificity 91.1 FP 34
PPV 100 FN 0 PPV 88.2 FN 22
NPV 100 TN 380 NPV 94 TN 346
Sensitivity vs  EIA more sensitive and specific than all commercial kits
reference method:
Turnaround time vs  Unclear
reference method
Economic evaluation: None provided
What the authors  The EIA is a useful test for isolates where identification is doubtful and for epidemiological 
conclude: studies
Assessment of authors’  Conclusion is appropriately cautious
conclusions:
Authors (year): Haggblom et al. (2002)99
Journal: Applied and Environmental Microbiology
Title: Quantitative analysis of cereulide, the emetic toxin of Bacillus cereus produced under various
conditions
Notes:
Setting: University laboratory Design: Development of a new assay
Sample characteristics: Reference B. cereus strains obtained from various laboratories
Sample size: 5 B. cereus strains
Target organism: B. cereus emetic strain 
Rapid test Methods
A quantitative and sensitive chemical assay for cereulide based on liquid chromatography
connected to ion trap mass spectrometry.  Requires 24 hours after isolation
Reference test Methods
Comparison with boar spermatozoan motility assay
Reported accuracy data: Not presented
Major confounders  None examined
or bias:
Economic evaluation: No economic data presented
What the authors  A sensitive and rapid chemical assay for cereulide was developed which correlated well with 
conclude: the sperm motility assay
Assessment of  Diagnostic accuracy data not presented. We are therefore unable to assess the effectiveness 
authors’ conclusions: of this assayAppendix 3
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Authors (year): Hansen and Freney (1993)167
Journal: Journal of Microbiological Methods
Title: Comparative evaluation of a latex agglutination test for the detection and presumptive
serogroup identification of Salmonella spp.
Notes:
Setting: Hospital laboratory, Belgium Design: Diagnostic comparison
Sample size: All 702 diarrhoeal stool samples, selected from 4953 collected at microbiology laboratory
between 1 January 1990 and 31 August 1990
Target organism: Salmonella species
Rapid test Methods
Wellcolex Colour Salmonella RPLA test designed to detect Salmonella antigens, using overnight selenite broth cultures.
Test performed as recommended by manufacturer
Reference test Methods
Standard culture Stool samples inoculated on to XLD agar, MacConkey agar heart infusion agar, and selenite
enrichment broth. Subcultures of selenite broth made after 24 hours at 36°C on to XLD and
MacConkey agar plates; these media also incubated overnight at 36°C
Reported accuracy data:
Sensitivity 100 TP 39
Specificity 98.34 FP 11
PPV 78 FN 0
NPV 100 TN 652
Economic evaluation: None provided
What the authors  Wellcolex Colour test provides a simple and rapid procedure for detection and presumptive 
conclude: serogroup identification of Salmonella spp. in enrichment broths
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Hindiyeh et al. (2000)168
Journal: Journal of Clinical Microbiology
Title: Rapid detection of Campylobacter jejuni in stool specimens by an enzyme immunoassay and
surveillance for Campylobacter upsaliensis in the Greater Salt Lake City area
Notes:
Setting: Hospital laboratory with samples from four centres
Design: Diagnostic comparison
Sample characteristics: Patients with suspected bacterial diarrhoea having liquid or non-formed stools were included
Sample size: 631 stool samples
Target organism: C. jejuni
Rapid test Methods
ProSpecT Microplate assay Commercial EIA (Alexon-Trend, USA), performed according to instructions of the
manufacturer. Incubated at room temperature for 1 hour, wells washed, enzyme conjugate
added, samples incubated for further 30 minutes.Wells washed and incubated with colour
substrate at room temperature for 10 minutes. Results read spectrophotometrically at
450 nm
Reference test Methods
Culture Culture on a Campy-CVA plate (Remel, Lenexa, KS, USA) and blood-free Campylobacter agar
with cefoperazone (20 µg ml–1), amphotericin B (10 µg ml–1) and teicoplanin (4 µg ml–1)
Reported accuracy data:
Sensitivity 88.89 TP 16
Specificity 99.67 FP 4
PPV 80.00 FN 2
NPV 99.35 TN 609
Agreement between 
methods:
Additional statistical  Observed difference between results of EIA compared with results from culture media 
analysis: were not statistically significant (by McNemar’s test, p > 0.25)
Economic evaluation: Cost-effectiveness of this assay requires evaluation since the direct cost of the EIA is $8
more than that of culture
What the authors  Assay is less sensitive than culture, has high specificity and results are available within 
conclude: 24 hours
Assessment of  Appropriate conclusion
authors’ conclusions:Appendix 3
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Authors (year): Iijima et al. (2004)117
Journal: Journal of Medical Microbiology
Title: Improvement in the detection rate of diarrhoeagenic bacteria in human stool specimens by a
rapid real-time PCR assay
Notes:
Setting: Hospital laboratory, Japan Design: Prospective, consecutive
Sample characteristics: Stool specimens from 16 healthy people, 40 people linked to food poisoning incidents and
105 outpatients receiving treatment for diarrhoea and/or abdominal pain
Sample size: 161 stool specimens in total
Target organism: Salmonella enterica, Vibrio parahaemolyticus, Campylobacter jejuni and shiga toxin-producing
Escherichia coli
Rapid test Methods
Multiplex rtPCR detection  Based on invA gene for S. enterica, yphC and gyrA genes for C. jejuni, and stx1, stx2 and eae
genes for STEC. Diagnosis, including DNA extraction and rtPCR, within 3 hours. PCR cycle
performed within 70 minutes
Reference test Methods
Standard culture Standard methods used, referencing Manual for Clinical Microbiology, 7th ed.
Reported accuracy data: S. enterica Reported accuracy data: C. jejuni
Sensitivity 81.82 TP 9 Sensitivity 84.21 TP 16
Specificity 96.00 FP 6 Specificity 95.07 FP 7
PPV 60.00 FN 2 PPV 69.56 FN 3
NPV 98.63 TN 144 NPV 97.83 TN 135
Additional analysis: Retest of PCR-positive, culture-negative by the PCR method produced identical results
Economic evaluation: None given
What the authors  This PCR-based method contributes to improved rapid diagnosis of enteric bacterial 
conclude: infections, while yielding higher detection rates of causative agents
Assessment of  Very promising assay which could allow multiplex reactions, for the simultaneous detection 
authors’ conclusions: of multiple pathogens
Authors (year): Imperatrice and Nachamkin (1993)53
Journal: Journal of Clinical Microbiology
Title: Evaluation of the Vitek EPS Enteric Pathogen Screen card for detecting Salmonella, Shigella
and Yersinia spp.
Notes:
Setting: Hospital laboratory, USA Design: Retrospective
Sample size: 125 Salmonella, Shigella or Yersinia isolates and 81 non-enteric pathogens tested with EPS
card; 300 stool cultures with suspicious colonies tested with TSI–urea screens
Target organism: Salmonella, Shigella or Yersinia
Rapid test Methods
AutoMicroBic EPS Enteric Pathogen Screen cards of the AutoMicroBic system (Vitek Systems)
Reference test Methods
Biochemical test media Triple sugar iron and urea agar
Reported accuracy data: EPS Reported accuracy data: TSI–urea screen
Sensitivity 99.46 TP 183 Sensitivity Unclear TP Unclear
Specificity 90.12 FP 8 Specificity 32.24 FP 166
PPV 95.81 FN 1 PPV Unclear FN Unclear
NPV 98.65 TN 73 NPV Unclear TN 79
Major confounders  Uses updated versions of Vitek software analysis program to Geers and Backes,52
or bias: so results may not be directly comparable
Economic evaluation: In an analysis of the cost of 100 cultures with a positive screen, the EPS card cost $288
versus $432 for the TSI–urea test and subsequent biochemical identification in our laboratory 
(US$ 1992)
What the authors  The Vitek EPS Screen card was both sensitive in detecting the spectrum of organisms 
conclude: isolated in the patient population and much more specific than our conventional TSI–urea
screen
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Kai et al. (1997)65
Journal: Kansenshogaku Zasshi (Journal of the Japanese Association for Infectious Diseases)
Title: Evaluation of a latex agglutination method for detecting and characterising verotoxin (VT)
produced by Escherichia coli
Notes: Japanese translation
Setting: Design:
Sample characteristics:
Sample size: 178 human strains – 147 VTEC, 31 controls
Target organism: E. coli (EHEC and VTEC)
Rapid test 1 Methods
PCR  Cultured in trypticase soy broth at 37°C for 18–24 hours. PCR detection of stx1 and stx2
genes following methods first described by Yamasaki et al.243
Rapid test 2 Methods
Latex agglutination and  Followed instructions published in Denka Seiken kit product insert. Uses monoclonal 
ELISA antibody and polyclonal antibody of vt1 and vt2 toxins
Reference test Methods
Vero cell assay Cultured in trypticase soy broth at 37°C for 18–24 hours. VT producability investigated
following methods first described by Konowalchuk et al.244
Reported accuracy data: PCR (human samples) Reported accuracy data: Latex agglutination (human
samples)
Sensitivity 100.00 TP 147 Sensitivity 100.00 TP 147
Specificity 100.00 FP 0 Specificity 100.00 FP 0
PPV 100.00 FN 0 PPV 100.00 FN 0
NPV 100.00 TN 31 NPV 100.00 TN 31
Agreement between  100% concordance for all tests on humans; however, lower concordance (97.5%) 
methods: experienced when 158 animal strains were tested using similar methods
Economic evaluation: None given
What the authors  Sensitivity, specificity and concordance rate were all 100% for Vero cell culture, PCR 
conclude: method and VTEC Screen test
Assessment of  Authors’ conclusions correct
authors’ conclusions:Appendix 3
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Authors (year): Karmali et al. (1999)169
Journal: Journal of Clinical Microbiology
Title: Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and
characterising verotoxins (shiga toxins) in Escherichia coli
Notes:
Setting: Pediatric hospital, Canada, and microbiology department, Czech Republic
Design:
Sample size: 165 banked reference strains – 68 VT positive (65 human isolates) and 104 VT negative (100
human isolates)
Target organism: Verotoxin (shiga toxin) E. coli
Rapid test Methods
Verotox-F assay RPLA performed according to manufacturer’s instructions. Examined for latex agglutination
after 20–24 hours
Reference test Methods Positive/negative controls Blinding
Vero cell assay “Performed as described previously”  Positive and negative 
(Karmali)245 controls
included in kit
Reported accuracy data:
Sensitivity 100 TP 65
Specificity 100 FP 0
PPV 100 FN 0
NPV 100 TN 100
Sensitivity vs reference  Equivalent
method:
Turnaround time vs  Results in 1 day compared with at least 3 days’ incubation for Vero cell assay
reference method:
Economic evaluation: None provided
What the authors  Rapid, reliable and easy to perform
conclude:
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Kehl et al. (1997)32
Journal: Journal of Clinical Microbiology
Title: Evaluation of the Premier EHEC assay for detection of shiga toxin-producing Escherichia
coli
Notes: Manufacturer funded, plus Government grant
Setting: Paediatric hospital laboratory, USA
Design: Prospective evaluation study
Sample characteristics: Consecutive samples from children’s hospitals (inpatients and outpatients)
Sample size: 974 with Premier EHEC and culture
Target organism: E. coli
Rapid test Methods
Premier EHEC  Performed according to manufacturer’s recommendations. Tested on overnight growth 
(Meridian Diagnostics) from MacConkey’s broth. Spectrophotometric reading set at 450 nm, optical density
>0.150
Reference test Methods
SMAC culture,  All samples cultured using standard method, incubated for 18–24 hours. Samples positive 
cytotoxicity tests, and  by any test (n = 16) confirmed by cytoxicity testing. Positive and negative controls 
immunoblot assay provided
Reported accuracy data:
Sensitivity 100 TP 13
Specificity 99.69 FP 3
PPV 81.25 FN 0
NPV 100 TN 956
Agreement between  Premier EHEC assay detected 40% more STEC than conventional SMAC culture. STEC 
methods: other than O157 accounted for 20% of STEC disease in children
Economic evaluation: The cost of the assay may limit its widespread use. Good criteria would allow for the cost-
effective utilisation of this assay to be determined
What the authors  Premier EHEC assay is a sensitive and specific method for the detection of all STEC isolates. 
conclude: Routine use would improve the detection of E. coli O157:H7 and allow for determination
of the true incidence of STEC other than O157:H7
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Klein et al. (2002)59
Journal: Journal of Pediatrics
Title: Shiga toxin-producing Escherichia coli in children with diarrhoea: a prospective point-of-care
study
Notes:
Setting: Paediatric hospital laboratory, USA
Design: Prospective evaluation study
Sample characteristics: Consecutive samples from children’s hospitals (inpatients and outpatients)
Sample size: 1851 with Premier EHEC and culture
Target organism: E. coli
Rapid test Methods
Premier EHEC  Performed according to manufacturer’s recommendations. Tested on overnight growth 
(Meridian Diagnostics) from MacConkey’s broth. Spectrophotometric reading set at 450 nm, optical density >0.150
Reference test Methods
SMAC culture,  All samples cultured using standard method, incubated for 18–24 hours. Samples positive by 
cytotoxicity tests and  any test (n = 16) confirmed by cytoxicity testing. Positive and negative controls provided
immunoblot assay
Reported accuracy data:
Sensitivity 89.29 TP 25
Specificity 100.00 FP 0
PPV 100.00 FN 3
NPV 99.84 TN 1823
Agreement between methods:
Economic evaluation: The cost of the assay may limit its widespread use. Good criteria would allow for the cost-
effective utilisation of this assay to be determined
What the authors  Premier EHEC assay is a sensitive and specific method for the detection of all STEC isolates. 
conclude: Routine use would improve the detection of E. coli O157:H7 and allow for determination of
the true incidence of STEC other than O157:H7
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Klotz et al. (2003)106
Journal: Journal of Clinical Microbiology
Title: Detection of Staphylococcus aureus enterotoxins A to D by real-time fluorescence PCR assay
Notes:
Setting: University research laboratory, Germany
Design: Diagnostic comparison 
Sample  93 banked reference strains
characteristics/size:
Target organism: S. aureus enterotoxins A to D
Rapid test Methods
Real-time fluorescence PCR Detection of S. aureus enterotoxins A to D by real-time fluorescence PCR assay. mecA gene
encoding methicillin resistance and the femB gene (a specific genomic marker for S. aureus)
were also used
Reference test Methods Positive/negative  Blinding
controls
SET-RPLA (Oxoid) Commercially available reverse-passive latex  Positive controls Unclear
agglutination kit used according to manufacturer’s  used
instructions
Reported accuracy data:
Sensitivity 100 TP 40
Specificity 92.45 FP 4
PPV 90.91 FN 0
NPV 100 TN 49
Sensitivity vs reference  More sensitive than SET-RPLA
method:
Turnaround time vs  rtPCR results available within 6 hours after isolation of S. aureus, compared with 2.5 days 
reference method: for SET-RPLA
Economic evaluation: Costs per strain are about $12 for SET-RPLA and about $8 for rtPCR
What the authors  Faster, less expensive and less labour intensive than reference standard
conclude:
Assessment of  Appropriate conclusions. This promising assay requires further assessment with a larger 
authors’ conclusions: sample studyAppendix 3
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Authors (year): Kulkarni et al. (2002)12
Journal: Journal of Clinical Pathology
Title: Detection of Campylobacter species: a comparison of culture and polymerase chain reaction
based methods
Notes: Shares part-authorship with Lawson et al.48
Setting: Public Health Laboratory, UK
Design: Prospective diagnostic accuracy study
Sample characteristics: All stool samples received in laboratory over a 10-week period from August to October
1998. Culture and DNA extraction performed on all samples within 24 hours of receipt by
laboratory
Sample size: 343 stool samples
Target organism: Campylobacter species
Rapid test Methods
PCR screen and  PCR screening performed on all samples using RoboCycler thermocycler.  Samples positive 
PCR–ELISA identification  for C. jejuni–C. coli undergo further PCR–ELISA to identify genetic composition – specifically 
based on 16s rRNA gene  hip gene of C. jejuni and asp gene of C. coli. Initial screening of all samples using PCR
technique can be performed in approximately 90 minutes, following DNA extraction. Gel
electrophoresis performed to analyse sample, taking additional 30 minutes. Further workup
on positive samples to confirm speciation by PCR–ELISA would increase time to results;
however, this is not recorded. All PCR results available on the same day the assays were
performed
Reference test Methods
Standard culture Selective culture performed with CCDA plates. Plates incubated microanaerobically for
2 days
Reported accuracy data:
Sensitivity 88.24% TP 15
Specificity 98.47% FP 5
PPV 75.00% FN 2
NPV 99.38% TN 321
Additional statistical  McNemar’s test used to compare alternative detection methods. No statistical differences 
analysis: between PCR and culture in detection of C. jejuni–C. coli
Major confounders  Unclear if blinding was used. By setting policy that DNA extraction must take place within 
or bias: 24 hours of sample arriving in the laboratory, the potential for cell degradation is reduced.
Economic evaluation: Hypothesises “using PCR in the enteric laboratory for the detection of campylobacters is
labour intensive and not cost-effective”; “advantages do not outweigh the expense”. No
formal economic evaluation is carried out
What the authors  The optimal method for the detection of Campylobacters spp. from stool samples in the 
conclude: diagnostic laboratory remains selective culture
Assessment of authors’  One of the few studies to provide an economic critique on test options. PCR methods used 
conclusions: in this study, including screening by PCR and further PCR–ELISA for identification, are
somewhat more labour intensive than most current PCR techniquesHealth Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): LaGier et al. (2004)170
Journal: Molecular and Cellular Probes
Title: A real-time multiplexed PCR assay for rapid detection and differentiation of Campylobacter
jejuni and Campylobacter coli
Notes:
Setting: Research laboratory, USA Design: Retrospective
Sample characteristics: Strains from bacteria isolate archive, originally isolated from primary patient specimens
Sample size: 67 strains – 25 known negative, 12 known C. coli, 30 known C. jejuni
Target organism: C. jejuni and C. coli
Rapid test Methods
Real-time multiplex PCR In-house multiplex C. jejuni–C. coli species-specific primer and TaqMan probe set designed 
detecting hipO for C. jejuni with Primer Express software. Qiagen DNA stool Mini Kit used for DNA extraction. 
and glyA for C. coli Roche LightCycler–FastStart DNA Master Hybridization Probe Kit used for rtPCR assay,
which followed format from Bopp et al.24 Turnaround time for PCR assay, including DNA
extractions, stated as 3.5–4.0 hours
Reference test Methods
Standard culture Strains previously confirmed. Time taken for gold standard culture methods stated as
2–5 days
Reported accuracy data:
Sensitivity 100.00 TP 40
Specificity 100.00 FP 0
PPV 100.00 FN 0
NPV 100.00 TN 25
Major confounders  Prohibited by sole use of reference strains – more applicable to routine diagnostic use if 
or bias: assay could be tested prospectively
Economic evaluation: Increased productivity highlighted as decreased turnaround time will free up laboratory
personnel working hours for other tasks
What the authors  This assay is the first successful attempt to identify and differentiate C. jejuni and C. coli
conclude: directly from clinical isolates in a single reaction
Assessment of  Paper very strong on analytical methodology, but to assess diagnostic accuracy more fully a 
authors’ conclusions: larger sample size, tested prospectively, would be requiredAppendix 3
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Authors (year): Law et al. (1994)171
Journal: Journal of Medical Microbiology
Title: Diagnosis of infections with shiga-like toxin-producing Escherichia coli by use of enzyme-
linked immunosorbent assays for shiga-like toxins on cultured stool samples
Notes:
Setting: Hospital Laboratory, UK Design:
Sample characteristics: Unselected cases, although they tend to have more severe illness 
Sample size: 475 stool specimens from 457 patients were examined
Target organism: STEC
Rapid test Methods
ELISA In-house-designed ELISA, as described in Law246
Reference test Methods
SMAC culture Cultured on SMAC, plus slide agglutination performed with E. coli O157 antiserum 
Reported accuracy data:
Sensitivity 100 TP 42
Specificity 97.2 FP 12
PPV 77.8 FN 0
NPV 100 TN 421
Sensitivity vs reference  Detects more than culture
method:
Turnaround time vs  Faster
reference method:
Economic evaluation: None provided
What the authors  Rapid and sensitive technique, especially where low numbers of organisms are present in 
conclude: faeces or for non-O157 serotypes
Authors (year): Lawson et al. (1998)47
Journal: Epidemiology and Infection
Title: Detection of Campylobacter in gastroenteritis: comparison of direct PCR assay of faecal
samples with selective culture
Notes:
Setting: PHLS Laboratory and national reference laboratory, UK
Design: Blinded evaluation
Sample characteristics: Unselected consecutive faecal samples
Sample size: 200
Target organism: Campylobacter species
Rapid test Methods
Conventional PCR
Rapid test Methods
Reference test Methods
Culture Cultured on modified CCDA agar
Reported accuracy data:
Sensitivity 93.75 TP 15 PCR positive 19
Specificity 97.83 FP 4 Culture positive 16
PPV 78.95 FN 1
NPV 99.44 TN 180
Economic evaluation: “As presently configured, PCR is relatively labour intensive, and costly compared to culture,
and thus is as yet unlikely to provide an alternative to culture diagnosis for C. jejeuni and
C. coli”
What the authors  16 samples (8%) of 200 unselected faecal samples sent for testing at a clinical laboratory 
conclude: proved to be culture positive for Campylobacter whereas 19 (9.5%) were positive by PCR
Assessment of authors’  Study highlights benefits of PCR when studying rarer forms of Campylobacter
conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Lawson et al. (1999)48
Journal: Journal of Clinical Microbiology
Title: Large-scale survey of Campylobacter species in human gastroenteritis by PCR and
PCR–enzyme-linked immunosorbent assay
Notes: Based on methods first described by Linton et al.15 (1997) and Lawson et al.47
Setting: Central Public Health Laboratory, UK
Design: Blinded prospective diagnostic accuracy study
Sample characteristics: Fresh stool samples submitted from outpatients, GPs or environmental health officer within
seven PHLS laboratories over a 2-year period
Sample size: 3738 faecal samples
Target organism: Campylobacter species, including C. jejuni, C. coli, C. upsaliensis, C. hypointestinalis and C. lari
Rapid test Methods
PCR and PCR-ELISA  PCR screening performed on all samples using RoboCycler thermocycler. Samples positive 
detecting the 16S rDNA  for C. jejuni–C. coli undergo further PCR–ELISA to identify genetic composition – specifically 
gene hip gene of C. jejuni and asp gene of C. coli. Initial screening of all samples using PCR
technique can be performed in approximately 90 minutes, following DNA extraction. Further
workup on positive samples to confirm speciation by PCR–ELISA would increase time to
results; however, this is not recorded
Reference test Methods
Standard culture Five laboratories cultured on Campylobacter Blood Free Selective Agar Base and CCDA
supplement, one cultured with cefoperazone–amphotericin B–teicoplanin supplement and
one used a cefoperazone and amphotericin B supplement. All plates were incubated for
48 hours under microaerobic conditions. Isolates were identified to genus level by
morphology and Gram staining; the time taken for this is not recorded
Reported accuracy data:
Sensitivity 89.01 TP 413
Specificity 97.59 FP 79
PPV 83.94 FN 51
NPV 98.43 TN 3195
Agreement between  0.78
methods:
Additional statistical  McNemar’s test used to compare alternative detection methods. No statistical differences 
analysis: between PCR and culture in detection of C. jejuni–C. coli
Major confounders  Time between culture and receipt of faecal sample for DNA extraction was up to 10 days. 
or bias: Culture-positive only samples may have been PCR negative due to degradation of
Campylobacter cells in this period
Economic evaluation: None
What the authors  1. Key area of concern for authors in the under-reporting of some Campylobacter species 
conclude: due to culture methods designed to detect only C. jejuni or C. coli. In particular, PCR
detection of previously unreported C. upsaliensis is highlighted. 
2. There are more positive samples by PCR–ELISA than by culture alone
Assessment of  1. Focuses on epidemiological context, allowing full identification to a species level. 
authors’ conclusions: 2. PCR assays designed for groups of enteropathogenic species rather than individual
species-specific PCRs show advancement within the field and may lead to development of
full multiplex designAppendix 3
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Authors (year): Letertre et al. (2003)29
Journal: Molecular and Cellular Probes
Title: Detection and genotyping by real-time PCR of the staphylococcal enterotoxin genes sea to
sej
Notes:
Setting: Research laboratory, France Design:
Sample size: Collection of 100 isolations – 83 S. aureus and 17 other bacteria
Target organism: S. aureus sea to sej
Rapid test Methods
rtPCR In-house-designed rtPCR detecting sea to sej genes performed using SYBR Green in
LightCycler system
Reference test Methods Positive/negative  Blinding
controls
Conventional block cycler  PCR using Staur4 and Staur6 primers to target  All banked strains –  Unclear
PCR and RPLA test sequence of 23S rRNA.  RPLA test by Oxoid 17 non-S. aureus and 
83 known S. aureus
Reported accuracy data:
Sensitivity TP 57
Specificity FP 11
PPV FN 0
NPV TN 32
Sensitivity vs  Full correlation between conventional and rtPCR
reference method:
Turnaround time vs  Yields data within 1 hour versus 5 hours with conventional block cycler PCR and gel 
reference method electrophoresis
Economic evaluation: None given
What the authors  A very quick, reliable and specific alternative to conventional block cycler PCRs to identify 
conclude: the enterotoxin profile of toxigenic S. aureus
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Linton et al. (1997)15
Journal: Journal of Clinical Microbiology
Title: PCR detection, identification to species level, and fingerprinting of Campylobacter jejuni and
Campylobacter coli direct from diarrhoeic samples
Notes:
Setting: PHLS Laboratory, UK Design: Retrospective
Sample characteristics: DNA extracted from 18 culture-positive diarrhoeic stools, 5 culture-negative diarrhoeic
stools, 20 culture-negative healthy stools
Sample size: 43 faecal samples
Target organism: C. jejuni (16s rRNA, hip) and C. coli (16S rRNA, asp)
Rapid test Methods
PCR  16s rRNA PCR annealing temperature 58°C, generating an amplicon of 853 bp. HipO PCR
annealing temperature 66°C, generating an amplicon of 735 bp
Reference test Methods
Culture Culture on modified CCDA, incubated microaerobically at 37°C for 48 hours. Identified
biochemically by Gram stain, oxidase and catalase activities, hippurate hydrolysis, indoxyl
acetate hydrolysis, hydrogen sulfide production from triple sugar iron agar and susceptibility
to nalidixic acid and cephalothin
Reported accuracy: 16s rRNA gene Reported accuracy: hipO gene
Sensitivity 100.00 TP 18 Sensitivity 100.00 TP 18
Specificity 100.00 FP 0 Specificity 100.00 FP 0
PPV 100.00 FN 0 PPV 100.00 FN 0
NPV 100.00 TN 25 NPV 100.00 TN 25
Major confounders  Study not blinded as culture results already known
or bias:
Economic evaluation: None provided
What the authors  This study assessed the ability of PCR to detect Campylobacter in stools that were already 
conclude: culture positive. Coidentification of C. hypointestinalis in one C. jejuni sample where this was
missed by culture indicates PCR may be more sensitive for all Campylobacter strains
Assessment of  Small (n = 45) study. Focus of paper on epidemiological study of Campylobacter spp., 
authors’ conclusions: including differentiation of coli/jejuni/less common species
Authors (year): Luk et al. (1997)51
Journal: Journal of Clinical Microbiology
Title: An enzyme-linked immunosorbent assay to detect PCR products of the rfbS gene from
serogroup D Salmonellae: a rapid screening prototype
Notes:
Setting: Hospital laboratory, Sweden Design: Prospective
Sample size: 203 consecutive stool samples from patients with diarrhoea
Target organism: Salmonella serotype D
Rapid test Methods
DIG-ELISA following a PCR Samples inoculated into enrichment Rappaport broth overnight at 37°C. DNA extracted,
followed by PCR and DIG–ELISA
Reference test Methods
Salmonella culture Standard procedures as described by Murray et al.9
Reported accuracy data:
Sensitivity 56.55 TP 82
Specificity 100 FP 0
PPV 100 FN 63
NPV 52.07 TN 58
Time allocation: Assay takes approximately 6 hours (PCR 4 hours; ELISA 2 hours) along with brief enrichment
cultivation of the samples (from 4 to 16 hours)
Economic evaluation: None provided
What the authors  A fast, accurate, semiquantitative means of detecting infectious agents such as Salmonellae, 
conclude and future robotic automation is possible
Assessment of authors’  Appropriate conclusions. Assay only designed to detect serotype D so low sensitivity for 
conclusions: species overall. Diagnostic value limited to serotype D onlyAppendix 3
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Authors (year): Mackenzie et al. (1998)33
Journal: Journal of Clinical Microbiology
Title: Sensitivities and specificities of premier E. coli O157 and premier EHEC enzyme
immunoassays for diagnosis of infection with verotoxin (shiga-like toxin)-producing
Escherichia coli. The SYNSORB Pk Study investigators
Notes: 2 × 2 data derived from ‘field’ cases (i.e. non-resolved) only, to mirror diagnostic practice
Setting: Paediatric emergency setting, Canada
Design: Prospective evaluation
Sample characteristics: 876 children aged between 1 month and 8 years presenting with acute diarrhoea to
emergency centres in Canada between 1 June 1996 and 31 October 1996
Sample size: 877 samples
Target organism: E. coli O157 and all enterohaemorrhagic strains of E. coli
Rapid test Methods 
Premier E. coli O157 and  Premier E. coli O157 evaluated against SMAC culture.  Premier EHEC evaluated against 
Premier EHEC initial Premier E. coli O157 results to assess prevalence of non-O157 strains. Results read
using spectrophotometer at 0.3 U at 450 nm. Both assays performed according to
manufacturer’s instructions (Meridian Diagnostics)
Reference test Methods
SMAC culture Stools cultured for E.coli O157 and for other bacterial stool pathogens, each centre using its
own routine procedure. All sites used SMAC
Reported accuracy data: E. coli O157 Reported accuracy data: EHEC
Sensitivity 86.36 TP 57 Sensitivity 89 TP 50
Specificity 98.4 FP 13 Specificity 92.32 FP 63
PPV 81.43 FN 9 PPV 44.25 FN 6
NPV 98.88 TN 798 NPV 99.21 TN 757
Agreement between  Discordant results tested in independent laboratory using cytoxicity and non-O157 
methods: verotoxin-producing E. coli culture 
Economic evaluation: “At this time, rapid immunological tests are the most economical way” to address problem
that SMAC culture can only confidently identify O157:H7 strains.
What the authors  The availability of a simple test for the presence of verotoxin will determine the true 
conclude: prevalence of non-O157 VTEC and of toxin production by organisms other than E. coli
Assessment of authors’  Appropriate conclusions
conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Mackenzie et al. (2000)67
Journal: Journal of Clinical Microbiology
Title: Performance of the ImmunoCard STAT! E. coli O157:H7 test for detection of Escherichia coli
O157:H7 in stools
Notes: 2 × 2 data derived from prospective evaluation only, to mirror diagnostic practice
Setting: Multi-site evaluation, Canada
Design: Prospective and retrospective
Sample characteristics: 277 samples in prospective study; 522 stored stool specimens in retrospective study
Sample size: 277 samples prospective; 522 retrospective
Target organism: E. coli O157 strain only
Rapid test Methods
ImmunoCard STAT! EIA  ImmunoCard STAT! O157:H7 test evaluated against SMAC culture.  Assay performed
according to manufacturers’ instructions (ICS, Meridian Diagnostics)
Reference test Methods
SMAC culture Stools cultured for E.coli O157 on SMAC and sorbitol-negative colonies were identified as
O157 by latex agglutination
Reported accuracy data: Prospective Reported accuracy data: Retrospective
Sensitivity 92.86 TP 13 Sensitivity 81.29 TP 339
Specificity 100 FP 0 Specificity 95.15 FP 5
PPV 100 FN 1 PPV 98.55 FN 78
NPV 99.62 TN 263 NPV 55.68 TN 98
Economic evaluation: None provided
What the authors  The ImmunoCard STAT! O157:H7 test has a high sensitivity and specificity. It is simple to 
conclude: perform, the direct test gives a result within 10 minutes and the test will be of particular
value in areas where E. coli O157:H7 is the predominant VTEC serotype
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Maher et al. (2003)172
Journal: Journal of Medical Microbiology
Title: Evaluation of culture methods and a DNA probe-based PCR assay for detection of
Campylobacter species in clinical specimens of faeces
Notes:
Setting: Research laboratory, Ireland
Sample characteristics: Faecal samples submitted from hospital and community
Sample size: 320 stool samples
Target organism: Campylobacter species
Rapid test Methods
PCR/DNA probe  DNA extracted with QIAamp DNA stool Minikit
membrane-based 
colorimetric assay, using 
16S/23S DNA
Reference test Methods
Standard culture Direct inoculation of faeces on to modified CCDA, comprising of blood-free selective agar
with Campylobacter-selective supplement and Campylobacter growth supplement. Enrichment
in modified Preston broth for 48 hours at 37°C prior to plating
Reported accuracy data:
Sensitivity 94.44 TP 17
Specificity 59.41 FP 41
PPV 29.31 FN 1
NPV 98.36 TN 60
Additional statistical  This study also provided comparison of direct CCDA culture and culture with 
analysis: pre-enrichment, using a sample of 320 faecal specimens
Major confounders  From the subset of 127 samples used to evaluate PCR methods against culture, it was not
or bias: possible to extract DNA from eight samples, one of which was culture positive
Economic evaluation: None provided
What the authors  Molecular diagnosis useful for more obscure Campylobacter species
conclude:
Assessment of  This assay detects Campylobacter species in 41 (38%) of culture-negative specimens. 
authors’ conclusions: A second 16s PCR/DNA probe assay confirmed that 35 of these were true positives. This
proves that 35 out of the total 320 (11%), of samples would remain undiagnosed using
conventional culture methodsHealth Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Malorny et al. (2003)173
Journal: Applied and Environmental Microbiology
Title: Multicenter validation of the analytical accuracy of Salmonella PCR: towards an international
standard
Notes:
Setting: International collaborative study Design: Validation study
Sample size: 12 Salmonella and 16 non-Salmonella coded (blind) DNA samples sent to 16 international
laboratories
Target organism: Salmonella species
Rapid test Methods
PCR targeting invA gene Validation study based on PCR assay with primer set 139–141, designed by Rahn et al.247
Reference test Methods
DNA from known strains Strains grown aerobically without shaking at 37°C for 16 hours in Luria–Bertani medium.
DNA extraction by conventional methods
Reported accuracy data:
Sensitivity 95.93 TP 495
Specificity 98.98 FP 7
PPV 98.61 FN 21
NPV 97.01 TN 681
Economic evaluation: None provided
What the authors  The collaborative study showed a high sensitivity and reproducibility of the PCR assay 
conclude: among the 16 international laboratories when identical batches of reagents were used
Assessment of  Appropriate conclusions; however, validation with fresh clinical samples is advised
authors’ conclusions:
Authors (year): Mpamugo et al. (1995)81
Journal: Journal of Medical Microbiology
Title: Enterotoxigenic Clostridium perfringens as a cause of sporadic cases of diarrhoea
Notes:
Setting: Reference laboratory, UK Design: Prospective
Sample characteristics: Consecutive stool samples collected in 2-month period
Sample size: 370 specimens
Target organism: C. perfringens
Rapid test Methods
Oxoid RPLA performed according to manufacturer’s instructions
Reference test Methods
Confirmation of positive cases with ELISA
Reported accuracy data:
Sensitivity Unclear TP 65 positive cases
Specificity Unclear FP Unclear
PPV Unclear FN Unclear
NPV Unclear TN 305 negative cases
Economic evaluation: None provided
What the authors  Diagnosis should be confirmed by the detection of enterotoxin, but further work is still 
conclude: required to assess whether an acceptable accuracy is obtained with RPLA kit or whether
ELISA is needed in all cases
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): McGowan and Rubenstein (1989)142
Journal: American Journal of Clinical Pathology
Title: Use of a rapid latex agglutination test to detect Salmonella and Shigella antigens from Gram-
negative enrichment
Notes:
Setting: Children’s hospital, USA Design: Consecutive, prospective
Sample characteristics: Children recruited from December to June 1988
Sample size: 2481 rectal or faecal swabs
Target organism: Salmonella and Shigella
Rapid test Methods
Wampole Bactigen After primary culture and incubation (max. 18 hours) in Gram-negative broth, Wampole
Bactigen Salmonella–Shigella latex agglutination test used. Three reagents used: (1) coated
with goat antibodies to more than 80 common Salmonella serogroups; (2) layered with rabbit
antibodies to Shigella group B and D; (3) bears rabbit antibodies to Shigella groups A and C
Reference test Methods
Standard culture Samples inoculated on a primary media culture and then placed in a Gram-negative broth.
After incubation, sample subcultured to XLD and MacConkey agars, which were aerobically
incubated at 35°C and examined every 24 hours for a total of 48 hours
Reported accuracy data:
Sensitivity 85.86 TP 85
Specificity 97.27 FP 65
PPV 56.67 FN 14
NPV 99.39 TN 2317
Economic evaluation: “In our institution, eliminating the workup of colonies from GNB subculture plates would
result in a media saving of $124 per 100 stool specimens cultured and a time saving of
approximately 20 hours per 100 stool specimens cultured” (US$ 1998)
What the authors  Tests such as the Bactigen latex test can decrease the overall turnaround time for a 
conclude: specimen, particularly those with negative results
Assessment of  Appropriate conclusions
authors’ conclusions:
Authors (year): Metzler and Nachamkin (1988)175
Journal: Journal of Clinical Microbiology
Title: Evaluation of a latex agglutination test for the detection of Salmonella and Shigella spp. by
using broth enrichment
Notes:
Setting: University laboratory, USA Design: Consecutive, prospective
Sample size: 1128 stool samples
Target organism: Salmonella and Shigella
Rapid test Methods
Bactigen Salmonella–Shigella Three reagents used: (1) coated with goat antibodies to more than 80 common Salmonella
latex agglutination serogroups; (2) layered with rabbit antibodies to Shigella group B and D; (3) bears rabbit
antibodies to Shigella groups A and C.
Reference test Methods
Standard culture Samples inoculated on a primary media culture and then placed in a Gram-negative broth
Reported accuracy data:
Sensitivity 86.21 TP 25
Specificity 96.54 FP 38
PPV 39.68 FN 4
NPV 99.62 TN 1061
Economic evaluation: None provided
What the authors  Salmonella test may be useful as an enrichment broth screening test
conclude:
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Munoz (1993)174
Journal: Clinical Microbiology and Infectious Diseases
Title: Rapid screening of Salmonella species from stool cultures
Notes: Results obtained on different selective media pooled for meta-analysis
Setting: Hospital laboratory, Spain Design: Prospective, consecutive
Sample characteristics: All clinical stool specimens received into laboratory in 3-month period
Sample size: 976 suspected colonies from 555 clinical samples and 480 patients
Target organism: Salmonella spp.
Rapid test Methods
MUCAP (Biolife, Italy) Based on a rapid detection of C8 esterase enzyme by using a fluorogenic 4-
methylumbelliferone-conjugated substrate
Reference test Methods
Standard culture MacConkey Agar, Salmonella–Shigella agar, and Brilliant Green agar, inoculated overnight. All
suspect colonies overwent Triple Sugar Iron agar test and subculture
Reported accuracy data:
Sensitivity 100 TP 176
Specificity 91.87 FP 65
PPV 73.03 FN 0
NPV 100 TN 735
Economic evaluation: “In Spain, the estimated cost is $1.00 per day (US$ 1993). Laboratories with a lower
incidence of Salmonella should determine whether it is worthwhile to incorporate the test in
routine procedures or reserve it for special circumstances”
What the authors  MUCAP can enhance the rate of recognition of Salmonella colonies in the presence of 
conclude: mixed-lactose-fermenting bacteria on the agar surface. It also facilitates the detection of rare
colonies with uncommon biochemical characteristics
Assessment of  Appropriate conclusions
authors’ conclusions:
Authors (year): Novicki et al. (2000)60
Journal: Journal of Clinical Microbiology
Title: Comparison of sorbitol MacConkey agar and a two-step method which utilises enzyme-
linked immunosorbent assay toxin testing and a chromogenic agar to detect and isolate
enterohemorrhagic Escherichia coli
Notes: Shares authorship with Carroll58
Setting: University research laboratory Design: Prospective evaluation
Sample size: 488 stool samples from adults and children
Target organism: EHEC
Rapid test Methods
Premier EHEC ELISA  Two-step method utilising chromogenic selective-differential medium (Rainbow Agar O157)
for the isolation of E. coli together with Premier EHEC ELISA to detect stx1 and stx2.
Reference test Methods
SMAC culture Using accepted biochemical and phenotypic tests. Discrepancy resolution by PCR method in
independent laboratory
Reported accuracy data:
Sensitivity 82.4 TP 14
Specificity 100 FP 0
PPV 100 FN 3
NPV 99.37 TN 471
Sensitivity vs  Compared with a Vero cell assay, SMAC had sensitivities of 23.5% for the identification of 
reference method: EHEC serotypes and 50.0% for the identification of O157:H7 alone. The two-step method
had sensitivities of 76.5% and 100%, respectively. The Premier EHEC alone had a 
sensitivity of 82.4% in the detection of stx1 and stx2. 
Economic evaluation: Comparative costs of materials provided
What the authors  ELISA–Rainbow Agar method proved superior to SMAC in isolating both O157:H7 and other 
conclude: EHEC serotypes
Assessment of  Well-structured paper
authors’ conclusions:Appendix 3
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Authors (year): Park et al. (1996)176
Journal: Journal of Clinical Microbiology
Title: Rapid immunoassay for detection of Escherichia coli O157 directly from stool specimens
Notes:
Setting: Hospital laboratory, USA Design: Prospective comparison 
Sample characteristics: 601 stool samples collected over 4-year period in hospital laboratory, plus four known
positive specimens
Sample size: 605
Target organism: E. coli O157
Rapid test Methods
E. coli O157 antigen  Kit developed by LMD Laboratories (NB no longer commercially available)
detection test
Reference test Methods
SMAC culture Standard SMAC plate – if organism not recovered in primary culture SMAC plate swept tube
of MacConkey broth used. Incubated at 35°C for 18–24 hours
Reported accuracy data:
Sensitivity 91.1765 TP 31
Specificity 99.4746 FP 3
PPV 91.1765 FN 3
NPV 99.4746 TN 568
Agreement between  Immunofluorescence stain used to arbitrate differences between SMAC culture and 
methods: ELISA results
Economic evaluation: “The cost of materials is higher for screening stool samples by ELISA than it is when
conventional culture methods are used. The average cost per ELISA is approximately $2 to
$3; however, its use saves the additional costs of technologist time associated with follow-up
testing of sorbitol-negative non-E. coli colonies from SMAC. The cost benefit in using ELISA
comes from the rapid turnaround time it provides”
What the authors  The assay is accurate and rapid (<1 hour) for the detection of serotype O157 only
conclude:
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Park et al. (2003)70
Journal: Journal of Clinical Microbiology
Title: Evaluation of the Duopath Verotoxin test for detection of shiga toxins in cultures of human
stools
Notes:
Setting: Hospital laboratory, USA Design: Retrospective and prospective evaluation
Sample characteristics: 41 frozen stool samples known to contain STEC isolates (O157:H7 and non-O157:H7
Target organism: Shiga toxin-producing E. coli
Rapid test Methods
Duopath Verotoxin (Merck) Immunochromogenic test designed to detect stx in food samples – applied to clinical
specimens for the first time. Samples previously isolated using SMAC (18–24 hours)
Reference test Methods Positive/negative Blinding
controls
Premier EHEC assay  Suspended in MacConkey broth and incubated for  41 known positive  Yes
(Meridian Bioscience) 18–24 hours. Procedure then performed according  samples included
to instructions of manufacturer
Reported accuracy data:
Sensitivity 100 TP 43
Specificity 100 FP 0
PPV 100 FN 0
NPV 100 TN 248
Sensitivity vs reference  Equivalence
method:
Turnaround time vs  Provides a turnaround time of 24 hours
reference method
Economic evaluation: None provided 
What the authors  Simple to perform and easy to interpret. Potential for clinical application
conclude:
Assessment of authors’  Suitable conclusions 
conclusions:
Authors (year): Paton and Paton (1998)177
Journal: Journal of Clinical Microbiology
Title: Detection and characterisation of shiga toxigenic Escherichia coli using multiplex PCR assays
for stx1, stx2, eaeA, enterohemorrhagic E. coli hlyA, rfbO111, and rfb157
Setting: Hospital laboratory Design: Diagnostic comparison
Sample characteristics: Banked isolates from 28 human, 7 animal and 17 food sources; 8 culture-positive clinical
STEC cases and 32 STEC culture-negative clinical samples
Sample size: 92 (52 strains and 40 fresh samples)
Target organism: EHEC
Rapid test Methods
Multiplex PCR  Detects stx1, stx2, eaeA and hlyA genes. Results read with electrophoresis
Reference test Methods
Traditional culture
Reported accuracy data:
Sensitivity 100 TP 60
Specificity 100 FP 0
PPV 100 FN 32
NPV 100 TN 0
Major confounders or bias: Use of banked reference strains may not demonstrate real-life diagnostic utility of this assay
Economic evaluation: Not carried out
What the authors  The assay can be used for determining the toxin genotype of STEC isolates, and also for 
conclude: direct detection of toxin genes in primary faecal culture extracts
Assessment of  Appropriate conclusion. Further prospective evaluation required
authors’ conclusions:Appendix 3
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Authors (year): Paton and Paton (2005)56
Journal: Journal of Clinical Microbiology
Title: Multiplex PCR for direct detection of shiga toxigenic Escherichia coli strains producing the
novel subtilase cytotoxin
Notes:
Setting: University laboratory, Australia Design:
Sample characteristics: 171 primary faecal cultures from patients with diarrhoea, plus 12 healthy controls
Sample size: 183 samples
Target organism: STEC 
Rapid test Methods
PCR Detection of toxin A subunit gene subA, stx1 and stx2, with amplification products of 556,
180, and 255 bp, respectively. Assay first used with 44 STEC strains to test efficacy, followed
by analysis of primary faecal culture extracts
Reference test Methods
Standard culture Methods not provided
Reported accuracy data:
Sensitivity 100.00 TP 171
Specificity 100.00 FP 0
PPV 100.00 FN 0
NPV 100.00 TN 83
Major confounders or bias: Time delay of up to 4 years between primary culture and PCR detection. Samples stored at
–15°C, but unclear how this affects pathogenicity
Economic evaluation: None provided
What the authors  Main focus of paper examines the prevalence of potent AB5 cytotoxin (SubAB) in STEC 
conclude: strains. The combination of stx1, stx2 and subAB target primers in this assay can successfully
identify shiga toxins in all 171 faecal cultures, and does not produce any false positives among
12 negative controls
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Pulz et al. (2003)22
Journal: Journal of Clinical Microbiology
Title: Comparison of a shiga toxin enzyme-linked immunosorbent assay and two types of PCR for
detection of shiga toxin-producing Escherichia coli in human stool specimens
Sample size: 295 stool specimens
Target organism: Shiga toxin-producing E. coli
Rapid test 1 Methods
rtPCR Detection of stx genes with LightCycler instrument performed with a single capillary tube
using melting point analysis
Rapid test 2 Methods
RIDASCREEN Verotoxin  Detects presence of stx1 and stx2. Absorbances measured at 450 nm using a 
ELISA (BioPharm) spectrophotometer. Positive and negative controls run with each test
Reference test Methods Positive/negative Blinding
controls
Conventional PCR Block cycler PCR followed by gel electrophoresis STEC strain EDL933 
used as positive control
Reported accuracy data: ELISA vs Conventional PCR Reported accuracy data: rtPCR vs Conventional PCR
Sensitivity 67.40 TP 31 Sensitivity 100.00 TP 46
Specificity 96.80 FP 8 Specificity 80.00 FP 5
PPV 79.50 FN 15 PPV 90.10 FN 0
NPV 94.10 TN 241 NPV 100.00 TN 244
Sensitivity vs reference  rtPCR better, immunoassay worse
method:
Turnaround time vs  Faster
reference method
Economic evaluation: None provided
What the authors  The detection of STEC by molecular methods is significantly more effective than detection 
conclude: by a licensed commercially available immunoassay
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Ramotar et al. (1995)178
Journal: Journal of Clinical Microbiology
Title: Direct detection of verotoxin-producing Escherichia coli in stool samples by PCR
Notes:
Setting: Hospital laboratory, Canada Design: Diagnostic comparison
Sample characteristics: Patients presenting at the outpatient clinics of the Calgary General Hospital (July to
September 1990, April to September 1993), the Alberta Children’s Hospital (May to August
1992), and the Calgary Medical Laboratories
Sample size: 121 faecal samples
Target organism: EHEC
Rapid test Methods
PCR for stx1 and stx2 genes Processed in Perkin-Elmer Cetus thermal cycler. Positive and negative controls provided.
Stool samples showing positive results by PCR were retested on two further occasions
several days and 4–8 weeks later to examine the reproducibility of PCR testing
Reference test Methods
SMAC culture Culture on STAC or by colony blots with gene probes. 2 × 2 data below correspond to
evaluation against SMAC culture only
Reported accuracy data:
Sensitivity 95.00 TP 19
Specificity 97.03 FP 3
PPV 86.36 FN 1
NPV 98.99 TN 98
Economic evaluation: Not carried out
What the authors  PCR of DNA extracted directly from stool samples provides a rapid method for the 
conclude: detection of stool samples containing verotoxin-producing E. coli compared with colony blot
testing
Assessment of  Appropriate conclusions. Well-designed study
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Reischl et al. (2002)71
Journal: Journal of Clinical Microbiology
Title: Real-time fluorescence PCR assays for detection and characterisation of shiga toxin, intimin,
and enterohemolysin genes from shiga toxin-producing Escherichia coli
Notes:
Setting: Research laboratory, Germany Design:
Sample characteristics: Banked reference strains
Sample size: 504
Target organism: Shiga toxin-producing E. coli
Rapid test Methods
rtPCR Duplex real-time fluorescence PCR Assay detecting stx1 and stx2 and intimin (eae) and
enterohemolysin (E-hly) genes. rtPCR performed on LightCycler machine
Reference test Methods Posistive/negative Blinding
controls
Conventional PCR Both Unclear
Reported accuracy data:
Sensitivity 100 TP 272
Specificity 100 FP 100
PPV 100 FN 100
NPV 100 TN 350
Sensitivity vs  Equivalent
reference method:
Turnaround time vs  Faster
reference method:
Economic evaluation: None performed
What the authors  Although they are currently more expensive to perform than block cycler PCR assays, the 
conclude: speed, greater information and reliability of the results make the LC-PCR assays attractive
alternatives to conventional block cycler PCR assays for the detection and characterisation 
of STEC
Assessment of  Useful study to show equivalence of conventional and quantitative PCR techniques
authors’ conclusions:
Authors (year): Rohner et al. (1992)179
Journal: Journal of Clinical Microbiology
Title: Evaluation of the Wellcolex Colour Salmonella test for detection of Salmonella spp. in
enrichment broths
Notes:
Setting: Hospital laboratory, Belgium Design: Diagnostic comparison
Sample size: 1010 routine stool samples from patients with diarrhoeal illness.
Target organism: Salmonella species
Rapid test Methods
Wellcolex Colour Salmonella Latex agglutination method with Selenite F Broth. 18–24 hours incubation necessary. Test
performed as recommended by manufacturer. Two latex reagents and three positive controls
included in kit.
Reference test Methods
Standard culture Stool samples inoculated on to MacConkey agar, Hektoen enteric agar and 10 ml of 
Gram-negative broth. Incubated for 18–24 hours at 35°C
Reported accuracy data:
Sensitivity 87.18 TP 34
Specificity 99.79 FP 2
PPV 94.44 FN 5
NPV 99.49 TN 969
Economic evaluation: None provided
What the authors  Simple to use, and positive results are easily interpretable. Allows the early diagnosis of 
conclude: salmonellosis
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Schraft and Griffiths (1995)180
Journal: Applied and Environmental Microbiology
Title: Specific oligonucleotide primers for detection of lecithinase-positive Bacillus spp. by PCR
Notes:
Setting: University laboratory Design: Evaluation of a new assay
Sample characteristics: B. cereus strains obtained from various laboratories
Sample size: 56 B. cereus strains, of which 35 were food poisoning outbreak isolates
Target organism: B. cereus 
Rapid test Methods
PCR assay and PCR–hybridisation assay. Requires isolation followed by 24 hours
Reference test Methods
Comparison with previous isolation
Reported accuracy data: Not given
Economic evaluation: No economic data presented
What the authors  The assay has high specificity based on three oligonucleotides for isolates of the B. cereus 
conclude: group. The detection limit for B. cereus in artificially contaminated milk was 1 cfu ml–1 of milk
using a combined PCR–hybridisation assay
Assessment of  Test requires evaluation of diagnostic accuracy
authors’ conclusions:
Authors (year): Sharma et al. (2000)107
Journal: Applied and Environmental Microbiology
Title: Development of a single-reaction multiplex PCR toxin typing assay for Staphylococcus aureus
strains
Notes:
Setting: University research laboratory, UK
Design: Diagnostic accuracy comparison
Sample size: 257 reference strains of S. aureus from various environmental sources, including 39 human
strains
Target organism: S. aureus strains
Rapid test Methods
Multiplex PCR Multiplex PCR for staphylococcal enterotoxins A to E. Results within 3–4 hours
Reference test Methods
SET-RPLA (Oxoid) Used according to manufacturer’s instructions
Reported accuracy data:
Sensitivity 100 TP 155
Specificity 98.73 FP 2
PPV 100 FN 0
NPV 100 TN 0
Economic evaluation: None provided
What the authors  Recommend use as a screening test for presence of enterotoxin genes
conclude:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Tan et al. (1997)96
Journal: Journal of Applied Microbiology
Title: The use of Bacillus diarrhoeal enterotoxin detection using an ELISA technique in the
confirmation of the aetiology of Bacillus mediated diarrhoea
Notes:
Setting: Public Health Laboratories Design: Evaluation of a commercial assay
Sample characteristics: Reference B. cereus strains obtained from various laboratories
Sample size: 28 faecal samples, 34 food samples and 41 isolates
Target organism: B. cereus diarrhoeal strain
Rapid test Methods
Tecra Bacillus Diarrhoea Enterotoxin Visual Immunoassay ELISA kit
Reference test Methods
Comparison with isolation of B. cereus for food samples and with food poisoning history for
faecal samples
Reported accuracy data:
Faecal Food
Sensitivity (10/15) (7/9) TP
Specificity (1/13) (0/8) FP
PPV FN
NPV TN
Economic evaluation: No economic data presented
What the authors  The study shows the usefulness of the Tecra Bacillus ELISA test for the diagnosis of 
conclude: diarrhoeal B. cereus food poisoning
Assessment of  This study demonstrates the usefulness of ELISA as an added test for supporting the 
authors’ conclusions: diagnosis of B. cereus food poisoning
Authors (year): Tansuphasiri et al. (2002)91
Journal: Journal of the Medical Association of Thailand
Title: PCR detection and prevalence of enterotoxin (cpe) gene in Clostridium perfringens isolated
from diarrhoea patients
Notes:
Setting: Reference laboratory, Thailand Design: Assay development
Sample characteristics: Consecutive 477 faecal colonies from 233 patients
Target organism: C. perfringens
Rapid test Methods
PCR  Duplex PCR using two sets of primers which amplify in the same reaction two different gene
fragments: the phospholipase C (plc, alpha-toxin) and the enterotoxin (cpe) genes in
C. perfringens
Reference test Methods
Culture Primary cultures of TSC–egg yolk agar and additional testing with Oxoid RPLA kit
Reported accuracy data: Not provided
Economic evaluation: “PCR assay is faster, less expensive and more suitable for large-scale use in epidemiological
studies than conventional procedures”
What the authors  Recommend this assay to screen for enterotoxigenic C. perfringens isolates from primary 
conclude: faecal spore isolation cultures, particularly in elderly patients with food-borne diarrhoea and
non-food related diarrhoea
Assessment of  Appropriate conclusions
authors’ conclusions:Appendix 3
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Authors (year): Tolcin et al. (2000)181
Journal: Journal of Clinical Microbiology
Title: Evaluation of the Alexon-Trend ProSpecT Campylobacter microplate assay
Notes:
Setting: Hospital laboratory with samples from three institutions
Design: Diagnostic comparison
Sample characteristics: Clinical stool samples 
Sample size: 164 stool samples from 164 individuals
Target organism: Campylobacter
Rapid test Methods
ProSpecT Microplate assay Commercial enzyme immunoassay (Alexon-Trend, USA), performed according to
instructions of the manufacturer. Reactions read visually and spectrophotometrically in a
single-wavelength spectrophotometer at 450 nm
Reference test Methods
Culture Not reported (referenced Manual of Clinical Microbiology, 7th ed.)
Reported accuracy data:
Sensitivity 96.00 TP 48
Specificity 99.12 FP 1
PPV 97.96 FN 2
NPV 98.26 TN 113
Additional statistical  “Excellent” interobserver agreement in both the visual and spectrophotometric test 
analysis: interpretations
Major confounders or bias: Blinding not possible as culture results known previously
Economic evaluation: Not carried out
What the authors  The assay demonstrated 96% sensitivity and 99% specificity and is an acceptable alternative 
conclude: method of Campylobacter detection
Assessment of  Appropriate conclusions
authors’ conclusions:
Authors (year): Villasante et al. (1987)54
Journal: Journal of Clinical Microbiology
Title: Rapid automated method for screening of enteric pathogens from stool specimens
Notes:
Setting: Hospital laboratory, Spain Design: Diagnostic comparison
Sample size: 800 colonies on stool differential agar media with characteristic biochemical activity of
Salmonella, Shigella or Yersinia
Target organism: Salmonella, Shigella or Yersinia
Rapid test Methods
AutoMicroBic EPS Entero Pathogen Screen cards of the AutoMicrobic system (Vitek Systems)
Reference test Methods
Biochemical test media Triple sugar iron agar, urea agar, and phenylalanine agar
Reported accuracy data:
Sensitivity 98.93 TP 185
Specificity 95.76 FP 26
PPV 87.68 FN 2
NPV 99.66 TN 587
Economic evaluation: None provided
What the authors  A fast, easy and sensitive method for screening for Salmonella, Shigella or Yersinia species
conclude:
Assessment of  Appropriate conclusions
authors’ conclusions:Health Technology Assessment 2007; Vol. 11: No. 36
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Authors (year): Welinder-Olsson et al. (2004)21
Journal: Epidemiology and Infection
Title: EHEC outbreak among staff at a children’s hospital – use of PCR for verocytotoxin detection
and PFGE for epidemiological investigation
Notes:
Setting: Community Design: Case report
Sample characteristics: Nursing staff at a children’s hospital with approximately 1600 employees
Sample size: 58
Target organism: E. coli
Rapid test Methods
PCR
Reference test Methods
SMAC agar for culture
Reported accuracy data:
Sensitivity 100 TP 9
Specificity 96 FP 2
PPV 81.81 FN 0
NPV 100 TN 48
Economic evaluation: Not carried out
What the authors  Propose routinely performed screening for EHEC using PCR for patients suffering from 
conclude: diarrhoea
Assessment of  Well executed evaluation of EHEC outbreak. Appropriate conclusions
authors’ conclusions:
Authors (year): Welinder-Olsson et al. (2000)57
Journal: European Journal of Clinical Microbiology and Infectious Diseases
Title: Improved microbiological techniques using the polymerase chain reaction and pulse-field gel
electrophoresis for diagnosis and follow-up of enterohaemorrhagic Escherichia coli Infection
Notes:
Setting: Hospital laboratory, Sweden Design: Large-scale prospective
Sample characteristics: Samples collected during 1997–8. All samples from under 15-year-olds with diarrhoea and
older patients with a reported diagnosis of bloody diarrhoea were sent to university hospital
for PCR detection
Sample size: 3948 fresh clinical samples
Target organism: EHEC
Rapid test Methods
PCR detection of EHEC  Suitable reference strains used for positive and negative controls. Gel electrophoresis run 
using primers for stx1,  time of 22 hours. Amplified in Perkin-Elmer DNA thermal cycler 9600, showing the 
stx2 and eae genes expected fragments of 130, 298, and 376 bp
Reference test Methods
Culture, toxin test,  All samples cultured on SMAC using standard methods. Partial verification also carried out on 
verocytotoxin test, exposure  PCR-positive culture-negative samples, namely 15 samples undergo additional verocytotoxin
or clinical symptoms test and four undergo additional direct toxin test
Reported accuracy data:  All patients EHEC-positive patients
Sensitivity 100 TP 55 Sensitivity 70 TP 55
Specificity 99.97 FP 1 Specificity 100 FP 24
PPV 98 FN 0 PPV 100 FN 0
NPV 100 TN 3893 NPV 61 TN 37
Economic evaluation: None provided
What the authors  PCR is more sensitive than culture for detecting EHEC in the gut
conclude:
Assessment of authors’  1. This study highlights attempts to use ‘true’ gold standard – by including toxin and 
conclusions: verocytotoxin tests to reference standard, a more accurate view of disease status is
recorded. 
2. Well-executed study, including full patient characteristics and clear outline of methods usedHealth Technology Assessment 2007; Vol. 11: No. 36
169
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Study characteristics for food studiesAppendix 4
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c
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c
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c
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p
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r
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f
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p
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i
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p
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p
r
o
p
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i
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c
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p
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p
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i
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p
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i
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c
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p
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c
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c
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p
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p
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i
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Appendix 5
Excluded studies
Organism Test Study
E. coli Multi-PCR Pan, 2002 – – + + + + – –
E. coli MLVA Noller, 2003 – – + – – + + –
E. coli Multi–PCR Gannon, 1997 – + – + + + – –
E. coli Multi–PCR Fratmanico, 1995 – – + + + + – –
E. coli Multi–PCR Cebula, 1995 – – + – + – – –
E. coli PCR Abdulmawjood,  2003 – + + + + + – –
E. coli Complex typing Milch, 1997 – + + + + + + – –
E. coli Unclear Gunzberg, 1993 – – + ? + + + + –
E. coli CoA Ram, 1995 – – ? – + + + – –
E. coli CoA Ram, 1993 – – – – + – – – –
E. coli PCR Okamoto,  1999 ? – – – ? – + + –
E. coli PCR Li,  2004 – + – – + + + + –
E. coli PCR Dutta,  2001 – – – – – – – + –
E. coli PCR Thomas,  1994 – – – – – + + – –
E. coli and Salmonella PCR Naravaneni,  2005 – + + + + + + – –
S. aureus Chrom Carricajo, 2001 + + – – – – – –
S. aureus PCR-RFLP Marcos, 1999 – + + + + + – –
S. aureus PCR Stuhlmeier,  2003 + + + + + + – –
S. aureus Chrom Samra, 2004 + + – – + + – –
S. aureus Chrom Gaillot, 2000 – – + + + + + – –
Salmonella Plating media Ruiz, 1996 – – – – – – + –
Salmonella Stool-processing Kongmuang,  1994 – – – – – + + -
methods
Salmonella Media plating Dusch, 1993 – – – – – – + –
Salmonella Biochemical Ryck, 1994 – + + + + + – –
Salmonella CoA Sanborn, 1980 – – – – – – – –
Salmonella Media plating Manafi, 1994 – – + – – – ? –
Salmonella LAT Benge, 1989 – – – – – – ? –
Salmonella ELISA, CoA, and  Rahman, 1991 – – + + – + + ? –
more
Salmonella PCR Widjojoatmodjo,  1992 – – – + + + + – –
Salmonella EIA Luk, 1991 – + – + + + + – –
Salmonella PCR Pathmanathan,  2003 – ? + + + + + – –
Salmonella ELISA Pelton,  1994 + + – – – – – – –
Salmonella ELISA Quang, 1997 + + – – – – – – –
Salmonella, E. coli,  Dot immunogold Dykman, 2000 – – – – ? – ? – –
S. aureus and others
Salmonella Selective Spanova,  2001 – + – – – – + – –
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Organism Test Study
Salmonella/typhoid Serodiagnosis Olsen, 2004 + + – – – – – – –
Campylobacter PCR–ELISA Metherell, 1999 – – – + – + + – –
Campylobacter PCR–ELISA Sails, 2001 – – + + + + + – –
Campylobacter Duplex PCR Misawa, 2002 – – – + + + + – –
Campylobacter DIG-ELISA Gunnarsson, 1998 – – – – + + + – –
Campylobacter PCR Stonnet,  1995 – – – – – – + – –
Campylobacter Chrom Bar, 1987 – – + + + – + + –
Campylobacter CoA Chattopadhyay, 2002 + – – – – – – – –
Campylobacter PCR Mahendru,  1997 – – – – + + + + –
Campylobacter PCR Englen,  2003 – – – – + + + – –
Campylobacter PCR Persson,  2005 – – + + + + + – –
Campylobacter ELISA Strid, 2001 – – – – + + + – –
Campylobacter PCR Best,  2003 – – + + – – + – –
C. perfringens Culture/DIG Giugliano, 1983 – + + + – – + + –
C. perfringens DNA probe Vela, 1999 – – – – + + + – –
C. perfringens PCR Yoo,  1997 + + – – + + + – –
C. perfringens PCR Saito,  1992 – – – – – – – – +
N
o
n
-
r
a
p
i
d
D
i
d
 
n
o
t
 
u
s
e
 
t
e
s
t
s
 
o
f
 
i
n
t
e
r
e
s
t
I
n
a
d
e
q
u
a
t
e
 
d
a
t
a
 
f
o
r
 
2
 
×
×
2
 
t
a
b
l
e
s
N
o
 
c
o
m
p
a
r
a
t
o
r
/
r
e
f
 
s
t
a
n
d
a
r
d
T
e
c
h
n
i
c
a
l
 
–
 
n
o
 
c
l
i
n
i
c
a
l
 
i
n
f
o
r
m
a
t
i
o
n
B
a
n
k
e
d
/
s
p
i
k
e
d
 
s
a
m
p
l
e
s
 
o
n
l
y
S
t
r
a
i
n
s
 
o
n
l
y
M
i
x
t
u
r
e
 
f
a
e
c
a
l
/
f
o
o
d
/
e
n
v
 
s
a
m
p
l
e
s
N
o
t
 
f
o
o
d
 
p
o
i
s
o
n
i
n
gHealth Technology Assessment 2007; Vol. 11: No. 36
181
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Appendix 6
Costing data
Summary of testing strategies
TABLE 47 Testing strategies for a moderately sized (10,000 tests/year) NHS laboratory
Strategy Test Organisms Patient group Total samples Total tests Description
PCR 1 rtPCR All All 10,000 30,000 rtPCR test all samples for all three
organisms
PCR 2 rtPCR All High-risk 2,500 7,500 Test high-risk samples for all three
organisms
PCR 3 rtPCR E. coli All 10,000 10,000 Test all samples for E. coli only 
ELISA 1 ELISA All All 10,000 30,000 ELISA test all samples for all three
organisms
ELISA 2 ELISA Local High-risk 2,500 7,500 ELISA test all samples for E. coli
only
Culture Culture Local All 10,000 30,000 Standard culture
TABLE 48 Detailed breakdown of staff costs
Medical laboratory 
assistant (MLA) (£)a
Staff costs plus  Min. Max. Biomedical  Hands-on  Isolation  Total staff  Average staff 
on-costs 17% scientist (£)b time taken  ratesc cost, 10,000  costs per 
(minutes) tests (£)d test (£)e
Salary (including 17%  13,898.43 17,244.63 26,123.76
indirect/on-costs)
Hourly rate 7.13 8.84 13.40
Per minute 0.12 0.15 0.22 (Hourly rate/60)
Campylobacter
Sample preparation  0.59 0.74 5 7,369.50
culture (all)
Campylobacter test culture 0.36 0.44 3 4,421.70
Campylobacter workup 2.23 10 5.04892132 1,127.32
positives Per positive sample
Reporting 0.11 0.5 1,116.40
14,034.92 1.40
Salmonella
Sample preparation  0.59 0.74 5 7,369.50
culture (all)
Salmonella test culture 0.36 0.44 3 4,421.70
Salmonella workup 2.23 10 0.75593768 168.79
positives
Reporting Per positive sample
0.11 0.5 1,116.40
13,076.39 1.31
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TABLE 48 Detailed breakdown of staff costs
Medical laboratory 
assistant (MLA) (£)a
Staff costs plus  Min. Max. Biomedical  Hands-on  Isolation  Total staff  Average staff 
on-costs 17% scientist (£)b time taken  ratesc cost, 10,000  costs per 
(minutes) tests (£)d test (£)e
E. coli O157
Sample preparation  0.59 0.74 5 7,369.50
culture (all)
E. coli O157 test culture 0.59 0.74 5 7,369.50
E. coli O157 workup 0.12 0.15 2.23 1 + 10  0.10771457 25.64
positives Per positive sample
Reporting 0.11 0.5 1,116.40
15,881.04 1.59
PCR test
Sample pre-enrichment 0.59 0.74 5 7,369.50
Sample loading PCR  0.08 0.10 0.65f 961.24
(60 minutes for 
92 samples)
Reading and reporting 0.11 0.5 1,116.40
9,447.14 0.94
ELISA test
Sample pre-enrichment 0.59 0.74 5 7,369.50
ELISA (load, wash, add  13.40 60
antibody, wash, add 
reagent, wash, read) 
per run
ELISA per sample 0.5 0.67 6,666.67
14,036.17 1.40
a Basic salary MLA grade, NHS Careers accessed November 2005.
b Basic salary Biomedical Scientist grade, NHS Careers accessed November 2005.
c Based on HPA data for 2005 isolation rates.
d Based on hypothetical, moderately sized laboratory testing 10,000 samples per year.
e Average staff costs per test = [MLA cost per minute  (time taken to prepare sample + time taken to plate on culture
dish] + [BioMedical Scientist cost per minute  (Time taken to work-up positives/isolation rate/100)].
f 60 minutes/92 samples = 0.65 minutes per sample.
Potential start-up costs to consider 
TABLE 49 Potential PCR training costs when implemented in routine practice: assume 1 biomedical scientist trains 9 laboratory
assistants (3 groups of 3) for 30 hours each
Grade Hourly rate (£)a Training time (hours) Total cost (£)
Biomedical scientist 13.40 90 1,205.71
Laboratory assistant 8.84 30 2,387.72
Training equipment/supplies 3,000.00
6,593.43
a Basic salary MLA and biomedical scientist grades, NHS Careers, accessed November 2005.Health Technology Assessment 2007; Vol. 11: No. 36
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Per sample costs
TABLE 50 Breakdown of costs of culture for hypothetical laboratory testing of 10,000 stool samples per year
Cost Breakdown Baseline (£) Max. value (£) Min. value (£)
Staff costs Campylobacter culture 1.22 0.98 1.46
Salmonella culture 1.14 0.91 1.37
E. coli O157 culture 1.36 1.09 1.63
Materials Campylobacter culture 3.99 3.19 4.79
Salmonella culture 3.67 2.93 4.40
E. coli O157 culture 3.63 2.91 4.36
Capital costs Culture capital costs 0.02 0.02 0.05
Total cost of Campylobacter culture per sample 5.21 4.17 6.25
Total cost of Salmonella culture test per sample 4.81 3.84 5.77
Total cost of E. coli O157 culture test per sample 4.99 4.00 5.99
Total cost per sample of routine culture tests 15.01 12.01 18.01
Campylobacter culture on 10,000 samples 52,119.86 41,695.89 62,543.83
Salmonella culture test on 10,000 samples 48,051.09 38,440.87 57,661.31
E. coli O157 culture test on 10,000 samples 49,941.10 39,952.88 59,929.31
Total cost of routine culture for 10,000 samples 150,112.05 120,089.64 180,134.46
TABLE 51 Breakdown of costs of PCR for hypothetical laboratory testing of 10,000 stool samples per year
Cost Breakdown Baseline (£) Max. value (£) Min. value (£)
Staff costs PCR test, staff costs 0.81 0.65 0.97
Pre-enrichment Campylobacter pre-enrichment 2.60 2.08 3.12
Salmonella pre-enrichment 0.12 0.10 0.14
E. coli O157 pre-enrichment 0.44 0.35 0.53
Materials Campylobacter PCR kit 3.75 3.75  5.25
Salmonella PCR kit 3.75 3.75  5.25
E. coli O157 PCR kit 3.75 3.75 5.25
Capital costs rtPCR thermal cycler  20,000 16,500 23,500
over 3 years over 5 years over 3 years
Annualised capital costs 6,666.67 3,300.00 7,833.33
All samples, 3 organisms 0.22 0.11 0.26
25% high-risk patients 0.89 0.37 1.74
50% high-risk patients 0.44 0.22 0.52
All samples, E. coli only 0.67 0.33 0.78
Total PCR costs All samples, 3 organisms 17.51 16.05 23.24
per sample  All samples, E. coli only 5.67 5.08 7.53
received Triage patients, all organisms 19.51 16.82 27.68
Total PCR costs All samples, 3 organisms 175,066.67 160,520.00 232,413.33
implementation All samples, E. coli only 56,666.67 50,800.00 75,333.33
Triage patients, all organisms 146,300.00 151,398.00 124,561.00
Total cost per sample of implementing PCR tests 17.51 16.05 23.24
Total replacement with PCR for 10,000 samples 175,066.67 160,520.00 232,413.33Appendix 6
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Options to centralise PCR testing
TABLE 53 Testing strategies for a large centralised laboratory testing 50,000 samples through rtPCR each year
Strategy Organisms Patient group Total samples Total tests Strategy description
PCR 1 All All 50,000 150,000 Send all samples to large laboratory: test
for all three organisms
PCR 2 All High-risk 12,500 375,000 Send high-risk samples to large
laboratory: test for all three organisms
PCR 3 E. coli High-risk 12,500 12,500 Send high-risk samples to large
laboratory: test for E. coli only
TABLE 52 Breakdown of costs of ELISA for hypothetical laboratory testing of 10,000 stool samples per year
Cost Breakdown Baseline (£) Max. value (£) Min. value (£)
Staff costs ELISA test, staff costs 1.30 1.04 1.56
Pre-enrichment Campylobacter pre-enrichment 2.60 2.08 3.12
Salmonella pre-enrichment 0.12 0.10 0.14
E. coli O157 pre-enrichment 0.44 0.35 0.53
Materials Campylobacter ProSpecT kit 3.64 3.64 4.37
Salmonella Wellcolex kit 1.41 1.41 1.66
E. coli Premier EHEC kit 3.65 3.65 4.30
Capital costs ELISA test, capital costs 0.05 0.03 0.10
Total cost of Campylobacter ELISA test per sample 7.54 6.03 9.05
Total cost of Salmonella ELISA test per sample 2.67 2.14 3.20
Total cost of EHEC ELISA test per sample 5.45 4.36 6.54
Total cost per sample of implementing ELISA tests 15.66 12.53 18.79
Campylobacter ELISA test on 10,000 samples 75,400.00
Salmonella ELISA test on 10,000 samples 26,700.00
EHEC ELISA test on 10,000 samples 54,489.36
Total replacement with ELISA for 10,000 samples 156,589.36 125,271.49 187,907.23Health Technology Assessment 2007; Vol. 11: No. 36
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TABLE 54 Breakdown of costs for a centralised PCR testing unit catering for 50,000 stool samples per year
Cost Baseline Max. value Min. value
(£) (£) (£)
Staff PCR test Staff costs 0.81 0.65 0.97
Campylobacter pre-enrichment Campylobacter pre-enrichment 2.60 2.08 3.12
Pre-enrichment Salmonella pre-enrichment Salmonella pre-enrichment 0.12 0.10 0.14
E. coli O157 pre-enrichment E. coli O157 pre-enrichment 0.44 0.35 0.53
PCR test Campylobacter PCR kit 3.75
PCR kit PCR test Salmonella PCR kit 3.75
PCR test E. coli O157 PCR kit 3.75 3.75 5.25
Courier Delivery costs Delivery 0.75 0.5 1
All samples, 3 organisms 150,000
Samples sent 500,00
Triage of patients – 25% 125,00 15,000 7,500
Capital cost  20,000 16,500 23,500 
over 3 years over 5 years over 3 years
Annualised capital costs 6,666.67 3,300.00 7,833.33
Capital costs All samples, 3 organisms Capital costs 0.09 0.04 0.10
Triage patients, all organisms Capital costs 0.18 0.07 0.35
Triage patients, E. coli only Capital costs 0.53 0.22 1.04
All samples, 3 organisms 17.86 16.35 23.77
Triage patients, all organisms 18.12 16.44 24.50
Total PCR costs Triage patients, E. coli only 6.28 5.47 8.79
All samples, 3 organisms 892,833.33 817700.00 1,384,011.11
Total PCR costs Triage patients, all organisms 226,541.67 246,630.00 183,768.33
implementation Triage patients, E. coli only 78,541.67 82,050.00 65,958.33Health Technology Assessment 2007; Vol. 11: No. 36
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T
his is the original protocol that was submitted
on 1 February 2005. 
Summary
This review will answer key questions on rapid
diagnostic tests for food poisoning in line with
HTA objectives.
1. Does it work? For whom? How does
it compare with alternatives? 
We will conduct a systematic review of the
literature to determine the diagnostic accuracy of
tests for rapid diagnosis of food poisoning in
clinical and public health practice. 
Search strategy
A systematic search of MEDLINE, EMBASE,
BIOSIS and other databases will be used to
assemble published literature. Other studies will
be identified from handsearching key journals,
screening reference lists of retrieved articles and
contacting clinical experts and test manufacturers.
Review strategy
Two reviewers will screen studies for relevance
independently. Study inclusion, data extraction
and quality assessment will be carried out by two
reviewers. Studies will be quality assessed using the
quality assessment tool developed for this project
based on standard methods. Meta-analysis will be
used to produce summary receiver operating
curves but if we detect significant heterogeneity a
narrative synthesis will be presented.
2. At what cost?
Economic evaluations will be reviewed and a
decision model will be developed to estimate the
cost-effectiveness of alternative tests. The
usefulness of the results in practice will be
explored using nominal group analysis of GPs’ and
CCDCs’ opinion.
1.0 Background
1.1 Definition
Food poisoning occurs after the consumption of
food containing toxins or organisms that multiply
to cause disease.1 The Advisory Committee on the
Microbiological Safety of Food (ACMSF) defined
food poisoning as “any disease of an infectious or
toxic nature caused by or thought to be caused by
the consumption of food or water”. This definition
was circulated by the Chief Medical Officer in
1992.2 The terms ‘food-borne infections’ and
‘food-borne intoxications’ are widely used to
highlight the different pathological mechanisms of
the two principal groups of food poisoning
bacteria.
1.2 Incidence
The commonest causes of bacterial food poisoning
outbreaks include Salmonella spp., Campylobacter
jejuni, Escherichia coli O157, Clostridium perfringens,
Bacillus cereus, Shigella spp. and Staphylococcus
aureus.3 A total of 26,528 cases of food poisoning
were notified to the Health Protection Agency and
laboratory reports of isolation of 14,844 cases of
Salmonella, 55,887 cases of Campylobacter, 896 cases
of E. coli 0157 and 1983 cases of Norovirus in
England and Wales in 2000. 
Organisms
There is a wide variety of food-borne pathogenic
microorganisms and natural toxins.4 The majority
of cases of food poisoning and outbreaks of food
poisoning are caused by a limited number of these
organisms. A list of organisms causing food
associated disease is summarised below. 
Pathogenic bacteria causing food poisoning
include Salmonella spp. and Campylobacter jejuni,
Escherichia coli O157, Clostridium perfringens,
Bacillus cereus, Shigella spp., Staphylococcus aureus,
Clostridium botulinum, Yersinia enterocolitica, Yersinia
pseudotuberculosis, Listeria monocytogenes, Vibrio
cholerae O1, Vibrio cholerae non-O1, Vibrio
vulnificus, Aeromonas hydrophila and other spp.,
Plesiomonas shigelloides, Miscellaneous enterics,
Streptococcus and Escherichia coli – enterotoxigenic,
enteropathogenic and enteroinvasive. 
Parasitic protozoa and worms causing food-
associated disease include: Giardia lamblia,
Cryptosporidium parvum, Entamoeba histolytica,
Cyclospora cayetanensis, Anisakis spp. The common
viral causes of food associated disease include:
Rotavirus, Norovirus, and hepatitis A virus. Several
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Original protocolnatural toxins cause food-associated disease.
However, they are uncommon and are usually
investigated at the National Reference Laboratory.
The causes include ciguatera poisoning, shellfish
toxins, scombroid poisoning, mushroom toxins,
aflatoxins, pyrrolizidine alkaloids,
phytohaemagglutinin and crayanotoxin. 
The systematic review will concentrate on six
bacterial causes of food poisoning – Salmonella
spp., Campylobacter jejuni, Escherichia coli O157,
Clostridium perfringens, Staphylococcus aureus, Bacillus
cereus. These organisms were selected mainly
because they are the commonest causes of food
poisoning and outbreaks of food poisoning in the
UK. We included E. coli 0157 because of the
severity of the disease it causes and S. aureus and
B. cereus because they are diagnosed with toxin
detection methods. Other organisms were not
included individually either because they are
uncommon, not relevant in community setting
(C. difficile), predominantly transmitted through
other routes (Norovirus, Shigella spp.), or self-
limiting of illness (Norovirus). However a broader
search covering all other organisms will be
conducted. A separate analysis will be conducted
for each diagnostic method/organism if literature
on a particularly efficient and effective method is
identified.
The diagnostic tests will be those that can be used
in clinical laboratories. The majority of rapid
methods have mainly been tried on food and
animal samples.4 We will review the diagnostic
methods applied in both human and food settings
and relate these to the industrial
production/commercial settings in which food is
prepared, served and consumed.
2.0 How the project has changed
since the outline proposal was
submitted
In view of the comments from the reviewers 
we have made a number of changes to the
protocol. We have clarified how we are going to
deal with poor quality studies, heterogeneity and
included improvements in the search strategy. We
have replaced the planned GP survey with a GP
and Consultants in Communicable Disease
Control nominal group analysis, a qualitative
technique that will enable us to obtain useful
information at a cheaper rate. A Senior Lecturer
in statistics has joined the review group as a 
co-applicant. 
3.0 Planned investigation
3.1 Research objectives
1. To identify studies on rapid diagnostic methods
for food poisoning due to Salmonella spp.,
Campylobacter, Escherichia coli O157, Clostridium
perfringens, Staphylococcus aureus and Bacillus
cereus relevant to both the food chain and
clinical samples.
2. To identify studies on rapid diagnostic methods
for all other causes of food poisoning, with
relevance as above.
3. To assess and summarise the sensitivity,
specificity and positive predictive values of each
diagnostic test for each organism compared to
a gold standard.
4. For tests designed and/or currently applied
only to food samples, to assess usefulness for
transfer to clinical testing.
5. To assess the time for full laboratory analysis
and reporting for each diagnostic test.
6. To assess based on identified studies the cost
and cost-effectiveness of each diagnostic test in
a clinical setting and in the management of
outbreaks.
7. To use a model to assess the impact of each
diagnostic test on the clinical care of individual
patients and on public health.
3.2 Existing research
Various methods have been tried for the rapid
diagnosis of organisms commonly causing food
poisoning. However, no systematic review of the
evidence of which tests are effective in practice was
identified. Several diagnostic studies were
identified using a sensitive search strategy. A total
of 750–1000 articles of varying quality were found.
Based on initial review of abstracts, about one-
third of these articles will be directly relevant and
require further assessment and possible inclusion
in a review. 
Rapid diagnostic methods for Salmonella spp.
include automated rapid enzyme immunoassay,5
polymerase chain reaction (PCR),6–9 random
amplified polymorphic DNA (RAPD)10 and latex
particle agglutination.11 Methods for the rapid
diagnosis of Campylobacter jejuni include PCR,12,13
DNA hybridisation, enzyme immunoassays
(EIAs)14 and hydrophobic grid membrane filters
(HGMFs).15 E. coli 0157 can be diagnosed rapidly
using latex agglutination16 and PCR.17 Recently,
rapid antibody-based dipstick detection methods
for O157 and other verotoxigenic serotypes have
been described by one of the co-applicants.18,19
Rapid methods for the diagnosis of Clostridium
perfringens include PCR.20 Rapid methods for the
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188diagnosis of Staphylococcus aureus include real-time
fluorescence PCR assay,21,22 detection of
enterotoxins,23 ELISA24 and latex agglutination
tests.25 The methods for the rapid diagnosis of
Bacillus cereus include PCR identification of emetic
toxin,26 HEp-2 cell assay27 and reversed passive
latex agglutination and ELISA.28
3.3 Research methods
This review will include a broad and comprehensive
search for and a critical assessment of studies on the
rapid diagnosis of food poisoning. The criteria for
inclusion and exclusion of studies in the review are:
● Organisms and diagnostic investigations: we will
review rapid diagnostic tests for common
organisms and for less common causes of food
poisoning, concentrating on comparison of tests
between individuals.
● Types of studies: all types of diagnostic studies
that compare a rapid test with a gold standard.
● Types of participants: patients with suspected
food poisoning at home or in primary care with
local laboratory diagnosis.
● Types of outcome measures: 1. diagnostic
accuracy – sensitivity, specificity and diagnostic
odds ratios; 2. impact on management of
patients and prevention of wider outbreaks; 
3. costs and cost-effectiveness.
3.3.1 Search strategy
We intend to combine a standardised search
strategy which creates a large set of high-validity
articles on diagnosis with the MESH term(s) for
each organism.
A. Standardised search strategy (1. exp "sensitivity
and specificity"/, 2. exp diagnostic errors, 3.
(sensitivity or false positive or false negative or
predict$ or observer variation).ti,ab,sh., 4. 1 or 2
or 3, 5. (blind$ or mask$ or compar$).ti,ab,sh., 6.
4 and 5 
B. Organisms and MESH terms search. Two
categories will be searched:
1. Common pathogenic bacteria – Salmonella
spp. (MESH) or Salmonella food poisoning
(MESH), Campylobacter jejuni (MESH),
Escherichia coli O157 (MESH), Clostridium
perfringens, Staphylococcus aureus (MESH),
Bacillus cereus (MESH).
2. All organisms using the MESH term “Food
Poisoning”, including all subheadings.
The standardised search "AND" the organism
MESH term(s) search will be combined.
We will apply the above strategy for each
pathogen using OVID interface to search the
following databases: (1) MEDLINE (1966 to date),
(2) EMBASE (1974 to date) and (3) BIOSIS (1969
to date). Other databases will be searched
including those that involve validation of the new
tests against standard methods in collaborative
trials, such as those in the AOAC Method
Validation Program. We will also search CINAHL
(Cumulative Index to Nursing and Allied Health
Literature), NHS EED (NHS Economic Evaluation
Database), Web of Knowledge, Dissertation
Abstracts Online database, Database of Abstracts
and Reviews and Conference Proceedings. Grey
literature: diagnostic equipment manufacturers
and individuals working in fields relevant to each
organism will be contacted to identify grey
literature. International and national experts on
food poisoning will be contacted to check the
completeness of any search conducted. Authors of
published articles will be contacted to enquire
about unpublished studies they may be aware of.
We will ask for any additional unpublished,
ongoing and planned studies from referees. The
reference list of published articles including
previous reviews will also be checked and authors
contacted if unpublished papers are identified.
Other databases that index grey literature such as
SIGLE (System for Information on Grey
Literature) and British National Bibliography for
Report Literature will be searched.
We will include articles in all languages and
studies carried out in humans or animals.
3.3.2 Review strategy
a. Study eligibility and application of inclusion
and exclusion criteria
The titles and abstracts of papers identified will be
screened by two independent reviewers. All articles
that are considered to potentially meet the
eligibility criteria outlined above by any of the
reviewers will be selected. The assessment of study
eligibility of this initial selection will not be
blinded to publication details such as journal or
author names.
b. Data extraction
Two reviewers will independently use standard
forms to extract data from all identified papers.
Key data items will include patient characteristics,
organism(s), test used, characteristics of the tests
(for instance PCR – type of probe, quantitative or
qualitative), location, outcome measures and the
source of funding. Other characteristics to be
recorded include study quality, publication details,
time for analysis, sensitivity, specificity and positive
predictive values of each rapid diagnostic test
compared with a gold standard (laboratory culture
Health Technology Assessment 2007; Vol. 11: No. 36
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The underlying numbers used in calculating these
measures of diagnostic accuracy will also be
recorded. 
c. Assessment of methodological quality
Two reviewers will independently assess the quality
of identified studies by recording the
characteristics of included studies on a standard
form. A third reviewer will settle disagreements.
The methodological quality of studies will be
assessed using the criteria suggested by the
Cochrane Methods Group on Screening and
Diagnostic Tests.29 Quality assessment criteria 
will not be over-utilised as suggested in the
Cochrane Handbook as these studies are
observational. We will deal with variation in
methodological quality by exploring the effect of
major sources of bias or variability in study quality
and examine its effect on the summary receiver
operating characteristic curve (see below). If
analysis of the studies with a particular bias (for
instance – independence of observations) does not
produce a difference from that obtained with high-
quality studies then they will be included to
increase precision of summary estimates. However,
if they differ we will restrict the analysis to studies
of high quality directly applicable to diagnosis of
food poisoning.
d. Statistical analysis – effectiveness
If meta-analysis is not found to be appropriate due
to clinical heterogeneity we will limit the analysis
to a qualitative narrative synthesis of the
diagnostic research available.
Statistical analysis will follow that suggested by
Lijmer.30 Accuracy is usually presented in
individual studies in terms of sensitivity and
specificity, i.e. dichotomous data rather than
differences in distributions. Standard meta-
analytic techniques, that is, a simple pooled
estimated of sensitivity and another of specificity,
will be inappropriate as these two statistics are
likely to be correlated. Therefore, we will
summarise accuracy across studies using a
Summary Receiver Operating Characteristic
(SROC) curve. This will be accomplished through
a meta-analytic regression model used to explain
variability in study diagnostic odds ratios (DOR).31
In particular, variability across studies due to the
use of different thresholds to define positivity can
be assessed and modelled using this approach.
Variability due to other sources, e.g. patient
characteristics (age), study quality and
characteristics such as inclusion criteria and
measurement of outcomes, can also be explicitly
modelled. The modelled DORs can be
transformed back into paired sensitivities and
specificities. In the unlikely case of sensitivity and
specificity appearing independent (as judged by
Spearman’s rank correlation, for example) then
standard meta-analytic techniques will be applied.
Heterogeneity can be assessed using the I2
statistic.32 We will conduct the analysis for each
organism and diagnostic test. 
Publication bias will be assessed using funnel plots
of DORs. Galbraith plots will be used to identify
outlying studies.
e. Costs and cost-effectiveness
The economic analysis will consist of reviewing
published studies considered adequate to address
and/or containing issues of cost and cost-
effectiveness. These aspects will be abstracted
along with the other variables outlined above by at
least another Health Economic reviewer. The
scope of the economic appraisal will be from a
personal, social and health sector perspective, i.e.
the ‘societal’ perspective. These costs will include
(1) inter alia private purchases of OTC medication;
lost family production (e.g. carer time); (2) work
days lost; lost revenue from closures, shut-downs,
sales, bad publicity, etc.; (3) testing, community
infection control measures, clean-up work,
monitoring, etc.; (4) related inpatient and
outpatient episodes, GP visits and laboratory tests
(including capital equipment, reagents, containers,
administration and other consumables). 
Cost information
Cost information will be obtained from a variety of
sources. In the first instance the availability of cost
data will be assessed from the appropriate
publications identified by the systematic review.
Some variability may be expected to occur in
individual studies because (a) baseline years may
differ, (b) the basis for costing is different, (c) costs
and prices are reported interchangeably and (d)
patterns of healthcare delivery may be the
underlying cause of cost variation, not the
procedure itself. An average estimate will be used
where there is compatibility between the estimates.
Also, relevant extreme values will be used in the
model where appropriate for purposes of
sensitivity analysis. 
It is very likely that other sources of cost data will
be required. The costs of the tests themselves (new
and existing) can be obtained from manufacturers’
specifications and relevant marketing information.
However, these costs will be assessed for their
underlying assumptions. In practice the total NHS
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consumables, etc.) will need to be derived not only
from discussions with suppliers but also with
laboratory managers and user groups. Our team
has experience in costing laboratory procedures,
e.g. LBC systems for cervical screening and NAATs
to detect Chlamydia trachomatis.
There will also be ‘flow on’ costs when treatment is
enacted from diagnostic results. In the first
instance these fall on healthcare providers (GPs,
hospitals, etc.). These direct healthcare costs can
be obtained from standard reference cost manuals
such as the NHS Reference Cost manual33 and other
published sources, such as the PSSRU’s Unit Costs
of Health and Social Care.34 We use these costs
regularly in our health economic work and, where
applicable, these will be included in the model.
Where relevant, costs falling on commercial
organisations from food poisoning alerts such as a
disruption of production or service will be
estimated from case reports and other literature.
However, modelling events such as these may be
better handled outside of the main model and
estimates of their incidence and cost developed
separately. 
Costs falling on individuals will include the actual
out-of-pocket personal care costs from contracting
food poisoning, e.g. purchase of over-the-counter
drugs; loss of wages; travel to a chemist/GP. We
shall assume for the purposes of this model that
time taken for personal care and lost leisure time
has only a ‘frictional’ value (i.e. there is a very low
value in the alternative use of time). The average
number of lost days’ productivity will be obtained
from relevant Health and Safety statistics and an
average cost per day used. In this way the
‘indirect’ or productivity costs can be estimated.
f. Impact on management of patients and
outbreaks
This study will be unique in extrapolating the
results of the review of effectiveness and cost-
effectiveness to a hypothetical population the size
of an average PCT. The most comprehensive of
the results from the literature review will be used
to assess the cost-effectiveness of selected tests.
The cost-effectiveness end-point will be cost per
case detected. The element of timeliness of testing
will captured in this measure by defining cost per
case detected within a pre-determined time-frame
that is (a) faster than normal tests, (b) technically
feasible and (c) and/or acceptable to decision-
makers. A full sensitivity analysis of key variables
considered to influence the cost-effectiveness will
be undertaken.
g. Economic modelling
The model will be based on standard decision
analysis (DA) theory. In the absence of a
randomised controlled trial a DA approach is a
useful means of determining the likely cost-
effectiveness of alternative treatments/diagnostic
pathways. It uses a decision tree approach that
allows the synthesis of existing clinical evidence
combined with other data sources (e.g. cost). For
example, a model could compare the existing test
with a new test taking into account the probability
of a higher detection and treatment rate and
lower re-test rate, etc. The relevant costs (tests,
follow-up procedures, etc.) and expected outcomes
(e.g. case detected) can be attached to these
branches of the model. It is important to set up
the model in a way that reflects current practice.
Unlike deterministic models (if X then Y),
uncertainty is included in the DA approach (if X
then pY) to reflect actual practice and variability
in the outcomes and other factors (e.g. costs).
Probability of Y is handled by including in the
model a distribution of the likelihood of Y
occurring. There may be several stages of the
model at which uncertainty occurs. There may also
be stages and feed-back loops in the model where
elapsed time is represented when stages of
treatment or diagnosis are repeated (referred to as
a Markov transition probabilities). Model can be
run using a simulation package to generate results
from large numbers of hypothetical patients with
the prescribed variance in inputs and outcomes.
Once built, the model is capable of being
interrogated in different ways (e.g. by changing
the probabilities and the costs, etc.) and hence
producing a sensitivity analysis of estimates within
which the true cost-effectiveness is expected to be
found.
h. Nominal group analysis of GPs and
Consultants in Communicable Disease Control
The rationale for exploring GP opinion is that, to
develop a valid model based on the literature, a
clinical evaluation of the impact of different
testing options will be important. For example,
what difference will a test result that is available
one or two days earlier than the current
convention make in terms of patient contacts or
prescriptions? Which would GPs and CCDCs
consider a priority?
We now propose to test GP and CCDC opinion on
aspects of the model using a modified focus group
approach which will be more efficient than a
survey, and will allow ranking of different factors
for consideration in the modelling. This is the
Health Technology Assessment 2007; Vol. 11: No. 36
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'nominal group technique’,35 where relevant
factors can be identified and validated by the
group, and they then prioritise those most likely to
be important to clinical and practical outcomes,
from which likely behavioural modifications can be
identified and costed. We shall run two groups of
ten attendees, one for GPs and one for CCDCs.
3.4 Expected output
To produce a comprehensive report of the
findings with recommendations to the NHS HTA
including evidence of impact of rapid tests in
clinical care and outbreak management of food
poisoning, cost-effectiveness and feasibility of
using rapid diagnostic methods in food poisoning.
We will also identify the need for further research
and the best way to answer questions arising from
the review using primary research.
4.0 Ethical arrangements
The nominal group analysis to seek the opinion of
healthcare professionals will require ethical
approval. Approval will be sought from the
Norwich Local Research Ethics Committee.
5.0 Timetable
The proposed start date of the study is 1 February
2005. We estimate that a 12-month period will be
required to conduct the review and produce a
report.
6.0 Expertise
Paul Hunter, Professor of Health Protection and
Consultant Medical Microbiologist, will contribute
a wide range of expertise including methodological
issues around the design of the systematic review,
knowledge and experience of using diagnostic
microbiological methods in food poisoning,
epidemiology and statistics. He chairs the HPA
Advisory Committee on Water and has been
involved in the investigation of many food and
waterborne outbreaks.
Ibrahim Abubakar is a Clinical Lecturer in Health
Protection. His main areas of expertise include
communicable disease epidemiology, review
methodology and coordination of the project.
Ibrahim is leading a Cochrane Review on the
prevention and treatment of cryptosporidiosis.
Ric Fordham is a Senior Lecturer in Health
Economics and Director of the NHS Health
Economics Support Programme. His expertise
includes economic evaluation and modelling and
he has an interest in the economic implications of
technology adoption in medicine. Ric is currently
involved in another HTA commissioned review on
the treatment of warts.
Professor Michael Peck, Head of the Food Safety
Microbiology and Computational Microbiology
Group of the Institute of Food Research, Norwich,
will contribute his expertise on rapid diagnostic
tests. Amanda Howe, Professor of Primary Care,
Months from the beginning of the study
–3 –2 –1 1 2 3 4 5 6 7 8 9 10 11 12
STAFF RECRUITMENT
Staff recruitment
DATA COLLECTION
Identify the studies
Obtain articles
DATA PROCESSING
Data extraction
Statistical analysis – meta-analysis and economic modelling
Nominal group analysis (GPs and CCDCs)
REVIEW 
REPORTING
Preparation of final report for HTA and paper writing
Milestones ★★ ★ ★will contribute to the nominal group analysis and
knowledge of the application of diagnostic
methods for food poisoning in primary care. Silke
Schelenz is a Consultant Medical Microbiologist
and her areas of expertise include the diagnosis of
intestinal pathogens causing food poisoning in a
clinical microbiology laboratory.
Lee Shepstone is a Senior Lecturer in Medical
Statistics and will provide statistical expertise to
the review.
7.0 Consumer involvement
The nominal group analysis of GPs and CCDCs
will ensure that two key groups of potential users
of the results of the diagnostic tests are involved in
the assessment of the impact of rapid diagnostic
testing.
8.0 Justification for support
required
We propose that the project will require a study
coordinator (research associate) based at the
Medical School, University of East Anglia. The
research associate will be a health economist
responsible for modelling the data and will be
directly responsible for daily supervision of the
project. We will require the time and resources of
an additional part-time research associate from the
Institute of Food Research in Norwich to
contribute to searching, collating and synthesising
findings relevant to diagnostic methods in food,
water, animals and the environment.
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Annex: Data for a review of diagnostic test accuracy
1. CRITERIA FOR STUDY VALIDITY
Was the test compared with a valid reference standard?  Studies categorised by reference
standard used
Were the test and reference standard measured independently?  In both directions or one
Was the choice of patients who were assessed by the reference standard independent 
of the test’s results? (Avoidance of verification bias)
Was the test measured independently of all other clinical information? 
Was the reference standard measured before any interventions were started with 
knowledge of test results (Avoidance of treatment paradox)
2. ADDITIONAL VALIDITY CRITERIA FOR STUDIES COMPARING TESTS
Validity of design? Categories in order of decreasing validity are: 
All tests done independently on each person
Different tests on randomly allocated individuals
Test all but not independent assess
Different test, not random selection of individuals
3. CRITERIA RELEVANT TO THE APPLICABILITY OF THE RESULTS 
3.1. The clinical problem
Spectrum of disease and non-disease Inclusion and exclusion criteria
Duration of illness before testing.
Previous tests/referral filter, i.e. to what clinical (including previous test) information 
is the test being evaluated
Co-morbid conditions
Demographic information: such as age
3.2. The test
Categories for how the test was done e.g. types of PCR methods
State the explicit threshold used
% excluded because test was infeasible or result indeterminate
Test reproducibility
4. INDIRECT MEASURES OF QUALITY AND APPLICABILITY
Year of study (or publication)
Disease prevalence
Sample size
Prospective or retrospective study designHealth Technology Assessment 2007; Vol. 11: No. 36
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